Document:

<PAGE>

                                                                   EXHIBIT 10.44

                           STOCK PURCHASE AGREEMENT

     This Stock Purchase Agreement dated as of December 5, 1999 (this
"Agreement") is entered into by and among STAAR Surgical Company, a Delaware
corporation (the "Purchaser"), Circuit Tree Medical, Inc., a California
corporation (the "Company"), Alex Urich, an individual, and Michael Curtis, an
individual (Urich and Curtis are sometimes herein referred to individually as
the "Shareholder" and collectively as the "Shareholders").

                                  WITNESSETH:

     WHEREAS, the Company has issued to each of the Shareholders five hundred
(500) shares of its common stock;

     WHEREAS, the Purchaser wishes to purchase from each Shareholder, and each
Shareholder wishes to sell to the Purchaser, four hundred (400) shares of the
Company's common stock, in accordance with the terms and provisions of this
Agreement;

     WHEREAS, the parties hereto believe it is desirable to enter into this
Agreement in order to set forth the representations and warranties made by the
Company and the Shareholders in connection with this transaction, and to set
forth certain covenants and agreements of the parties and to set forth various
other provisions relating to this transaction and the relative rights and
obligations of the parties with respect thereto.

     NOW, THEREFORE, in consideration of the premises and the mutual covenants
and agreements hereinafter set forth, the parties hereto agree as follows:

                                   ARTICLE I
                                 SALE OF STOCK

     1.1  Sale And Purchase Of Stock. Upon execution of this Agreement, each
          --------------------------
Shareholder shall sell to the Purchaser, and the Purchaser shall purchase from
each Shareholder, four hundred (400) shares of the Company's common stock.  (The
total eight hundred (800) shares of common stock which shall be purchased by the
Purchaser pursuant to this Agreement shall be referred to herein, collectively,
as the "Stock".)

     1.2. Purchase Price And Payment Terms.
          --------------------------------

          (a)  The purchase price for the Stock shall be Two Million Five
Hundred Thousand Dollars ($2,500,000). The purchase price shall be paid as
follows:

                    (i)  At the Closing, the Purchaser shall deliver to each
     Shareholder good funds in the amount of Two Hundred Fifty Thousand Dollars
     ($250,000); and

                    (ii) Within ten (10) days from the Closing, the Purchaser
     shall deliver to the Escrow Holder, for distribution to the Shareholders,
     certificates representing unregistered shares of the Purchaser's common
     stock (the "Purchaser's Shares"). The number of Purchaser's Shares to be
     issued shall be determined as of the Closing Date by dividing the balance
     of the purchase price, or One Million Five Hundred Thousand Dollars
     ($1,500,000), by the average of the closing bid and ask prices of the
     Purchaser's common stock for the five

                                       1
<PAGE>

     trading days immediately preceding the Closing Date. Each Shareholder shall
     receive a certificate for the Purchaser's Shares having a value, on the
     Closing Date, of Seven Hundred Fifty Thousand Dollars ($750,000); and

                    (iii)  On or before January 5, 2000, the Purchaser shall
     deliver to the Escrow Holder, for distribution to each Shareholder, good
     funds in the amount of Two Hundred Fifty Thousand Dollars ($250,000).

          (b)  The Shareholders and the Purchaser shall sign an escrow agreement
(the "Escrow Agreement") in the form of Exhibit "1". Pursuant to the Escrow
Agreement each Shareholder shall deposit with the Escrow Holder (as that term is
defined in the Escrow Agreement) (i) a certificate representing two hundred
forty (240) shares of the Company's common stock (collectively, four hundred
eighty (480) shares of the Stock), along with a Stock Assignment Separate From
Certificate duly endorsed for transfer and (ii) a certificate representing
eighty (80) shares of the Company's common stock (collectively one hundred sixty
(160) shares of the Stock), along with a Stock Assignment Separate From
Certificate duly endorsed for transfer and the Purchaser shall deposit with the
Escrow Holder (i) Two Hundred Fifty Thousand Dollars ($250,000) and (ii) the
Purchaser's Shares. The Escrow Holder shall hold the certificates pursuant to
the terms of the Escrow Agreement and, upon receipt of the Purchaser's Shares
and the Two Hundred Fifty Thousand Dollars ($250,000), shall release the
certificates, with the Assignment Separate From Certificate, to the Purchaser,
all pursuant to the terms and conditions of the Escrow Agreement.

          (c)  As part of the consideration for this purchase and sale, the
Shareholders and the Purchaser shall sign a Shareholders Agreement in the form
of Exhibit "2".

          1.3. Closing Date.  The closing date of this transaction shall take
               ------------
place on or before December 3, 1999 (the "Close" or the "Closing Date").

                                   ARTICLE II
                REPRESENTATIONS AND WARRANTIES OF THE PURCHASER

The Purchaser represents and warrants to the Company and the Shareholders as
follows:

     2.1. Organization and Capital Structure of the Purchaser.  The Purchaser
          ---------------------------------------------------
is a corporation duly organized, validly existing and in good standing under the
laws of the State of Delaware and has full corporate power and authority to
carry on its business as now conducted.

     2.2. Authorization.  The Purchaser has full corporate power and authority
          -------------
to enter into this Agreement, the Escrow Agreement, the Shareholders Agreement,
the Urich Employment Agreement and the Curtis Employment Agreement,
(collectively, the "Transaction Documents"), to consummate the transactions
contemplated hereby and thereby and to comply with the terms, conditions and
provisions hereof and thereof.  The execution, delivery and performance by the
Purchaser of each of the Transaction Documents, and the actions to be taken by
the Purchaser contemplated hereby and thereby have been duly and validly
authorized by the Board of Directors of the Purchaser and no other corporate
proceedings on the part of the Purchaser are necessary with respect hereto or
thereto.  Each of the Transaction Documents constitutes the valid and binding
obligations of the Purchaser, in each case enforceable in accordance with its
terms, subject to (i) general principles of equity, regardless of whether
enforcement is sought in a proceeding in equity or

                                       2
<PAGE>

at law, and (ii) bankruptcy, reorganization, insolvency, fraudulent conveyance,
moratorium, receivership or other similar laws relating to or affecting
creditors' rights generally.

     2.3. Non-Contravention.  Except as set forth in Schedule 2.3 attached
          -----------------
hereto, neither the execution or delivery of the Transaction Documents by the
Purchaser, nor the consummation of the transactions contemplated hereby or
thereby by the Purchaser, will (i) conflict with or result in the breach of any
term or provision of, or constitute a default under, the Certificate of
Incorporation or By-laws of the Purchaser or any material agreement, instrument
or indenture to which the Purchaser is a party or by which it is bound; (ii)
violate any order, writ, injunction, decree, statute, rule or regulation
applicable to the Purchaser; or (iii) require, as of the date hereof, the
approval, consent, waiver, authorization or act of, or the making by the
Purchaser of any declaration, filing or registration with, any third party or
any Governmental Body and such other consents, orders, authorizations,
registrations, declarations and filings the failure of which to be obtained or
made would not, individually or in the aggregate, have a Material Adverse Effect
on the Purchaser, materially impair the ability of the Purchaser to perform its
obligations hereunder or prevent the consummation of any of the transactions
contemplated hereby.

     2.4. Valid Shares.  The issuance of the Purchaser's Shares in connection
          ------------
with the transaction has been duly authorized on behalf of the Purchaser and the
Purchaser's Shares, when issued pursuant to this Agreement, will be duly and
validly issued and outstanding, fully paid and nonassessable.

                                  ARTICLE III
                         REPRESENTATIONS AND WARRANTIES
                      OF THE COMPANY AND THE SHAREHOLDERS

     The Company and the Shareholders, jointly and severally, represent and
warrant to the Purchaser as follows:

     3.1. Organization.  The Company is a corporation duly organized and
          ------------
validly existing under the laws of the state of California.  The Company is duly
qualified to transact business as a foreign corporation and is in good standing
in each of the jurisdictions in which the ownership or leasing of its properties
or the conduct of its business requires such qualification, and no other
jurisdiction has demanded, requested or otherwise indicated that the Company is
required to so qualify.  The Company has full corporate power and authority to
own or lease and to operate and use its properties and assets and to carry on
its business as now conducted.  The Company has delivered or otherwise made
available to the Purchaser true and complete copies of the Company's Articles of
Incorporation, as in effect on the date hereof, By-laws, as in effect on the
date hereof, minute books and stock transfer records.

     3.2. Subsidiaries and Investments.  The Company does not, directly or
          ----------------------------
indirectly, (a) own, of record or beneficially, or own or hold the right to
acquire, any outstanding voting or equity securities or other voting or equity
interests in any corporation, partnership, joint venture or other entity or (b)
otherwise control any such corporation, partnership, joint venture or other
entity.

     3.3. Capital Stock of the Company.  The authorized capital stock of the
          ----------------------------
Company consists of one thousand (1,000) shares of Common Stock, without par
value ("Company Common Stock"), of which one thousand (1,000) shares are duly
and validly issued and outstanding, fully paid and nonassessable, and none of
which are held by the Company as treasury shares.  None of the

                                       3
<PAGE>

issued and outstanding shares of Company Common Stock has been issued in
violation of the preemptive rights of any person or in violation of applicable
federal or state securities laws. Except for this Agreement, and except as set
forth on Schedule 3.3 hereof, there are no agreements, arrangements, warrants,
options, puts, calls, rights or other commitments, plans or understandings of
any character relating to the issuance, sale, purchase, redemption, conversion,
exchange, registration, voting, or transfer of any shares of Company Common
Stock or any other securities of the Company. Schedule 3.3 sets forth a true and
complete list of the names and addresses of each of the holders of record of the
Company Common Stock and the respective number of outstanding shares held of
record by each such holder.

     3.4. Non-Contravention.  Except as set forth on Schedule 3.4 attached
          -----------------
hereto, neither the execution or delivery of this Agreement by the Company nor
the consummation of the transactions contemplated hereby or thereby by the
Company will (i) conflict with or result in the breach of any term or provision
of, or constitute a default under, the Articles of Incorporation or By-laws of
the Company; (ii) result in a default, or give rise to any right of termination,
cancellation or acceleration, under any provisions of any material agreement
(including, without limitation, any loan agreements or promissory note),
indenture or instrument to which the Company is a party or by which the Company
or is bound; (iii) result in the creation or imposition of any Encumbrance on
any of the property of the Company; (iv) violate any order, writ, injunction,
decree, statute, rule or regulation applicable to the Company; or (v) require on
the part of the Company or the Shareholders, as of the date hereof, the
approval, consent, waiver, authorization or act of, or the making by the Company
of any declaration, filing or registration with, any third party or any
Governmental Body.

     3.5. Financial Statement.  Schedule 3.5 contains the balance sheet of the
          -------------------
Company as of December 31, 1998, (the "Company's Financial Statement").  Except
as set forth on Schedule 3.5, the Company's Financial Statement is true and
correct and presents fairly the financial condition and the results of
operations and cash flows of the Company as of the date and for the period
indicated.  The Company's Financial Statement does not contain any material
items of special or nonrecurring income except as expressly specified therein.

     3.6. Operations Since Balance Sheet Date.
          -----------------------------------

          (a)  Except as set forth on Schedule 3.6, during the period from the
Balance Sheet Date to the date hereof, inclusive, there has been: (i) no
material adverse change in the Business or the results of operations, properties
or condition (financial or otherwise) of the Company, and no fact or condition
exists or is contemplated or threatened which might reasonably be expected to
cause such a change in the future; and (ii) no damage, destruction, loss or
claim made or filed against the Company (whether or not covered by insurance) or
condemnation or other taking which materially adversely affects the Business or
the results of operations, properties or condition (financial or otherwise) of
the Company.

          (b)  Except as set forth on Schedule 3.6, since the Balance Sheet
Date, the Company has conducted the Business only in the ordinary course and in
conformity with past practice. Without limiting the generality of the foregoing,
since the Balance Sheet Date, except as set forth on Schedule 3.6, the Company
has not: (i) issued, delivered or agreed (conditionally or unconditionally) to
issue or deliver, or granted any option, warrant or other right to purchase, any
of its capital stock or other equity interest or any security convertible into
its capital stock or other equity interest; (ii) paid any obligation or
liability (absolute or contingent) other than current liabilities reflected on
the Balance Sheet and current liabilities incurred since the Balance Sheet Date

                                       4
<PAGE>

in the ordinary course of business consistent with past practice; (iii)
undertaken or committed to undertake capital expenditures exceeding $50,000 for
any single project or related series of projects; (iv) made charitable donations
in excess of $10,000 in the aggregate; (v) sold, leased, transferred or
otherwise disposed of (including any transfers from the Company to any of its
Affiliates), or mortgaged or pledged, or imposed or suffered to be imposed any
Encumbrance (other than Permitted Encumbrances) on, any of the assets reflected
on the Balance Sheet or any assets acquired after the Balance Sheet Date, except
for sales of inventory in the ordinary course of business consistent with past
practice; (vi) canceled any debts owed to or claims held by the Company
(including the settlement of any claims or litigation) or waived any rights of
material value; (vii) created, incurred, guaranteed or assumed any indebtedness
for borrowed money or entered into any capitalized leases; (viii) accelerated
collection of any note or account receivable to a date prior to the date such
collection would have occurred in the ordinary course of business consistent
with past practice; (ix) delayed payment of any account payable or other
liability of the Company beyond its due date or the date when such liability
would have been paid in the ordinary course of business consistent with past
practice (x) allowed the levels of raw materials, supplies, work-in-process,
finished goods or other materials included in its inventory to vary in any
material respect from levels customarily maintained; (xi) granted any bonus or
other special compensation or increased the compensation or benefits payable or
to become payable to any directors, officers or employees, or instituted any
increase in or otherwise amended any profit sharing, bonus, incentive, deferred
compensation, insurance, pension, retirement, medical, hospital, disability,
welfare or other employee benefit plan except for increases required by law;
(xii) sold, assigned or transferred any patents, trademarks, service marks,
trade names, copyrights, Software (as defined in Section 3.17) (except in the
ordinary course of business consistent with past practice), trade secrets or
other similar intangible assets, or disclosed any proprietary or confidential
information to any person or entity (other than to the Purchaser, its Affiliates
and agents), (xiii) extended credit other than in the ordinary course of
business or permitted any change in credit practices or in the method of
maintaining books, accounts or business records; (xiv) declared, set aside or
paid any dividend or made any other distribution (whether in cash, stock or
other property) to the Shareholders in respect of any Company Common Stock or
other securities of the Company; (xv) purchased, redeemed, called for purchase
or redemption or otherwise acquired any shares of Company Common Stock or any
other securities of the Company; (xvi) made any write-down of the value of any
inventory or write-offs as uncollectible of any notes or accounts receivable
except for write-downs and write-offs in the ordinary course of business and
consistent with past practice, none of which would reasonably be expected to
have a Material Adverse Effect on the Business or the results of operations,
properties or condition (financial or otherwise) of the Company; (xvii) except
as otherwise contemplated herein, entered into any transaction other than in the
ordinary course of business or any transaction (not involving purchases and
sales of inventory) including commitments for expenditures in excess of $50,000;
(xviii) made any changes in the accounting methods or practices followed by the
Company; (xix) agreed or committed to do or authorized any of the foregoing; or
prepared or filed any Tax Return inconsistent with past practice or, on any such
Tax Return taken any position, made any election, or adopted any method that is
inconsistent with positions taken, elections made or methods used in preparing
or filing similar Tax Returns in prior periods (including, without limitation,
positions, elections or methods which would have the effect of deferring income
to periods ending after the Closing Date or accelerating deductions to periods
ending on or prior to the Closing Date).

     3.7. No Undisclosed Liabilities, Working Capital.  Except as set forth on
          -------------------------------------------
Schedule 3.7, the Company is not subject to any obligation or liability of a
kind required to be included as a liability on the Company's Balance Sheet
(including, without limitation, unasserted claims whether known or unknown),
whether absolute, contingent, accrued or otherwise, which is not shown or

                                       5
<PAGE>

which is in excess of amounts shown or reserved for on the Balance Sheet, other
than liabilities reasonably incurred in the ordinary course of business after
the Balance Sheet Date, none of which, individually or in the aggregate, would
have a Material Adverse Effect on the Company and none of which is a liability
for breach of contract, breach of warranty, tort, infringement or other lawsuit.

     3.8. Taxes.
          -----

          (a)  Except as set forth on Schedule 3.8, (i) all Tax Returns,
required to be filed by or on behalf of the Company prior to the Closing Date
have been or will be timely filed and such Tax Returns as so filed are or will
be complete and accurate and disclose all Taxes required to be paid for the
periods covered thereby and all Taxes shown to be due on such Tax Returns have
been timely paid; (ii) no extension of time in which to file any such Tax
Returns is in effect or has been requested; (iii) all Taxes for which the
Company is liable relating to any period ending on or prior to the Closing Date
(or the portion of any Tax period beginning before and ending after the Closing
Date) shall have been paid or, if not yet due and payable, properly accrued for
as of the Closing Date; (iv) all Taxes which the Company is required by law to
withhold or to collect for payment have been duly withheld and collected, and
have been paid or will be paid to the proper Governmental Body; (v) there are no
Tax liens (except for liens relating to current Taxes not yet due) on any
property of the Company and no basis exists for any such liens; (vi) the Tax
Returns referred to in clause (i) have been examined by the appropriate taxing
authority or the period for assessment of the Taxes in respect of which such
Tax Returns were required to be filed has expired; (vii) no audit of any kind
has been conducted with respect to any Tax Return by an appropriate Taxing
authority; (viii) all deficiencies which have been asserted as a result of such
examinations have been fully paid or finally settled, and no issue has been
raised in any such examination which, by application of similar principles,
reasonably would be expected to result in assertion of a deficiency for any
other year not so examined; (ix) the Company has neither executed nor entered
into a closing agreement pursuant to Section 7121 of the Internal Revenue Code
of 1986, as amended (the "Code"), or any predecessor provision or any similar
provision of state, local or foreign law; (x) there are no outstanding
agreements or waivers extending the statutes of limitations with respect to the
assessment of any Tax and no such agreements or waivers have been requested;
(xi) the Company has not incurred any liability with respect to Taxes based upon
income, operations, purchases, sales, payroll, licenses, compensation, business,
capital stock or surplus, properties or assets except in the ordinary course of
business, or any liabilities for interest or penalties with respect to the
foregoing; (xii) there is no action, suit, investigation, audit, claim or
assessment pending or proposed or threatened with respect to Taxes of the
Company and no basis exists therefor; (xiii) the accruals for Taxes reflected on
the Balance Sheet are adequate to cover any Tax liability of the Company; (xiv)
since the Balance Sheet Date, none of the Shareholders or the Company has taken
any action not in accordance with past practice that would have the effect of
deferring any Tax liability for the Company from any taxable period ending on or
before the Closing Date to any taxable period ending after the Closing Date; and
(xv) no claim has ever been made by a Taxing Authority in a jurisdiction where
the Company has never paid Taxes or filed Tax Returns asserting that the Company
is or may be subject to Taxes assessed by such jurisdiction.

          (b)  No transaction contemplated by this Agreement is subject to
withholding under Section 1445 of the Code and no stock transfer Taxes, sales
Taxes, use Taxes, real estate transfer or gains Taxes, or other similar Taxes
will be imposed on the transactions contemplated by this Agreement.

                                       6
<PAGE>

           (c)  For any Taxable period as to which the relevant statute of
limitations will not have expired as of the Closing Date, the Company has not
been a member of an affiliated group (as defined in Section 1504(a) of the Code
without regard to the limitations contained in Section 1504(b) of the Code) or
has filed Tax Returns with a group of corporations filing a combined,
consolidated or unitary income Tax Return.

     3.9.  Availability of Assets and Legality of Use.  Except as set forth on
           ------------------------------------------
Schedule 3.9, the assets owned or leased by the Company, or which the Company is
entitled to use under license or other agreements, constitute all the assets
used by the Company in the conduct of the Business (including, but not limited
to, all books, records, computers and computer programs and data processing
systems), and the tangible assets owned or leased by the Company are in good
condition (subject to normal wear and tear) and serviceable condition and are
suitable for the uses for which they are intended.  Except as set forth on
Schedule 3.9, to the knowledge of the Company or any of the Shareholders, (i)
all such assets and their uses conform to all applicable laws, regulations,
rules, ordinances, codes, licenses, franchises and permits (including, without
limitation, all electrical, building, zoning, environmental and occupational
safety and health Requirements of Law), and (ii) no written notice of any
existing violation of any of such matters relating to such assets or their use
has been received by the Company.

     3.10. Governmental Permits.  The Company owns, holds or possesses all
           --------------------
governmental licenses, franchises, permits, privileges, variances, immunities,
approvals and other authorizations which are necessary to entitle it to own,
lease, operate and use its assets and properties and to carry on and conduct the
Business substantially as currently conducted (herein collectively called
"Governmental Permits"), except for such Governmental Permits as to which the
failure to so own, hold or possess would not have a Material Adverse Effect on
the Company.  Schedule 3.10 sets forth a list and brief description of each such
Governmental Permit.  The Company has fulfilled and performed its respective
obligations under each of such Governmental Permits, and no event has occurred
or condition or state of facts exists which constitutes or, after notice or
lapse of time or both, would constitute a breach or default under any such
Governmental Permit, or permits or, after notice or lapse of time or both, would
permit revocation or termination of any such Governmental Permit, or which might
adversely affect the right of the Company under any such Governmental Permit.
No notice of cancellation, of default or of any dispute concerning any
Governmental Permit, or of any event, condition or state of facts described in
the preceding sentence, has been received or is known by the Company or the
Shareholders.  Except as set forth on Schedule 3.10, each of the Governmental
Permits is valid, subsisting and in full force and effect and will continue in
full force and effect after the Closing, in each case without (i) the occurrence
of any breach, default or forfeiture of rights thereunder or (ii) the consent,
approval, or act of, or the making of any filing with, any Governmental Body or
other party.

     3.11. Real Property.  Schedule 3.11 contains a brief description of each
           -------------
parcel of real property owned by the Company (the "Owned Real Property") and of
each option held by the Company to acquire any real property.  Complete and
correct copies of any instruments evidencing Encumbrances, commitments for the
issuance of title insurance, title opinions, surveys and appraisals in the
possession of the Company or the Shareholders or any policies of title insurance
currently in force and in the possession of the Company or the Shareholders with
respect to each such parcel have heretofore been delivered to the Purchaser.

     3.12. Real Property Leases.  Schedule 3.12 sets forth a list and brief
           --------------------
description of each lease or similar agreement under which the Company is lessee
of, or holds or operates, any real

                                       7
<PAGE>

property owned by any third party. Except as set forth on Schedule 3.12, (i)
there are no subleases, tenancies or other rights of occupancy affecting all or
any part of such leases, (ii) the Company has the right to quiet enjoyment of
the premises described in any lease identified on such Schedule for the full
term of each such lease or similar agreement (and any renewal option related
thereto) relating thereto, and (iii) the leasehold or other interest of the
Company therein is not subject or subordinate to any Encumbrance held by persons
claiming by, through or under the Company, except for Permitted Encumbrances.

     3.13.  Condemnation.  Neither the whole nor any part of any real property
            ------------
listed on Schedule 3.11 or Schedule 3.12 is subject to any pending suit for
condemnation or other taking by any public authority and, to the knowledge of
the Company or the Shareholders, no such condemnation or other taking is
threatened.

     3.14.  Personal Property.  Schedule 3.14 contains a detailed list as of the
            -----------------
date of this Agreement of all machinery, equipment, vehicles, furniture and
other personal property owned by the Company having an original cost of $10,000
or more.

     3.15.  Personal Property Leases.  Schedule 3.15 contains a brief
            ------------------------
description of each lease or other agreement or right, whether written or oral,
under which the Company is lessee of, or holds or operates, any machinery,
equipment, computer hardware and related peripheral equipment, vehicle or other
tangible personal property owned by a third party.

     3.16.  Intellectual Property.
            ---------------------

            (a)  Schedule 3.16 contains a list and detailed description of (i)
all United States and foreign patents and patent applications and patent
disclosures owned or controlled by the Company; (ii) all United States and
foreign copyrights, registered or unregistered, copyrighted works and copyright
registration applications owned or controlled by the Company; (iii) all computer
software programs and software systems (including, without limitation, all data,
databases, compilations, tool sets, related documentation and materials, whether
in source code, object code or human readable form and regardless of media),
developed by or for the Company or otherwise used in the Business ("Software");
(iv) all United States, state and foreign trademarks, service marks and trade
names for which registrations have been issued or applied for by the Company,
and all other United States, state and foreign trademarks, service marks and
trade names owned or used by the Company or in which the Company holds any
right, license, sublicense or interest; (v) all agreements, commitments,
contracts, understandings, licenses, sublicenses, assignments and indemnities
which relate or pertain to any asset, property or right of the character
described in the preceding clause to which the Company is a party; (vi) all
licenses, sublicenses or agreements which are material to the Business and which
relate or pertain to mailing lists, know-how, trade secrets, disclosures or uses
of ideas to which the Company is a party, showing in each case the parties and
the material terms and (vii) all registered and unregistered assumed or
fictitious names under which the Company is conducting the Business or has
within the previous three years conducted the Business.

            (b)  All patents listed on Schedule 3.16 as being owned, controlled
or used by the Company are valid and in force and all patent applications of the
Company listed therein are in good standing, all without challenge of any kind,
and, except as otherwise set forth on Schedule 3.16, the Company owns the entire
right, title and interest in and to such patents and patent applications, free
and clear of all Encumbrances, except Permitted Encumbrances. All of the
registrations for trademarks, service marks, trade names and copyrights listed
on Schedule 3.16 as being owned,

                                       8
<PAGE>

controlled or used by the Company are valid and in force and all applications
for such registrations are pending and in good standing, all without challenge
of any kind, and, except as otherwise set forth on Schedule 3.16, the Company
owns the entire right, title and interest in and to all such trademarks, service
marks, trade names and copyrights so listed as well as the registrations and
applications for registration therefor, free and clear of all Encumbrances,
except Permitted Encumbrances. Correct and complete copies of all the patents
and patent applications and of all of the trademarks, service marks, trade names
and copyrights and registrations, applications or deposits therefor and all the
agreements, commitments, contracts, understandings, licenses, sublicenses,
assignments, and indemnities listed on Schedule 3.16 have heretofore been
delivered or otherwise made available by the Company to the Purchaser.

           (c)  Except as set forth in Schedule 3.16, all of the Company's
Computerized Assets are Year 2000 Compliant.

     3.17. Accounts Receivable, Inventories.
           --------------------------------

           (a)  All accounts receivable of the Company have arisen from bona
fide transactions by the Company in the ordinary course of business and, to the
knowledge of the Company or the Shareholders, are not subject to counterclaims
or setoffs. Except as set forth on Schedule 3.17, no such receivable has been
outstanding for more than 90 days beyond its due date. All of the accounts
receivable reflected on the Balance Sheet, taken as a whole, are good and
collectible in the ordinary course of business at the aggregate amounts recorded
in respect thereof, net of any applicable allowance for doubtful accounts, which
allowances will be determined on a basis consistent with the basis used in
determining the allowances for doubtful accounts reflected in the Balance Sheet.

           (b)  The inventories of the Company (including raw materials,
supplies, work-in-process, finished goods and other materials) are in good,
merchantable and useable condition and (i) are reflected in the Balance Sheet in
accordance with generally accepted accounting principles and (ii) are reflected
in the books and records of the Company at the lower of average cost or market
value. The inventory obsolescence policies of the Company are appropriate for
the nature of the products sold and the marketing methods used by the Company
and the reserve for inventory obsolescence contained in the Balance Sheet fairly
reflects the amount of obsolete inventory as of the Balance Sheet Date. The
Company has heretofore delivered to the Purchaser a list of places where
material inventories of the Company are located.

     3.18. Title to Assets.  The Company has good and marketable title in fee
           ---------------
simple absolute to all Owned Real Property and to all buildings, structures and
other improvements thereon, in each case free and clear of all Encumbrances,
except for Permitted Encumbrances and except as set forth in Schedule 3.18.  The
Company has good title to all of its other assets reflected on the Balance Sheet
as being owned by it and all of the assets thereafter acquired by it (except to
the extent that such assets have been disposed of after the Balance Sheet Date
in the ordinary course of business consistent with past practice), free and
clear of all Encumbrances, except for Permitted Encumbrances and except as set
forth in Schedule 3.18.

     3.19. Employees.  Schedule 3.19 contains a list of the employees of the
           ---------
Company as of the date of Closing, and the annual compensation and a description
of the fringe benefits provided to each such employee as of such date.  As of
the date hereof, all bonuses payable to employees of the Company for services
performed on or prior to the date hereof have been paid in full and there are no

                                       9
<PAGE>

outstanding agreements, understandings or commitments of the Company with
respect to any bonuses or increases in compensation.

     3.20.  Employee Matters.  The Company has complied in all material respects
            ----------------
with all applicable laws, rules and regulations which relate to wages, hours,
discrimination in employment and collective bargaining and to the operation of
its business and is not liable for any arrears of wages or any taxes or
penalties for failure to comply with any of the foregoing.  The Company and the
Shareholders believe that the Company's relations with its employees are
satisfactory.  Except as set forth in Schedule 3.20, the Company is not a party
to any collective bargaining agreement, the Company has complied in all material
respects with all collective bargaining agreements listed in such Schedule and
the Company is not a party to, and it is not affected by or threatened with, any
dispute or controversy with a union or with respect to unionization or
collective bargaining involving its employees.  The Company is not materially
affected by any dispute or controversy with a union or with respect to
unionization or collective bargaining involving any supplier or customer of the
Company.  Schedule 3.20 sets forth a description of any union organizing or
election activities involving any non-union employees of the Company which have
occurred since January 1, 1995 or, to the knowledge of the Company or the
Shareholders, are threatened as of the date hereof.

     3.21.  Employee Benefit Plans.
            ----------------------

            (a)  Set forth on Schedule 3.21(a) is a true and complete list of
each "employee pension benefit plan" (as such term is defined in Section 3(2) of
ERISA) (the "Pension Plans") and each "employee welfare benefit plan" (the
"Welfare Plans") maintained by the Company or which provides or will provide
benefits to present or prior employees of the Company (the Pension Plans and
Welfare Plans being the "ERISA Benefit Plans"). In addition, set forth on
Schedule 3.21(a) is a true and complete list of each stock ownership, stock
purchase, stock option, phantom stock, bonus, deferred compensation, incentive
compensation, severance or termination pay, change of control and death benefit
plan, agreement or arrangement maintained by the Company (the "Non-ERISA
Commitments"). Except as set forth on Schedule 3.21(a), the Company has never
maintained or been required to contribute to any "employee pension benefit plan"
subject to Section 302 or Title IV of ERISA or any multiemployer plan," as such
term is defined in Section 3(37) of ERISA. The Company does not have, and has
never had, any ERISA Affiliate. Except as disclosed on Schedule 3.21(a), true
copies of each ERISA Benefit Plan and Non-ERISA Commitment, the annual reports
required to be filed under ERISA for the last two years with respect to any
ERISA Benefit Plans, and the financial statements and actuarial reports for the
most recent two years for which such statements and reports exist with respect
to any Pension Plan have been delivered or made available to The Purchaser.

            (b)  Neither the Company nor the Shareholders, any other
"disqualified person" (within the meaning of Section 4975 of the Code) or any
"party in interest" (within the meaning of Section 3(14) of the Code) has
engaged in any non-exempt prohibited transaction (within the meaning of Section
4975 of the Code or Section 406 of ERISA), nor has any breach of fiduciary duty
occurred, with respect to any of the ERISA Benefit Plans. Except as disclosed on
Schedule 3.21(b), each of the ERISA Benefit Plans (i) has been administered in
accordance with its terms and (ii) complies in form, and has been maintained in
accordance with, the requirements of ERISA and, where applicable, the Code.
Except as disclosed on Schedule 3.21(b), the Company has no obligations under
any of the ERISA Benefit Plans or otherwise to provide health benefits to its
former employees, except as specifically required by law. The Company has at all
times complied with the health care continuation requirements of Part 6 of
Title I of ERISA. Except as disclosed on

                                       10
<PAGE>

Schedule 3.21(b), each Pension Plan intended to be qualified under
Section 401(a) of the Code has received a favorable determination letter from
the Internal Revenue Service, and to the knowledge of the Company or the
Shareholders nothing has occurred and no condition exists that could cause the
loss of such qualification. All contributions or payments that are due from the
Company with respect to the ERISA Benefit Plans and Non-ERISA Commitments have
been paid and any related insurance and third party administration contracts
remain in full force and effect. There is no pending or to the knowledge of the
Company or the Shareholder threatened claim in respect of any of the ERISA
Benefit Plans or Non-ERISA Commitments other than routine claims for benefits in
the ordinary course of business. The Company has not taken any action, nor has
any event occurred, which has resulted or will likely result in any liability
under Title IV of ERISA, including any withdrawal liability with respect to any
"multiemployer plan" as defined in Section 4001(a) of ERISA.

     3.22.  Contracts.  Except as set forth on Schedule 3.22 or any other
            ---------
Schedule hereto, the Company is not a party to or bound by:

            (a)  any contract for the purchase, sale or lease of real property
or any option to purchase or sell real property;

            (b)  any indebtedness, obligation or liability for borrowed money,
or liability for the deferred purchase price of property in excess of $50,000,
or any instrument guaranteeing any indebtedness, obligation or liability, or any
obligation to incur any of the foregoing;

            (c)  any joint venture, partnership or other arrangement involving a
sharing of profits involving the Company;

            (d)  any agreement which is material to the Business and which
includes provisions regarding minimum volumes or volume discounts, excluding
outstanding price quotations;

            (e)  any agreement which is material to the Business and pursuant to
which a rebate, discount, bonus, commission or other payment with respect to the
sale of any product of the Company will be payable or required after the
Closing;

            (f)  any guarantee of the obligations of the Company's customers,
suppliers, officers, directors, employees or Affiliates or others;

            (g)  any consignment, distributor, dealer, manufacturer's
representative, sales agency, advertising representative or advertising or
public relations contract which is material to the Business;

            (h)  any agreement limiting the Company's ability to engage in any
business anywhere in the world;

            (i)  any contract which provides for, or relates to, any non-
competition or confidentiality arrangement with any Person, including any
current or former officer or employee of the Company;

            (j)  any contract or group of related contracts for capital
expenditures in excess of $50,000 for any single project or related series of
projects;

                                       11
<PAGE>

           (k)  any contract which involves payments or receipts by the Company
of more than $50,000; or

           (1)  any contract not made in the ordinary course of business.

     3.23. Status of Contracts.  Each of the leases, contracts and other
           -------------------
agreements listed on Schedules 3.12, 3.15, 3.16, 3.21(a) and 3.22,
(collectively, the "Material Contracts"), constitutes a valid and binding
obligation of the Company and, to the knowledge of the Company or the
Shareholders, the other parties thereto, and is in full force and effect and
each of the Material Contracts (except as set forth in Schedule 3.23 and except
for those Material Contracts which by their terms will expire prior to the
Closing Date or will be otherwise terminated prior to the Closing Date in
accordance with the provisions hereof) will continue in full force and effect
after the Closing Date, in each case without breaching the terms thereof or
resulting in the forfeiture or impairment of any rights thereunder and without
the consent, approval or act of, or the making of any filing with, any other
party.  The Company has fulfilled and performed its obligations under each of
the Material Contracts and the Company is not in, or, to the knowledge of the
Company or the Shareholders, alleged to be in, breach or default under, nor is
there or, to the knowledge of the Company or the Shareholders, is there alleged
to be any basis for termination of any of the Material Contracts.  To the
knowledge of the Company or the Shareholders, no other party to any of the
Material Contracts has breached or defaulted thereunder.  No event has occurred
and no condition or state of facts exists which, with the passage of time or the
giving of notice or both, would constitute such a default or breach by the
Company or, to the knowledge of the Company or the Shareholders, by any other
party.  The Company is not currently renegotiating any of the Material Contracts
or paying liquidated damages in lieu of performance thereunder.

     3.24. No Violation, Litigation or Regulatory Action.  Except as set forth
           ---------------------------------------------
on Schedule 3.24:

           (a)  The Company has complied with all laws, regulations, rules,
writs, injunctions, ordinances, franchises, decrees, stipulations, awards or
orders of any Governmental Body which are applicable to the Company or its
Business;

           (b)  No notice has been served upon the Company by any Governmental
Body or other person of any violation of any Requirements of Law or calling
attention to the necessity of any work, repairs, new construction, installation
or alteration of any real or personal property owned, leased or used by the
Company;

           (c)  There are no lawsuits, claims, suits, or proceedings pending or,
to the knowledge of the Company or the Shareholders, threatened against the
Company or investigations pending regarding the Company nor, to the knowledge of
the Company or the Shareholders, is there any basis for any of the same, and
there are no lawsuits, suits or proceedings pending or contemplated in which the
Company is the plaintiff or claimant; and

           (d)  There is no action, suit or proceeding pending or, to the
knowledge of the Company or the Shareholders, threatened which questions the
legality or propriety of the transactions contemplated by this Agreement.

     3.25. Insurance.  The Company maintains policies of fire and casualty,
           ---------
liability (general, products and other liability), workers' compensation and
other forms of insurance and bonds in such

                                       12
<PAGE>

amounts and against such risks and losses as are insured against by companies
engaged in the same or a similar business. Schedule 3.25 sets forth a list and
brief description (including nature of coverage, limits, deductibles, premiums
and the loss experience for the most recent five years with respect to each type
of coverage) of all policies of insurance maintained, owned or held by the
Company during the period from January 1, 1995 up to and including the date
hereof. The Company has complied with each of such insurance policies and has
not failed to give any notice or present any claim thereunder in a due and
timely manner. Except as disclosed in Schedule 3.25, the full policy limits
(subject to deductibles provided in such policies) are available and unimpaired
under each such policy and to the knowledge of the Company or the Shareholders,
no insurer under any of such policies has a basis to void such policy on grounds
of non-disclosure on the part of the policyholder or the insured thereunder.
Each of such policies is in full force and effect and will not in any way be
affected by or terminate or lapse by reason of the transactions contemplated by
this Agreement.

     3.26.  Environmental Protection.
            ------------------------

            (a)  All Facilities whether currently or heretofore owned, operated
or leased by the Company were, during any period of ownership, operation or
leasing by the Company, and, to the extent currently owned, operated or leased
by the Company, continue to be in compliance with all applicable federal, state
or local statutes, laws, ordinances, codes, rules, regulations, guidelines or
any binding determinations of any Governmental Body (including consent decrees
and administrative orders) relating to protection of the environment or public
or worker health and safety (collectively, "Environmental Laws").

            (b)  Except as set forth in Schedule 3.26(b): (i) the Company's past
and present operations have complied and are in compliance with all applicable
Environmental Laws; (ii) the Company has obtained all environmental, health and
safety Governmental Permits necessary for the operation of the Business, and all
such Governmental Permits are in good standing and the Company is in compliance
with all material terms and conditions of such permits; (iii) none of the
Company, nor any of the Company's Facilities or its past or present operations,
is subject to any on-going investigation by, order from or agreement with any
Person (including without limitation any prior owner or operator of any Company
property) respecting (x) any Environmental Laws, (y) any Remedial Action or (z)
any claim of Losses and Expenses arising from the Release or threatened Release
of a Contaminant into the environment; and (iv) the Company is not subject to
any judicial or administrative proceeding, order, judgment, decree or settlement
alleging or addressing a violation of or liability under any Environmental Laws.

            (c)  There has been no Release by the Company of any Contaminant on,
in, or under or from any Facility now or previously owned, operated or leased by
the Company.

            (d)  The Company is not subject to the environmental liabilities of
any third party, whether by contractual agreement or operation of law.

     3.27.  Customers and Suppliers.  Set forth in Schedule 3.27 hereto is (i) a
            -----------------------
list of names and addresses of the ten largest customers and the ten largest
suppliers (measured by dollar volume of purchases or sales in each case) of the
Company and the percentage of the Company's business which each such customer or
supplier represents or represented during each of the years ended December 31,
1997 and December 31, 1998; and (ii) copies of the forms of purchase order for
inventory and other supplies and sales contracts for finished goods used by the
Company.  Except as set forth in Schedule 3.27, there exists no actual or
threatened termination, cancellation or limitation

                                       13
<PAGE>

of, or any modification or change in, the business relationship of the Company
with any customer or group of customers or supplier or group of suppliers listed
in Schedule 3.27, of whose purchases or sales individually or in the aggregate
are material to the operations of the Business.

     3.28.  Shareholders' Assets.  The Shareholders do not own, directly or
            --------------------
indirectly, any assets or properties relating to or used by the Company in the
Business.

     3.29.  No Finder.  The Company has not paid or become obligated to pay any
            ---------
fee or commission to any broker, finder or intermediary for or on account of the
transactions contemplated by this Agreement.

     3.30.  Transactions with Affiliates.  Except as set forth on Schedule 3.30,
            ----------------------------
since January 1, 1998, there have been no transactions in respect of the Company
between the Company and any officer, director or other Affiliate of the Company
(including spouses, children and other relatives of any of the foregoing).

     3.31.  Disclosure.  None of the representations or warranties of the
            ----------
Company contained herein, none of the information contained in the Schedules
referred to in this Article III, and none of the other information or documents
furnished or to be furnished to the Purchaser or any of its representatives by
the Company, the Shareholders or their representatives pursuant to the terms of
this Agreement, is false or misleading in any material respect or omits to state
a fact herein or therein necessary to make the statements herein or therein not
misleading in any material respect.  There is no fact which adversely affects or
in the future is likely to adversely affect the Company's assets or the Business
in any material respect which has not been set forth or referred to in this
Agreement or the Schedules hereto.

                                   ARTICLE IV
                       REPRESENTATIONS AND WARRANTIES OF
                                THE SHAREHOLDERS

     The Shareholders represent and warrant to the Purchaser as follows:

     4.1.   Authority.  The Shareholders have the capacity to enter into this
            ---------
Agreement, to consummate the transactions contemplated hereby and thereby and to
comply with the terms, conditions and provisions hereof and thereof.  This
Agreement constitutes the valid and binding obligation of the Shareholders,
enforceable in accordance with its terms, subject to (i) general principles of
equity, regardless of whether enforcement is sought in a proceeding in equity or
at law, and (ii) bankruptcy, reorganization, insolvency, fraudulent conveyance,
moratorium, receivership or other similar laws relating to or affecting
creditors' rights generally.

     4.2.   Non-Contravention, Required Consents.  Except as set forth on
            ------------------------------------
Schedule 4.2 attached hereto, neither the execution of this Agreement by the
Shareholders nor the consummation of the transactions contemplated hereby or
thereby (i) will result in the breach of any term or provision of, constitute a
default under, or accelerate or change the performance otherwise required under,
or result in the creation of any Encumbrance upon any Company Common Stock owned
by the Shareholders pursuant to any agreement (including without limitation any
loan agreement or promissory note), indenture, instrument, order, law or
regulation to which the Shareholders are a party or by which the Shareholders
are bound or (ii) require the approval, consent, waiver,

                                       14
<PAGE>

authorization or act of, or the making by the Shareholders of any declaration,
filing or registration with any third party or any Governmental Body.

     4.3. Ownership of Company Common Stock.  The number and percentage of the
          ---------------------------------
shares of Company Common Stock held by the Shareholders are set forth on
Schedule 3.3 attached hereto.  Such shares are owned by the Shareholders as
indicated on said Schedule 3.3 of record and beneficially, free and clear of all
Encumbrances (other than restrictions under the Securities Act of 1933, as
amended (the "Securities Act"), and the rules and regulations thereunder, and
state securities laws).

     4.4. Compliance with Law.  The Shareholders acknowledge that the shares of
          -------------------
the Purchaser's Shares have not been and will not be registered under the
Securities Act or any state securities laws and may not be resold without
compliance with the Securities Act, any applicable state securities laws and the
provisions of Article X.  The Shareholders further represent, warrant and
covenant that (i) the Purchaser's Shares are being acquired solely for their own
accounts, for investment purposes only, and with no present intention of
distributing, selling or otherwise disposing of it in connection with a
distribution, and (ii) none of the Purchaser's Shares will be offered, sold,
assigned, pledged, hypothecated, transferred or otherwise disposed of except
after full compliance with all of the applicable provisions of the Securities
Act and the rules and regulations of the Securities and Exchange Commission and
after full compliance with any applicable state securities laws and the
provisions of Article X.

     4.5. Economic Risk, Sophistication.  The Shareholders represent and
          -----------------------------
warrant that each Shareholder (i) is an "accredited investor" as such term is
defined in Regulation D promulgated under the Securities Act, (ii) is able to
bear the economic risk of an investment in the shares of the Purchaser's common
stock to be acquired pursuant to this Agreement, (iii) can afford to sustain a
total loss of such investment, and (iv) has such knowledge and experience in
financial and business matters that he is capable of evaluating the merits and
risks of the proposed investment in the Purchaser's common stock.  The
Shareholders further represent and warrant that each Shareholder has received,
or had access to, information to which a reasonable investor would attach
significance in making investment decisions and, without limiting the generality
of the foregoing, has had an adequate opportunity to ask questions and receive
answers from the officers of the Purchaser concerning any and all matters
relating to the Purchaser and the transactions described herein, including the
background and experience of the current officers and directors of the
Purchaser.  The Shareholders represent and warrant that they have asked any and
all questions in the nature described in the preceding sentence and all
questions have been answered to their satisfaction.

                                   ARTICLE V
                      ADDITIONAL AGREEMENTS OF THE PARTIES

     5.1. Ordinary Course.  The Company and the Shareholders, jointly and
          ---------------
severally, covenant that prior to the Closing, without the Purchaser's written
consent, the Company shall not:  (i) take or authorize any of the actions set
forth in Section 3.6(b); (ii) issue or sell any shares of its capital stock of
any class, or issue or sell any securities convertible into, or options with
respect to, or warrants to purchase or rights to subscribe to, any shares of its
capital stock of any class, or make any commitment to issue or sell any such
shares or securities; (iii) directly or indirectly solicit or negotiate with
respect to any inquiries or proposals from any person relating to: (x) the
merger or consolidation of the Company with any person; (y) the direct or
indirect acquisition by any person of any of the assets of the Company (other
than the sale of assets in the ordinary course of business

                                       15
<PAGE>

consistent with past practice, not otherwise prohibited by this Section 5.1); or
(z) the acquisition of direct or indirect beneficial ownership or control of the
Company or any securities thereof by any person; (iv) prepare or file any Tax
Return inconsistent with past practice or, on any such Tax Return, take any
position, make any election, or adopt any method that is inconsistent with
positions taken, elections made or methods used in preparing or filing similar
Tax Returns in prior periods (including, without limitation, positions,
elections or methods which would have the effect of deferring income to periods
ending after the Closing Date or accelerating deductions to periods ending on or
prior to the Closing Date); or (v) agree or commit to do or authorize any of the
foregoing.

     5.2. Access Prior to Closing; Certain Notices.
          ----------------------------------------

          (a)  Upon reasonable notice, the Company, each of its directors,
officers, agents and employees, and the Shareholders shall afford the Purchaser
and its representatives, (including, without limitation, its independent public
accountants, banks or other lenders' representatives and attorneys) reasonable
access during regular business hours from the date hereof through the Closing to
any and all of the premises, properties, contracts, books, records, data and
personnel of the Company or relating to its operations.  The Purchaser may
contact the customers and vendors of the Company upon prior notice to the
Company.  The Company, its directors, officers, agents and employees, and the
Shareholders shall cooperate fully in connection with the foregoing.  The
Company and the Shareholders shall use their respective best efforts to provide
to the Purchaser such information and documents concerning the Company as
reasonably may be requested and obtained without undue effort or expense upon
the part of the Company or the Shareholders.  The Company and the Shareholders
promptly shall notify the Purchaser of any change or event which would
reasonably be expected to materially and adversely affect the Business or the
results of operations, properties or condition (financial or otherwise) of the
Company.

          (b)  The Company covenants that prior to the Closing the Company will
promptly notify the Purchaser of any notice of any pending, threatened or
contemplated lawsuit, claim, suit, proceeding or Governmental Body investigation
which, if existing on the date hereof, would have been disclosable pursuant to
Section 3.24(b) or (c).

     5.3. Regulatory and Other Authorizations.
          -----------------------------------

          (a)  The Company, the Purchaser and the Shareholders will act
diligently and reasonably, and shall cooperate in good faith with each other, to
secure before the Closing Date, each consent, approval or waiver, in form and
substance reasonably satisfactory to the Company or the Purchaser, required to
be obtained to satisfy the conditions set forth in Section 6.1 and Section 6.2
below; provided that none of the Company, the Shareholders or the Purchaser
shall have any obligation to pay any consideration in order to obtain any such
consents or approvals.

          (b)  During the period prior to the Closing Date, the Company, the
Purchaser and the Shareholders shall act diligently and reasonably, and shall
cooperate with each other, to secure any consents and approvals of any
Governmental Body required to satisfy the conditions set forth in Sections 6.1
and 6.2 below; provided, however, that the Company shall not make any agreement
               -----------------
or understanding affecting its assets or the Business as a condition for
obtaining any such consents or approvals except with the prior written consent
of the Purchaser.

                                       16
<PAGE>

     5.4. Further Assurances.  At any time and from time to time at or after
          ------------------
the Closing, the parties agree to cooperate with each other, to execute and
deliver such other documents, instruments of transfer or assignment, files,
books and records and do all such further acts and things as may be reasonably
required to carry out the transactions contemplated hereby.

     5.5. Company's Financial Statements.  The Company shall promptly provide
          ------------------------------
to the Purchaser copies of any financial statements prepared with respect to the
Company as of a date or for a period subsequent to that reflected in the
Company's Financial Statements.

     5.6. Delivery of Documents.  Subject to the satisfaction of the conditions
          ---------------------
to their respective obligations contained in Article VI, the parties shall cause
the delivery of the respective documents required to be delivered or caused to
be delivered by them pursuant to Article VII.

     5.7. Covenant Not to Compete or Solicit Business.  In consideration of the
          -------------------------------------------
purchase price paid to the Shareholders, and to more effectively protect the
value and goodwill of the assets and business of the Company to be acquired
hereby, the Shareholders covenant and agree that, for a period ending on the
third anniversary of the Closing Date, neither Shareholder nor any of the
Shareholder's Affiliates will:

          (i)  directly or indirectly (whether as principal, agent, independent
     contractor, partner or otherwise) own, manage, operate, control,
     participate in, perform services for, or otherwise carry on, a business
     similar to or competitive with the business of the Company or any of its
     Subsidiaries or Affiliates (collectively, the "Managed Companies") anywhere
     in the states in which the Company does business; or

          (ii) induce or attempt to persuade any employee, agent or customer of
     the Managed Companies to terminate such employment, agency or business
     relationship in order to enter into any such relationship on behalf of any
     other business organization in competition with the Managed Companies.

In addition, each Shareholder covenants and agrees that neither he nor any of
his Affiliates will divulge or make use of any trade secrets or other
confidential information of the business of the Managed Companies other than to
disclose such secrets and information to the Purchaser or its Affiliates.
Without limiting the right of the Purchaser to pursue all other legal and
equitable rights available to it for violation of this Section 5.7 by a
Shareholder or his Affiliates, it is agreed that other remedies cannot fully
compensate the Purchaser or the Company for such a violation and that the
Purchaser and the Company shall each be entitled to injunctive relief to prevent
violation or continuing violation thereof.  It is the intent and understanding
of each party hereto that if, in any action before any court or agency legally
empowered to enforce this Section 5.7, any term, restriction, covenant or
promise in this Section 5.7 is found to be unreasonable and for that reason
unenforceable, then such term, restriction, covenant or promise shall be deemed
modified to the extent necessary to make it enforceable by such court or agency.
Nothing contained in this Section 5.7 shall limit or otherwise affect a
Shareholder's obligation under any employment agreement entered into with the
Purchaser.

     5.8. Continued Relationships.  After the date hereof and through the
          -----------------------
Closing the Company shall use all reasonable efforts to preserve intact the
business of the Company and keep available the services of its officers and
employees and maintain good relationships with suppliers, advertising and other
customers and others having business relations with the Company.

                                       17
<PAGE>

     5.9.  Transfer of the Company's Common Stock.  The Shareholders covenant
           --------------------------------------
that, prior to the Closing, without the Purchaser's written consent, the
Shareholders shall not (i) sell, transfer' mortgage, pledge, otherwise dispose
of or suffer to be imposed any Encumbrance on any share of Company Common Stock
held by them or (ii) grant to any person (other than the Purchaser) any proxy or
other right to vote any shares of Company Common Stock held by them or over
which they exercise voting power in a manner that would be inconsistent with its
covenants set forth in this Agreement.

     5.10. Preserve Accuracy of Representations and Warranties.  Between the
           ---------------------------------------------------
date hereof and the Closing Date, each of the parties hereto shall refrain from
taking any action which would render any of its or his respective
representations or warranties contained in Articles II, III, or IV of this
Agreement inaccurate as of the Closing Date.  Each party shall promptly notify
the other of any action, suit or proceeding that shall be instituted or
threatened against such party to restrain, prohibit or otherwise challenge the
legality of any transaction contemplated by this Agreement.

     5.11. Notification by the Company of Certain Matters.  The Company shall
           ----------------------------------------------
promptly advise the Purchaser in writing of (i) any change or event having a
Material Adverse Effect on the Company, (ii) any notice or other communication
from any third Person alleging that the consent of such third Person is or may
be required in connection with the transactions contemplated by this Agreement,
and (iii) any material default under any Material Contract or event which, with
notice or lapse of time or both, would become such a default on or prior to the
Closing Date and of which the Company or the Shareholders have knowledge.

     5.12. Necessary Actions.  The Purchaser, the Company and the Shareholders
           -----------------
shall use all reasonable efforts to effect the purchase and sale of the Stock as
promptly as possible after the date hereof.

     5.13. Taxes.  Any stock transfer Taxes, sales Taxes, use Taxes, or gains
           -----
Taxes, or other similar Taxes attributable to the purchase and sale of the Stock
shall be paid by the Shareholders.

     5.14. Working Capital.  The Working Capital of the Company as of the
           -----------------
Closing shall be no less than $____________________.  On the Closing Date the
Shareholders shall deliver to the Purchaser a statement (the "Working Capital
Statement") setting forth their calculation of the Working Capital of the
Company as of the Closing.

                                   ARTICLE VI
                             CONDITIONS TO CLOSING

     6.1.  The Company's and the Shareholders' Conditions to Close.  The
           -------------------------------------------------------
obligations of the Company and the Shareholders under this Agreement are subject
to the satisfaction at or prior to the Closing of each of the following
conditions, but compliance with any or all of such conditions may be waived, in
writing, by the Company or the Shareholders, as the case may be:

           (a) The representations and warranties of the Purchaser contained in
this Agreement shall be true and correct on the date hereof and on the Closing
Date (except to the extent that they expressly relate to an earlier date);

                                       18
<PAGE>

          (b)  The Purchaser shall have performed and complied in all material
respects with all of the covenants and agreements contained in this Agreement
and satisfied all of the conditions required by this Agreement to be performed
or complied with or satisfied by the Purchaser at or prior to the Closing;

          (c)  The Purchaser and the Company shall have received all approvals
and actions of or by all Governmental Bodies, which are necessary to consummate
the transactions contemplated hereby;

          (d)  On the Closing Date, there shall be no injunction, restraining
order or decree of any nature of any court or Governmental Body in effect that
restrains or prohibits the consummation of the transactions contemplated by this
Agreement;

          (e)  No action, suit or proceeding shall have been instituted by any
person or entity, or threatened by any Governmental Body, before a court or
Governmental Body, to restrain or prevent the carrying out of the transactions
contemplated by this Agreement;

          (f)  A certificate, dated as of the Closing, signed by an officer of
the Purchaser to the effect set forth in clauses (a) through (e), inclusive, of
this Section 6.1;

          (g)  The Purchaser shall have entered into the Escrow Agreement, in
the form of Exhibit "1" hereto, the Shareholders Agreement, in the form of
            -----------
Exhibit "2" hereto, and the Urich Employment Agreement, and the Curtis
----------
Employment Agreement, in the form of Exhibits "3-A" and "3-B" hereto.
                                     -------------       ---

     6.2. The Purchaser's Conditions to Close.  The obligations of the
          -----------------------------------
Purchaser under this Agreement are subject to the satisfaction at or prior to
the Closing of each of the following conditions, but compliance with any or all
of any such conditions may be waived, in writing, by the Purchaser:

          (a)  The Purchaser shall have conducted a thorough due diligence
review (the "Due Diligence Review") of the Business and the Company and shall be
satisfied with the results and findings thereof. The Company and the
Shareholders agree that the Purchaser and the Purchaser's representatives, legal
counsel, accountants, advisors and representatives shall be given, until the
Closing, full access to: (i) the assets and properties of the Company; (ii) the
books and records (including electronic records) of the Company pertaining to
the Business, including, but not limited to, income tax returns, sales and use
tax returns, the Company's Financial Statements, and related materials, bank
statements, invoices, accounts receivable, accounts payable and supplier lists;
and (iii) all files maintained by the Company and the Company's attorneys,
brokers or other agents relating to the Business. The Company shall permit the
Purchaser to copy, at the Purchaser's expense, the contents of all such books,
records and files. The Purchaser shall treat all information obtained as a
result of the Due Diligence Review as confidential and proprietary information
belonging to the Company;

          (b)  The representations and warranties of the Company and the
Shareholders contained in this Agreement shall be true and correct on the date
hereof and on the Closing Date (except to the extent that they expressly relate
to an earlier date);

                                       19
<PAGE>

          (c)  The Company and the Shareholders shall have performed and
complied in all material respects with all the covenants and agreements
contained in this Agreement and satisfied all the conditions required by this
Agreement to be performed or complied with or satisfied by it or them at or
prior to the Closing;

          (d)  The Purchaser and the Company shall have received all approvals
and actions of or by all Governmental Bodies, which are necessary to consummate
the transactions contemplated hereby;

          (e)  On the Closing Date, there shall be no injunction, restraining
order or decree of any nature of any court or Governmental Body in effect that
restrains or prohibits the consummation of the transactions contemplated by this
Agreement;

          (f)  No action, suit or proceeding shall have been instituted by any
person or entity, or threatened by any Governmental Body, before a court or
Governmental Body, to restrain or prevent the carrying out of the transactions
contemplated by this Agreement or that would, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect on the Business or the
results of operations, properties or condition (financial or otherwise) of the
Company;

          (g)  The Company shall have received all necessary consents or
approvals (including an approval of the transaction by the Company's Board of
Directors and its remaining shareholders), in form and substance reasonably
satisfactory to the Purchaser, to the transactions contemplated by this
Agreement;

          (h)  Since the Balance Sheet Date, there shall not have occurred any
change which would have or would be likely to have a Material Adverse Effect
with respect to the Company;

          (i)  The Shareholders shall have entered into the Escrow Agreement, in
the form of Exhibit "1" hereto and the Shareholders Agreement, in the form of
            -----------
Exhibit "2" hereto, Alex Urich shall have entered into the Urich Employment
-----------
Agreement, in the form of Exhibit "3-A" hereto, and Michael Curtis shall have
                          -------------
entered into the Curtis Employment Agreement, in the form of Exhibit "3-B"
                                                             -------------
hereto;

          (j)  The Purchaser shall have received the Working Capital Statement;

          (k)  Certificates, dated as of the Closing, signed by the Shareholders
and by the President of the Company, respectively, to the effect set forth in
clauses (b) and (c) of this Section 6.2, with the Certificate signed by the
President of the Company to the additional effect set forth in clauses (b)
through (h), inclusive, of this Section 6.2.

                                  ARTICLE VII
                                  THE CLOSING

     7.1. Deliveries by the Company and the Shareholders.
          ----------------------------------------------

          (a)  At the Closing, the Company and the Shareholders shall deliver
the following to the Purchaser:

                                       20
<PAGE>

               (i)   A certificate of status as of ten (10) days prior to the
     Closing Date from the California Secretary of State stating that the
     Company is a domestic corporation organized under the laws of the State of
     California and has not filed articles of dissolution.

               (ii)  The Agreement, duly executed;

               (iii) The duly executed Shareholders Agreement, Urich Employment
          Agreement and Curtis Employment Agreement;

               (iv)  The certificates described in Sections 6.2(k);

               (v)   The Working Capital Statement;

               (vi)  A true and complete copy of the Articles of Incorporation,
     as in effect on the Closing Date, of the Company, certified by the
     Secretary of State of the State of California and a true and complete copy
     of the By-laws, as in effect on the Closing Date, of the Company, certified
     by the Secretary of the Company; and

               (vii) A certificate from each Shareholder representing eighty
     (80) shares of the Company's common stock (collectively, one hundred sixty
     (160) shares of the Stock), together with a duly executed Assignment
     Separate From Certificate transferring the certificates to the Purchaser.

          (b) At the Closing, each of the Shareholders shall deliver to the
Escrow Holder a certificate representing two hundred forty (240) shares of the
Company's common stock (collectively, four hundred eighty (480) shares of the
Stock), together with a duly executed Assignment Separate From Certificate
transferring the certificates to the Purchaser, a certificate representing
eighty (80) shares of the Company's common stock (collectively one hundred sixty
(160) shares of the Stock), together with a duly executed Assignment Separate
From Certificate transferring the certificates to the Purchaser, and a duly
executed copy of the Escrow Agreement.

     7.2. Purchaser's Deliveries.
          ----------------------

          (a)  At the Closing, the Purchaser shall deliver the following to the
Company and the Shareholders:

               (i)   Copies of duly adopted resolutions of the Purchaser's
     Boards of Directors approving the execution, delivery and performance of
     this Agreement, certified by the Secretary or an Assistant Secretary of the
     Purchaser;

               (ii)  The Agreement, duly executed;

               (iii) Good funds in the amount of Two Hundred Fifty Thousand
          Dollars ($250,000) to each Shareholder;

               (iv)  The duly executed Shareholders Agreement, Urich Employment
          Agreement and Curtis Employment Agreement;

               (v)   The certificate described in Section 6.1(f).

                                       21
<PAGE>

          (b)  At the Closing, the Purchaser shall deliver to the Escrow Holder
a duly executed copy of the Escrow Agreement.

                                 ARTICLE VIII
                                INDEMNIFICATION

     8.1. Indemnification by Shareholders.  The Shareholders agree to indemnify
          -------------------------------
and hold harmless the Purchaser from and against any and all Losses and Expenses
incurred by the Purchaser in connection with or arising from:

          (a)  any breach by the Shareholders or the Company of, or other
failure by the Shareholders or the Company to perform, any of the covenants of
the Shareholders or the Company contained in this Agreement or in any other
agreement (other than the Urich Employment Agreement and the Curtis Employment
Agreement) executed and delivered by or on behalf of the Shareholders or the
Company pursuant to this Agreement or in any certificate or other document
delivered by the Shareholders or the Company pursuant to this Agreement;

          (b)  any breach of any warranty or the inaccuracy of any
representation of the Company or the Shareholders contained in this Agreement or
any certificate or other document delivered by or on behalf of the Company or
the Shareholders pursuant to this Agreement; and

          (c)  any and all stock transfer Taxes or gains Taxes, sales Taxes, or
other similar Taxes imposed by the State of California or any other state, or
any political subdivision thereof, as a result of the transactions contemplated
by this Agreement.

Section 8.1 is an obligation solely of the Shareholders and, from and after the
Closing, the Shareholders shall not have any right of contribution from the
Company, its successors, or any assigns or any of them in respect of the
obligations of the Shareholders under this Section 8.1. The right to recover
from the Shareholders shall not require the Purchaser to seek any recovery from
the Company in respect of any Loss or Expense.

     8.2. Indemnification by Purchaser.  The Purchaser agrees to indemnify and
          ----------------------------
hold harmless the Shareholders from and against any and all Losses and Expenses
incurred by the Shareholders in connection with or arising from:

          (a)  any breach by the Purchaser of, or other failure by the Purchaser
to perform, any of the Covenants of Purchaser contained in this Agreement or in
any other agreement (other than the Urich Employment Agreement or the Curtis
Employment Agreement) executed on behalf of the Purchaser pursuant to this
Agreement or in any certificate or other document delivered by the Purchaser
pursuant to this Agreement; and

          (b)  any breach of any warranty or the inaccuracy of any
representation of the Purchaser contained in this Agreement or any certificate
or other document delivered on behalf of the Purchaser pursuant to this
Agreement.

                                       22
<PAGE>

     8.3.  Notice of Claims.
           ----------------

          (a)  If a party entitled to indemnity pursuant to section 8.1 or 8.2
(the "Indemnified Party") believes that he or it has suffered or incurred any
Loss or incurred any Expense, the Indemnified Party shall so notify the party
obligated to provide indemnification to the indemnifying party (the
"Indemnitor") promptly in writing describing such Loss or Expense, the amount
thereof, if known, and the method of computation of such Loss or Expense, all
with reasonable particularity and containing a reference to the provisions of
this Agreement or other agreement, instrument or certificate delivered pursuant
hereto in respect of which such Loss or Expense shall have occurred. If any
action at law or suit in equity is instituted by or against a third party with
respect to which the Indemnified Party intends to claim any liability or expense
as Loss or Expense under this Article VIII, the Indemnified Party shall promptly
notify the Indemnitor of such action or suit.

          (b)  The amount to which the Indemnified Party shall be entitled under
this Article VIII shall be determined: (i) by written agreement between the
Indemnified Party and the Indemnitor; (ii) by arbitration in accordance with
Section 11.13 hereof, or (iii) by any other means to which the Indemnified Party
and the Indemnitor shall agree. The judgment or decree of a court, or binding
arbitration award, shall be deemed final when the time for appeal, if any, shall
have expired and no appeal shall have been taken or when all appeals taken have
been finally determined. The Indemnified Party shall have the burden of proof in
establishing the amount of the Loss and Expense suffered by it.

          (c)  Notwithstanding the foregoing, the failure of any person hereto
to give any notice described in this Section 8.3 shall not relieve any party
hereto of its obligations hereunder, except to the extent such failure shall
have prejudiced such party.

     8.4. Third Party Claims.
          ------------------

          (a)  Subject to Section 8.4(b), any Indemnified Party under this
Article VIII shall have the right to conduct and control, through counsel of its
choosing, any third party claim, action, suit, proceeding, investigation or
other claim giving rise to a claim for indemnification hereunder (a "Third Party
Claim") and the Indemnified Party may compromise or settle the same, provided
that the Indemnified Party shall give the Indemnitor at least 10 days' advance
notice of any proposed compromise or settlement. The Indemnified Party shall
permit the Indemnitor to participate in the defense of any Third Party Claim
through counsel chosen by it, provided that the fees and expenses of such
counsel shall be borne by the Indemnitor. Subject to Section 8.4(b), any
compromise or settlement with respect to a claim for money damages effected
after the Indemnitor by notice to the Indemnified Party shall have disapproved
such compromise or settlement shall discharge the Indemnitor from liability with
respect to the subject matter thereof, and no amount in respect thereof shall be
claimed as Loss or Expense under this Article VIII.

          (b)  If the remedy sought in any Third Party Claim is solely money
damages and will have no continuing effect on the business, reputation or future
business prospects of any Indemnified Party, the Indemnitor shall have 15 days
after receipt of the notice referred to in the last sentence of Section 8.3(a)
to notify the Indemnified Party that it elects to conduct and control such Third
Party Claim. If the Indemnitor gives the foregoing notice, the Indemnitor shall
have the right to undertake, conduct and control, through counsel of its own
choosing and at the sole expense of the Indemnitor, the conduct and settlement
of such Third Party Claim, and the Indemnified Party shall

                                       23
<PAGE>

cooperate with the Indemnitor in connection therewith; provided that (x) the
                                                       -------------
Indemnitor shall not thereby permit to exist any lien, encumbrance or other
adverse charge upon any asset of any Indemnified Party; (y) the Indemnitor shall
permit the Indemnified Party to participate in such conduct or settlement
through counsel chosen by the Indemnified Party, but the fees and expenses of
such counsel shall be borne by the Indemnified Party except as provided in
clause (z) below; and (z) the Indemnitor shall agree promptly to reimburse the
Indemnified Party for the full amount of any Loss arising from or relating to
such Third Party Claim and all related Expense incurred by the Indemnified
Party, except fees and expenses of counsel for the Indemnified Party incurred
after the assumption of the conduct and control of such Third Party Claim by the
Indemnitor. So long as the Indemnitor is contesting any such Third Party Claim
in good faith, the Indemnified Party shall not pay or settle any such Third
Party Claim. Notwithstanding the foregoing, the Indemnified Party shall have the
right to pay or settle any such Third Party Claim without the Indemnitor's
approval, provided that in such event the Indemnified Party shall waive any
right to indemnity therefor by the Indemnitor, and no amount in respect thereof
shall be claimed as Loss or Expense under this Article VIII.

                                  ARTICLE IX
                                  TERMINATION
                                  -----------

     9.1.  Termination.  Anything contained in this Agreement to the contrary
           -----------
notwithstanding, this Agreement may be terminated at any time prior to the
Closing Date:

     (a)   By the mutual consent of the Shareholders and the Purchaser;

     (b)   By the Shareholders or the Purchaser if the Closing shall not have
occurred on or before December 3, 1999 (or such later date as shall be mutually
agreed to in writing by the Shareholders and the Purchaser); provided that the
party seeking termination is not in default or breach of this Agreement;

     (c)   By the Shareholders in the event of a breach by the Purchaser of any
of its representations, warranties or covenants contained in this Agreement,
which breach is not cured by the Purchaser within 10 days after written notice
of such breach;

     (d)   By the Purchaser in the event of a breach by the Company or the
Shareholders of any of their respective representations, warranties and
covenants contained in this Agreement, which breach is not cured by the Company
or the breaching Shareholder with ten (10) days after written notice of such
breach;

     (e)   By the Purchaser if the Purchaser is not satisfied with the results
and findings of its Due Diligence Investigation. If the Purchaser terminates
this Agreement pursuant to this section, then all books, records and files
copied by the Purchaser during the Due Diligence Investigation shall be
immediately returned to the Company; or

     (f)   By the Purchaser if, in the Purchaser's reasonable opinion, there has
been a Material Adverse Effect on the condition (financial or otherwise),
affairs, business, assets or prospects of the Company.

     9.2.   Effect of Termination.  In the event of the termination of this
            ---------------------
Agreement pursuant to the preceding Section of this Agreement, all further
obligations of the parties under this Agreement

                                       24
<PAGE>

shall be terminated without further liability of any party or its shareholders,
directors or officers to the other parties, provided (i) that Section 11.1 shall
survive any such termination and (ii) that nothing herein shall relieve any
party from liability for its willful breach of this Agreement.

                                   ARTICLE X
RESTRICTIONS ON TRANSFERABILITY OF SECURITIES; COMPLIANCE WITH SECURITIES ACT,
                                 REGISTRATION

     10.1.  Restrictions on Transferability.  The Purchaser's Shares acquired by
            -------------------------------
the Shareholders in connection with the Transaction, which shall include any
other securities issued in respect of such Purchaser's Shares upon any
conversion, stock split, stock dividend, recapitalization, merger, consolidation
or similar event, shall not be sold, assigned, transferred or pledged except
upon the conditions specified in this Article X, which conditions are intended,
among other things, to ensure compliance with the provisions of the Securities
Act. The Shareholders will cause each proposed purchaser, assignee, transferee
or pledgee of such to agree to take and hold such Purchaser's Shares subject to
the provisions and upon the conditions specified in this Article X, subject,
nevertheless, to any requirement of law that the Shareholder's property remain
within such Shareholder's control.

     10.2.  Restrictive Legend.  Each certificate representing the Purchaser's
            ------------------
Shares shall (unless otherwise permitted by the provisions of Section 10.3) be
stamped or otherwise imprinted with a legend in the following form (in addition
to any legend required under applicable state securities laws):

THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT
PURPOSES AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR THE
SECURITIES LAWS OF ANY STATE. SUCH SHARES MAY NOT BE SOLD, TRANSFERRED OR
PLEDGED IN THE ABSENCE OF SUCH REGISTRATION OR UNLESS STAAR SURGICAL COMPANY
RECEIVES AN OPINION OF COUNSEL (WHICH MAY BE COUNSEL FOR STAAR SURGICAL COMPANY)
REASONABLY ACCEPTABLE TO STAAR SURGICAL COMPANY STATING THAT SUCH SALE OR
TRANSFER IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF
SAID ACT AND THE SECURITIES LAWS OF ANY APPLICABLE STATE.

The Shareholders consent to the Purchaser making a notation on its records and
giving instructions to any transfer agent of such Purchaser's Shares in order to
implement the restrictions on transfer established in this Section 10.2 and
Section 10.3.

     10.3.  Notice of Proposed Transfers.  The holder of each certificate
            ----------------------------
representing Purchaser's Shares required to bear the legend set forth in Section
10.2 ("Restricted Securities") by acceptance thereof agrees to comply in all
respects with any provisions of this Section 10.3 applicable to such Restricted
Securities. At least 10 days prior to any proposed sale, assignment, transfer or
pledge of any Restricted Securities (other than a transfer not involving a
change in beneficial ownership), unless there is in effect a registration
statement under the Securities Act covering the proposed transfer, the holder
thereof shall give written notice to the Purchaser of such holder's intention to
effect such transfer, sale, assignment or pledge. Each such notice shall
describe the manner and circumstances of the proposed transfer, sale, assignment
or pledge in sufficient detail and shall be accompanied, at such holder's
expense, by either (i) a written opinion of legal counsel (such opinion to be
reasonably satisfactory to the Purchaser), addressed to the Purchaser, to the
effect

                                       25
<PAGE>

that the proposed transfer of the Restricted Securities may be effected without
registration under the Securities Act or (ii) a "no action" letter from the
Securities and Exchange Commission to the effect that the transfer of such
securities without registration will not result in a recommendation by the staff
of the Securities and Exchange Commission that action be taken with respect
thereto, whereupon the holder of such Restricted Securities shall be entitled to
transfer such Restricted Securities in accordance with the terms of the notice
delivered by the holder to Purchaser. Each certificate evidencing the Restricted
Securities transferred as above provided shall bear, except if such transfer is
made in compliance with Rule 144 of the Securities Act, the appropriate
restrictive legend set forth in Section 10.2, except that such certificate shall
not bear such restrictive legend if in the opinion of counsel for such holder
and the Purchaser such legend is not required in order to establish compliance
with any provisions of the Securities Act.

                                  ARTICLE XI
                                 MISCELLANEOUS
                                 -------------

     11.1.  Expenses.
            --------

            (a)  The Shareholders shall bear the expenses and fees of counsel to
the Company or the Shareholders' and the Company's accountants incurred by the
Company or the Shareholders in connection with the preparation, negotiation and
execution of the Transaction Documents and consummation of the transactions
contemplated hereby and thereby.

            (b)  Except as otherwise provided herein, the Purchaser shall bear
its own expenses and fees and commissions (including, but not limited to, all
compensation and expenses of counsel, consultants and accountants) incurred in
connection with its preparation, negotiation and execution of the Transaction
Documents and consummation of the transactions contemplated hereby or thereby.

     11.2.  Notices.  Any notices or other communications required under this
            -------
Agreement shall be in writing, shall be deemed to have been given when delivered
in person, by telex or telecopier, when delivered to a recognized next business
day courier, or, if made, when deposited in the United States mail, first class,
registered or certified, return receipt requested, with proper postage prepaid,
addressed as follows or to such other address as notice shall have been given
pursuant hereto:

If to the Shareholders or the Company prior to Closing, to:

               Mr. Alex Urich
               Mr. Michael Curtis
               Circuit Tree Medical, Inc.
               23322 Madero Road, Suite F
               Mission Viejo, California 92691

and if to the Shareholders after the Closing, to:

               Mr. Alex Urich
               27402 Via Caudaloso
               Mission Viejo, California 92691

                                       26
<PAGE>

               Mr. Michael Curtis
               26421 Pebble Creek
               Lake Forest, California 92630

If to the Purchaser to:

               STAAR Surgical Company
               1911 Walker Avenue
               Monrovia, California 91016
               Attn: Chief Financial Officer

with a copy to:

               Pollet Law
               10900 Wilshire Boulevard, Suite 500
               Los Angeles, California 90024
               Attn.:  Andrew F. Pollet, Esq.

     11.3.  Assignment.  Prior to the Closing Date, this Agreement may not be
            ----------
assigned, by operation of law or otherwise.  Following the Closing Date, any
party may assign any of its rights hereunder, but no such assignment shall
relieve him or it of his or its obligations hereunder.

     11.4.  Interpretation.  The article and section headings contained in this
            --------------
Agreement are for reference purposes only and shall not in any way affect the
meaning or interpretation of this Agreement.  Whenever the context may require,
any pronoun used herein shall include the corresponding masculine, feminine or
neuter forms.

     11.5.  Counterparts.  This Agreement may be executed in two or more
            ------------
counterparts, each of which shall be deemed to be an original, but all of which
together shall constitute one and the same instrument; and shall become binding
when two or more counterparts have been signed by each of the parties hereto and
delivered to each of the Purchaser, the Shareholders and the Company.

     11.6.  Amendment.  This Agreement may not be amended, modified or
            ---------
supplemented except by a writing signed by an authorized representative of each
of the parties hereto.

     11.7.  Entire Agreement.  This Agreement (including the Schedules and
            ----------------
Exhibits attached hereto) constitute the entire agreement and supersede all
prior agreements and understandings, both written and oral, among the parties
with respect to the subject matter hereof.  With respect to the Schedules, an
item is only deemed disclosed in connection with the specific representation to
which it is explicitly referenced.

     11.8.  Binding Effect.  This Agreement shall be binding upon and inure to
            ---------------
the benefit of the parties hereto and their respective heirs, personal
representatives, successors and permitted assigns.

     11.9.  Survival.  The covenants, agreements, representations and warranties
            --------
of the Company, the Shareholders or the Purchaser made in or pursuant to this
Agreement shall survive the Closing Date notwithstanding any investigation made
or information obtained by or on behalf of the Purchaser; provided, however,
                                                          -----------------
that the representations and warranties of the Company, the Shareholders or the
Purchaser contained herein or in any certificate delivered with respect thereto

                                       27
<PAGE>

(other than the representations and warranties contained in Sections 2.3, 3.3,
3.4, 3.9, 3.22, 3.27, 4.1, 4.3 or 4.4 which shall survive for all applicable
statute of limitations periods) shall terminate twelve months after the Closing
Date. Except as otherwise expressly provided in Article VIII, no claim shall be
made for breach of any representation or warranty contained herein or in any
certificate delivered with respect thereto under this Agreement after the date
on which such representations and warranties shall terminate as set forth in
this Section; provided, however, that nothing shall effect or otherwise limit
              -----------------
the obligations of the Shareholders or rights of the Purchaser under Article
VIII in respect of any breach of any representation or warranty of the
Shareholders or the Company as to which the Purchaser has notified the
Shareholders in accordance with Section 8.2 or prior to the date such
representations or warranties would otherwise terminate in accordance with this
Section 11.9.

     11.10.  Severability.  Wherever possible, each provision hereof shall be
             ------------
interpreted in such manner as to be effective and valid under applicable law,
but in case any one or more of the provisions contained herein shall, for any
reason, be held to be invalid, illegal or unenforceable in any respect, such
provision shall be ineffective in the jurisdiction involved to the extent, but
only to the extent, of such invalidity, illegality or unenforceability without
invalidating the remainder of such invalid, illegal or unenforceable provision
or provisions or any other provisions hereof, unless such a construction would
be unreasonable.

     11.11.  Third Parties.  Nothing contained in this Agreement or in any
             -------------
instrument or document executed by any party in connection with the transactions
contemplated hereby shall create any rights in, or be deemed to have been
executed for the benefit of, any person or entity that is not a party hereto or
a successor or permitted assign of such a party.

     11.12.  Waivers.  Any term or provision of this Agreement may be waived, or
             -------
the time for its performance may be extended, by the party or parties entitled
to the benefit thereof Any such waiver shall be validly and sufficiently
authorized for the purposes of this Agreement if, as to any party, it is
authorized in writing by an authorized representative of such party. The failure
of any party hereto to enforce at any time any provision of this Agreement shall
not be construed to be a waiver of such provision, nor in any way to affect the
validity of this Agreement or any part hereof or the right of any party
thereafter to enforce each and every such provision. No waiver of any breach of
this Agreement shall be held to constitute a waiver of any other or subsequent
breach.

     11.13.  Governing Law, Arbitration.  This Agreement shall be governed by
             --------------------------
and construed in accordance with the internal laws (as opposed to the conflicts
of law provisions) of the State of California.

             (i)   Any dispute, controversy or claim arising out of or relating
     to this Agreement or its breach, interpretation, termination or validity,
     including any question whether a matter is subject to arbitration
     hereunder, is referred to herein as a "Dispute."

             (ii)  If the parties fail to settle any Dispute within 30 days
     after any party has given notice to the other parties hereto of the claimed
     existence of a Dispute, the Dispute shall be resolved by a confidential,
     binding arbitration. All such Disputes shall be arbitrated in Los Angeles,
     California pursuant to the arbitration rules and procedures of the American
     Arbitration Association before an arbitrator or arbitrators selected in the
     manner provided in such rules and procedures, except that the "Final Offer
     (or Baseball)" Arbitration Option shall not be used unless otherwise agreed
     in writing.

                                       28
<PAGE>

             (iii) Judgment upon any award rendered by the arbitrators may be
     entered in any court having jurisdiction, and each party hereto consents
     and submits to the jurisdiction of such court for purposes of such action.
     The statute of limitations, estoppel, waiver, laches and similar doctrines,
     which would otherwise be applicable in any action brought by a party, shall
     be applicable in any arbitration proceeding, and the commencement of an
     arbitration proceeding shall be deemed to the commencement of an action for
     those purposes. The Federal Arbitration Act shall apply to the
     construction, interpretation and enforcement of this arbitration provision.
     Each party shall bear its own expenses (including without limitation the
     fees and expenses of legal counsel and accountants) in connection with such
     arbitration and the Purchaser and the Shareholder shall each bear one-half
     of the arbitrators' fees and expenses, provided that the arbitral award
     shall allocate such fees and expenses of counsel, accountants, other
     advisors and arbitrators according to the relative success of the
     contesting parties in the arbitration, as determined by the arbitrators.
     The arbitrators shall award an amount equal to the actual monetary damages
     suffered by each contesting party, which may include interest costs
     incurred by such party, but the arbitrators shall not have the authority to
     award punitive damages.

     11.14.  Definitions.  In this Agreement, the following terms have the
             -----------
meanings specified or referred to in this Section 11.14 and shall be equally
applicable to both the singular and plural forms.

     "Affiliate" shall mean: any person or entity (i) that directly or
      ---------
indirectly, through one or more intermediaries, controls or is controlled by, or
is under common control with, the person or entity involved, including, without
limitation, officers and directors, (ii) that directly or beneficially owns or
holds 5% or more of any equity interest in the person or entity involved, or
(iii) 5% or more of whose voting securities (or in the case of a person which is
not a corporation, 5% or more of any equity interest) is owned directly or
beneficially by the person or entity involved. As used herein, the term
"control" shall mean possession, directly or indirectly, of the power to direct
or cause the direction of the management or policies of a person or entity,
whether through ownership of securities, by contract or otherwise.

     "Balance Sheet" means the unaudited Balance Sheet of the Company dated as
      -------------
of December, 31, 1998.

     "Balance Sheet Date" means December 31, 1998.
      ------------------

     "Business" means the businesses engaged in by the Company as of the date of
      --------
this Agreement.

     "Closing" has the meaning specified in Section 1.3.
      -------

     "Closing Date" has the meaning specified in Section 1.3.
      ------------

     "Code" means the Internal Revenue Code of 1986, as amended.
      ----

     "Company Common Stock" has the meaning specified in Section 3.3.
      --------------------

     "Company's Financial Statements" has the meaning specified in Section 3.6.
      ------------------------------

                                       29
<PAGE>

     "Computerized Assets" means all information processing systems, operating
      -------------------
systems and delivery systems, internal environmental systems dependent on
embedded microchips and all other computerized and electronic functions that are
used by a Person in the conduct of its business.

     "Contaminant" means any waste, pollutant, hazardous substance, toxic
      -----------
substance, hazardous waste, medical waste, special waste, asbestos, petroleum or
petroleum-derived substance, radioactive material or waste, or any constituent
of any such substance or waste and including, without limitation, any substance
which any Governmental Body or lawful representative thereof requires to be
controlled,-removed, monitored, encapsulated or remediated or otherwise
addressed for the purposes of protection of the environment or public or worker
health and safety.

     "Current Assets" means those assets classified as current assets of the
      --------------
Company in accordance with GAAP.

     "Current Liabilities" means those liabilities classified as current
      -------------------
liabilities of the Company in accordance with GAAP.

     "Debt" means any and all indebtedness for borrowed monies and any other
      ----
long-term liabilities.

     "Dispute" has the meaning specified in Section 11.13.
      -------

     "Encumbrance" means any lien, claim, charge, security interest, mortgage,
      -----------
pledge, easement, conditional sale or other title retention agreement, defect in
title, covenant or other restriction of any kind.

     "Environmental Laws" has the meaning specified in Section 3.26(a).
      ------------------

     "ERISA" means the Employee Retirement Income Security Act of 1974, as
      -----
amended.

     "ERISA Affiliate" means (a) any corporation which at, or at any time
      ---------------
before, the Closing Date is or was a member of the same controlled group of
corporations (within the meaning of Section 414(b) of the Code) as the Company
or any predecessor of the Company; (b) any partnership, trade or business
(whether or not incorporated) which at, or at any time before, the Closing Date
is or was under common control (within meaning of Section 414(c) of the Code)
with the Company; and (c) any entity, which at, or at any time before, the
Closing Date is or was a member of the same affiliated service group (within the
meaning of Section 414(m) of the Code) as either the Company or any predecessor
of the Company, any corporation described in clause (a) or any partnership,
trade or business described in clause (b).

     "ERISA Benefit Plans" has the meaning specified in Section 3.21(a).
      -------------------

     "Expenses" means any and all reasonable expenses incurred in connection
      --------
with investigating, defending or asserting any claim, action, suit or proceeding
incident to any matter indemnified against hereunder (including, without
limitation, court filing fees, court costs, arbitration fees or costs, witness
fees, and reasonable fees and disbursements of legal counsel, investigators,
consultants, expert witnesses, accountants and other professionals).

                                       30
<PAGE>

     "Facility" means any real or personal property, plant, building, facility,
      --------
structure, underground storage tank, or equipment or unit, or other asset owned,
used, leased or operated by the Company.

     "GAAP" means generally accepted accounting principles in the United States
      ----
of America.

     "Governmental Body" means any court, government (federal, state, local or
      -----------------
foreign), department, commission, board, bureau, agency, official or other
regulatory, administrative or governmental authority.

     "Losses" means any and all losses, costs, obligations, liabilities,
      ------
settlement payments, awards, judgments, fines, penalties, excise taxes, damages,
expenses, deficiencies or other charges.

     "Managed Companies" has the meaning specified in Section 5.7(i).
      -----------------

     "Material Adverse Effect" means any change or effect (or any development
      -----------------------
that, insofar as can be reasonably foreseen, would result in any change or
effect) that is materially adverse to the assets, business, financial condition,
results of operations or prospects of the applicable Person or Persons.

     "Material Contracts" has the meaning specified in Section 3.23.
      ------------------

     "Non-ERISA Commitments" has the meaning specified in Section 3.21(a).
      ---------------------

     "Purchaser Shares" has the meaning specified in Section 1.2(a)(ii).
      ----------------

     "Pension Plans" has the meaning specified in Section 3.21(a).
      -------------

     "Permitted Encumbrances" means: (a) encumbrances for taxes or assessments
      ----------------------
or other governmental charges which are not yet due and payable; (b)
materialmen's, merchants', carriers', worker's, repairer's, or other similar
Encumbrances arising in the ordinary course of business which are not yet due or
payable and; (c) purchase money security interests.

     "Person" means any individual, corporation, partnership, joint venture,
      ------
association, joint-stock company, trust, unincorporated organization or
Governmental Body.

     "Release" means any release, spill, emission, leaking, pumping, injection,
      -------
deposit, disposal, discharge, dispersal, leaching or migration into the indoor
or outdoor environment or into or out of any Facility of any Contaminant,
including the movement of Contaminants through or in the air, soil, surface
water, groundwater or Facility.

     "Remedial Action" means actions required to (i) clean up, remove, treat or
      ---------------
in any other way address Contaminants in the indoor or outdoor environment; (ii)
prevent the Release or threatened Release or minimize the further Release of
Contaminants or (iii) investigate and determine if a remedial response is needed
and to design such a response and post-remedial investigation, monitoring,
operation and maintenance and care.

     "Requirements of Law" means any federal, state or local law, rule or
      -------------------
regulation, Governmental Permit or other binding determination of any
Governmental Body.

                                       31
<PAGE>

     "Restricted Securities" has the meaning specified in Section 10.3.
      ---------------------

     IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
signed as of the date first above written.

                                             "PURCHASER"
                                             STAAR Surgical Company

                                             By /s/  William Huddleston
                                                ----------------------------
                                             Its: Executive Vice President

                                             "SHAREHOLDERS"

                                             /s/ Alex Urich
                                             -------------------------------
                                             Alex Urich

                                             _______________________________
                                             Michael Curtis

                                             "COMPANY"
                                             Circuit Tree Medical, Inc.

                                             By:  Alex Urich   President
                                                ----------------------------
                                             Its:

                                       32
<PAGE>

                                  EXHIBIT "1"

                               ESCROW AGREEMENT
<PAGE>

                               ESCROW AGREEMENT
                               ----------------

     This ESCROW AGREEMENT dated as of December 3, 1999 by and among STAAR
Surgical Company, a Delaware corporation (the "Purchaser"), Alex Urich, an
individual, and Michael Curtis, an individual (Urich and Curtis are referred to
individually as the "Shareholder" and collectively as the "Shareholders"), and
Pollet Law (the "Escrow Agent"), all of whom are sometimes collectively referred
to herein as the "parties".

                             W I T N E S S E T H:
                             -------------------

     WHEREAS, the Purchaser and the Shareholders have entered into a Stock
Purchase Agreement dated as of the date hereof (the "Stock Purchase Agreement"),
pursuant to which the Purchaser is acquiring 80% of the Shareholders'
outstanding common stock (the "Stock") in Circuit Tree Medical, Inc. (the
"Company"); and

     WHEREAS, in order to complete the transfer of the purchase price for the
Stock, which includes:  (i) the transfer of good funds to each Shareholder in
the amount of Two Hundred Fifty Thousand Dollars ($250,000) (the "Cash") and
(ii) the transfer to each Shareholder of shares of the Purchaser's common stock
(the "Purchaser's Shares"), the Shareholders and the Purchaser have agreed to
enter into this Escrow Agreement;

     NOW, THEREFORE, in consideration of the mutual promises of the parties, and
of other good and valuable consideration, the sufficiency of which is hereby
acknowledged, the parties hereby respectively act and agree as follows:

     1.  Appointment of Escrow Agent.  The Purchaser and the Shareholders hereby
         ---------------------------
appoint Pollet Law as Escrow Agent, and Pollet Law hereby accepts such
appointment and agrees to act as Escrow Agent under the terms and conditions of
this Agreement.

     2.  Escrow Deposit by the Shareholders.  On the Closing Date, as that term
         ----------------------------------
is defined in the Stock Purchase Agreement, each Shareholder shall deposit with
the Escrow Agent, pursuant to Article I, Section 1.2(b) of the Stock Purchase
Agreement, (i) a certificate representing eighty (80) shares of the Company's
common stock, which certificate represents that portion of the Stock
attributable to the purchase price to be paid with the Cash, and (ii) a
certificate representing one hundred twenty (120) shares of the Company's common
stock, which certificate represents that portion of the Stock attributable to
the portion of the purchase price to be paid with the Purchaser's Shares, in
each case together with a duly executed Assignment Separate From Certificate
(the "Stock Power") and (iii) cross-receipts (collectively, the "Property
Deposited by the Shareholders").  The Escrow Agent shall hold, manage,
administer, and distribute the Property Deposited by the Shareholders in
accordance with the terms and conditions of this Agreement.

     3.  Escrow Deposit by the Purchaser.  The Purchaser shall deposit with
         -------------------------------
the Escrow Agent, pursuant to Article I, Section 1.2(a)(ii) of the Stock
Purchase Agreement, (i) certificates

                                      -1-
<PAGE>

for the Purchaser's Shares registered in the names of the Shareholders, (ii)
cross-receipts, and (iii) the Cash (collectively, the "Property Deposited by the
Purchaser"). The certificates for the Purchaser's Shares shall be deposited
within ten (10) days from the Closing Date, as that term is defined in the Stock
Purchase Agreement, and the Cash shall be deposited with the Escrow Agent or
wired to the Escrow Agent no later than 5:00 p.m. on January 5, 2000. The Escrow
Agent shall hold, manage, administer, and distribute the Property Deposited by
the Purchaser in accordance with the terms and conditions of this Agreement.

     4.  Distributions to the Shareholders and the Purchaser.  Within twenty-
         ---------------------------------------------------
four (24) hours of the Escrow Agent's receipt of the certificates for the
Purchaser's Shares registered in the names of the Shareholders, the Escrow Agent
shall distribute:  (i) to the Purchaser the stock certificates and Stock Powers
attributable to the portion of the purchase price to be paid with the
Purchaser's Shares and the cross receipts and (ii) to the Shareholders the
Purchaser's Shares and the cross receipts.  Within twenty-four (24) hours of the
Escrow Agent's receipt of the Cash, the Escrow Agent shall distribute:  (i) to
the Purchaser the stock certificates and Stock Powers attributable to the
portion of the purchase price to be paid with the Cash and the cross receipts
and (ii) to the Shareholders the Cash and the cross receipts.

     5.  Escrow Agent.
         ------------

         (a)  Fees and Costs.  The normal fees and reasonable expenses incurred
              --------------
by the Escrow Agent in connection with its duties hereunder shall be paid one-
half by the Purchaser and one-half by the Shareholders.

         (b)  Duties.  The duties of the Escrow Agent are only such as are
              ------
herein specifically provided, being purely ministerial in nature, and the Escrow
Agent shall incur no liability whatever hereunder except for gross negligence or
bad faith.  The Escrow Agent shall be under no responsibility in respect of any
of the items deposited with it other than to follow faithfully the instructions
herein contained.  The Escrow Agent is not charged with knowledge of any duties
or responsibilities in connection with any other document or agreement.  The
Escrow Agent may consult with counsel and shall be fully protected in any action
taken in good faith in accordance with such advice.  The Purchaser and the
Shareholders jointly and severally agree to assume liability for and do hereby
agree to indemnify, protect, save, and hold harmless the Escrow Agent from and
against any and all liabilities, obligations, losses, damages, claims, actions,
suits, costs, and expenses of whatever kind and nature, including reasonable
attorneys' fees, imposed upon, incurred by, or asserted against the Escrow Agent
in any way relating to or arising out of this Agreement.  The Escrow Agent shall
not be required to institute legal proceedings of any kind.  The Escrow Agent
shall be fully protected in acting in accordance with any written notices,
directions, or instructions given to it hereunder and believed by it to have
been signed by the proper parties.

     6.  Resignation, Removal, Successorship and Accounting.  The Escrow Agent
         --------------------------------------------------
may resign at any time by giving sixty (60) days prior written notice thereof to
the Purchaser and the Shareholders.  The Purchaser and the Shareholders may
remove the Escrow Agent at any time upon written notice to the Escrow Agent at
least ten (10) days prior to the date of removal.  In

                                      -2-
<PAGE>

any such event, the Escrow Agent shall render to the Purchaser and the
Shareholders an account in writing of the property held in the Escrow and any
notices received by it. If the Purchaser and the Shareholders approve such
account in writing or fail to object in writing to such account within twenty
(20) days after the date of receipt of such account, the Escrow Agent shall be
released forever from any and all claims or liabilities with respect to any
actions or omissions hereunder. Simultaneously with such release, the Escrow
Agent shall deliver the property held in the Escrow to its successor designated
in writing by the Purchaser and the Shareholders. If the Purchaser and the
Shareholders fail to agree on a successor Escrow Agent within such twenty (20)
day period, the Escrow Agent may designate any California bank or trust company
which has assets in excess of $500,000,000 as successor, which shall agree in
writing to be bound by all of the provisions hereof, or the Escrow Agent may
apply to the appropriate court for appointment of a successor. If either the
Purchaser or the Shareholders object in writing to the account of the Escrow
Agent within such twenty (20) day period, the Escrow Agent shall not be released
hereunder and the parties hereto shall use their best efforts to reconcile their
differences. Nothing in this Escrow Agreement shall prevent the Escrow Agent
from bringing an action to settle its accounts, and obtain its release
hereunder, in any court of competent jurisdiction; and in such case, the costs
and expenses of the Escrow Agent incurred in such action, including its
reasonable attorneys' fees, shall be paid by the party contesting the accounts
if the Escrow Agent prevails. Any successor to the Escrow Agent appointed under
any of the methods provided herein shall have all of the rights, obligations,
and immunities of the Escrow Agent set forth herein and shall agree in writing
to be bound by all of the provisions hereof.

     7.  Termination.  This Agreement shall terminate upon the distribution of
         -----------
the Property Deposited by the Purchaser to the Shareholders and the Property
Deposited by the Shareholders to the Purchaser.

     8.  Notices.  Any notices or other communications required under this
         -------
Agreement shall be in writing, shall be deemed to have been given when delivered
in person, by telex or telecopier, when delivered to a recognized next business
day courier, or, if made, when deposited in the United States mail, first class,
registered or certified, return receipt requested, with proper postage prepaid,
addressed as follows or to such other address as notice shall have been given
pursuant hereto:

If to the Shareholders:    Mr. Alex Urich
                           27402 Via Caudaloso
                           Mission Viejo, California 92691

                           Mr. Michael Curtis
                           26421 Pebble Creek
                           Lake Forest, California 92630

If to the Purchaser:       STAAR Surgical Company
                           1911 Walker Avenue
                           Monrovia, California 91016
                           Attn: Chief Financial Officer

                                      -3-
<PAGE>

with a copy to:           Pollet Law
                          10900 Wilshire Boulevard, Suite 500
                          Los Angeles, California 90024
                          Attn.: Andrew F. Pollet, Esq.

If to the Escrow Agent:   Pollet Law
                          10900 Wilshire Boulevard, Suite 500
                          Los Angeles, California 90024
                          Attn.: Andrew F. Pollet, Esq.

or to such other address as the addressee may hereafter designate by written
notice to the other parties.

     9.   Waivers.  No waivers by any party hereto of any condition or of any
          -------
breach of any provision of this Agreement shall be effective, unless in writing
signed by the party waiving compliance.

     10.  Amendments.  This Agreement may be amended only with the written
          ----------
consent of the Purchaser, the Shareholders and the Escrow Agent.

     11.  Governing Law.  This Agreement shall be governed by and construed in
          -------------
accordance with the internal laws of the State of California, without regard to
its conflict of laws provisions.

     12.  Headings.  The section headings herein are inserted for convenience of
          --------
reference only and are not intended to be a part of or to affect the meaning or
interpretation of this Agreement.

     13.  Entire Agreement.  This Agreement constitutes the entire agreement
          ----------------
between the parties hereto as to the subject matter hereof and supersedes all
prior agreements and understandings relating thereto.

     14.  Severability.  If any term or provision of this Agreement or the
          ------------
application thereof to any person or circumstance shall to any extent be invalid
or unenforceable, the remainder of this Agreement or the application of such
term or provision to persons or circumstances other than those as to which it is
invalid or unenforceable, shall not be affected thereby and each term and
provision of this Agreement shall be valid and enforced to the fullest extent
permitted by law.

     15.  Counterparts.  This Agreement may be executed in one or more
          ------------
counterparts, each of which shall be deemed to be an original, but all of which
together shall constitute one and the same instrument.

                                      -4-
<PAGE>

     16.  Successors and Assignment.  This Agreement shall be enforceable by,
          -------------------------
and shall inure to the benefit of and be binding upon, the parties hereto and
their respective successors, assigns, and representatives.  No party may assign
any of its rights or obligations hereunder without the prior written consent of
all parties hereto.

     IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
signed under seal as of the date first above written.

                                 STAAR Surgical Company

                                 By____________________________________
                                   Its:

                                 ________________________________________
                                 Alex Urich

                                 ________________________________________
                                 Michael Curtis

                                 Pollet Law

                                 By:_____________________________________
                                    Its:

                                      -5-
<PAGE>

                                  EXHIBIT "2"

                            SHAREHOLDERS AGREEMENT
<PAGE>

                             SHAREHOLDERS AGREEMENT
                             ----------------------

          The parties to this Shareholders Agreement (this "Agreement") made
this 3rd day of December, 1999 are Circuit Tree Medical, Inc., a California
corporation (the "Company"), Alex Urich and Michael Curtis (collectively, the
"Founders"), and STAAR Surgical Company, a Delaware corporation ("STAAR").

          As used herein, the term "Shareholders" refers collectively to the
Founders and STAAR.

          Simultaneously with the execution and delivery of this Agreement,
STAAR is purchasing from the Founders eighty percent (80%) of the issued and
outstanding common stock of the Company.

          The parties wish to provide for certain matters regarding the transfer
of the Company's issued and outstanding common stock and the governance of the
Company.  Accordingly, intending to be legally bound by the terms of this
Agreement, the parties agree as follows:

          1.    Restriction on Transfer of Shares
                ---------------------------------

          1.1.  Transfers to be Made Only as Permitted by this Agreement.  No
                --------------------------------------------------------
Founder may transfer any Shares (as defined in Section 6.1) acquired on, before
or after the date of this Agreement, except to his spouse, children, parents or
grandchildren or a trust for the benefit of any of the foregoing (a "Permitted
Transferee") or as specifically required or permitted by this Agreement, and any
purported transfer in any other manner shall be void.  In addition, no Permitted
Transferee may transfer any Shares, except as specifically required or permitted
by this Agreement, and any purported transfer in any other manner shall be void.
No transfer may be made to a Permitted Transferee unless the Permitted
Transferee (or his or her custodian or guardian) executes and delivers a written
agreement, in form and substance satisfactory to the Company, agreeing to be
bound by the provisions of this Agreement, and thereupon such Permitted
Transferee shall be deemed a "Shareholder" for all purposes of this Agreement.
STAAR may transfer its Shares without any restriction whatsoever, other than
compliance with Section 3.1 of this Agreement, compliance with applicable
securities laws and the requirement that the transferee agree to be bound by the
terms of this Agreement, subject to the same rights and obligations as STAAR.
Any person to whom STAAR transfers its Shares under this Agreement shall be
deemed a "Shareholder" for all purposes.  The Company shall not issue any shares
of common stock (including upon exercise of options issued by the Company)
unless the person to whom such shares are issued executes and delivers a written
agreement, in form and substance satisfactory to STAAR, agreeing to be bound by
the provisions of this Agreement as a Shareholder.

          1.2.  Legend on Certificates.  Each certificate representing Shares
                ----------------------
from time to time owned by the Shareholders shall bear a legend substantially as
follows:

                "Transfer of the shares represented by this certificate is
          restricted by a Shareholders Agreement dated as of December 3,
<PAGE>

          1999, as the same may be amended, a copy of which is on file at the
          office of the Corporation."

               "The shares represented by this certificate have not been
          registered under the Securities Act of 1933, and may not be sold,
          pledged, hypothecated or otherwise transferred or offered for sale
          unless a registration statement has become and is then effective with
          respect to such shares or a written opinion that the proposed sale or
          transfer is exempt from registration under the Act has been rendered
          by counsel for the Company."

          2.   Purchase and Sale of Shares.
               ---------------------------

          2.1. Purchase Upon Termination of Employment of Founder.
               --------------------------------------------------

          (a)  If the employment of a Founder is terminated for any reason,
including his death, retirement, termination by the Company of his employment
with or without cause (as hereinafter defined), resignation or disability (as
hereinafter defined), then the Company shall have the option (exercisable by
notice given to such Founder (or his personal representative) within the 90-day
period (the "Option Period") following the termination of employment of the
Founder) to purchase all, but not less than all, of his, and his Permitted
Transferees, Shares.  The purchase price for the Shares purchased pursuant to
this Section 2.1(a) shall be determined by (i) the agreement of the Founder (or
his personal representative) and STAAR or (ii) if for any reason they do not
reach an agreement, using the following formula:  (x) if a Founder's employment
terminates at any time prior to December 3, 2000, the per share value of such
Founder's Shares shall be determined by multiplying $3,000,000 times 120% and
dividing the product by the number of all Shares issued and outstanding; (y) if
a Founder's employment terminates during the period from December 3, 2000
through December 2, 2004, the per share value of such Founder's Shares shall be
determined by multiplying $3,000,000 times 150% and dividing the product by the
number of all Shares issued and outstanding; and (z) if a Founder's employment
terminates at any time after December 2, 2004, the per share value of such
Founder's Shares shall be determined in good faith by the Company's board of
directors.

          (b)  If, for any reason, the Company does not exercise its option
pursuant to Section 2.1(a) with respect to any applicable Shares, STAAR shall
have the option (exercisable by notice to the Founder (or his personal
representative) given at any time within 90 days following expiration of the
Option Period) to purchase those Shares on the terms and conditions set forth in
Section 2.1(a).

          2.2. Right of First Refusal.  If any Founder (or his personal
               ----------------------
representative) or Permitted Transferee (an "Offeree") receives from an
unrelated third party a bona fide offer to purchase for cash any of the
                        ---- ----
Offeree's Shares and the Offeree wishes to accept the offer, the Offeree shall
give notice of the offer to the Company and to STAAR (setting forth the name and
address of the third party, the proposed purchase price and the other terms and
conditions of the offer), and the Company shall have the option (exercisable by
notice to the Offeree given within sixty (60) days after receipt of notice of
the offer) to purchase all (but not fewer than all) of the Offeree's Shares at
the same price.  If the Company does not exercise its option with respect to
<PAGE>

all the Shares covered by the third party offer, STAAR shall be entitled to
purchase all (but not fewer than all) such remaining Offeree's Shares at the
same price. If neither the Company nor STAAR exercise their option with respect
to all the Shares covered by the third party offer, then the Offeree (or his or
her personal representative) may, within sixty (60) days after termination of
the Company's option, transfer all (but not fewer than all) of his Shares to the
third party upon the terms and conditions of the original offer (but, if the
Shares are not transferred within that 60-day period, they shall again be
subject to this Agreement); no such transfer may be made, however, unless the
third party executes and delivers to the Company a written agreement, in form
and substance satisfactory to the Company, agreeing to be bound by the
provisions of this Agreement.

          2.3.  Closing.  The closing of any purchase of Shares under this
                -------
Section 2 shall be held at a place and date specified by the purchaser of such
Shares, but not more than sixty (60) days after the exercise by the Company or
other purchaser of its option under this Section 2.  At the closing, each
Founder (or his personal representative) or Permitted Transferee shall deliver
to the Company a certificate or certificates for the Shares being sold, duly
endorsed in blank and with all stock transfer stamps attached, and the Company
or other purchaser shall pay the purchase price for the Shares being purchased
(net of withholding taxes, if any).  The purchase price shall be payable in cash
by the Company or other purchaser.  If a Founder's personal representative is
selling the Shares, he shall deliver to the Company at the closing all
applicable estate tax waivers.

          2.4   Insufficient Surplus. If, at any time the Company is required to
                --------------------
make any payment for any Shares purchased by it under this Section 2, and such
payment is not legally permitted by applicable law, the entire amount legally
permitted by applicable law shall be applied to the payment (and the Company
shall promptly take all action, if any, that may be permitted by law in order to
permit the payment to be made in full). To the extent that any such required
payment would violate such law, then the payment shall be postponed until
permitted and the amount of any postponed payment shall bear interest on the
unpaid balance from time to time outstanding at eight percent (8%) per annum.

          3.    Other Rights.
                ------------

          3.1.  Transfer of Shares by STAAR.  If STAAR desires to sell any of
                ---------------------------
its Shares pursuant to an arm's length, bona fide transaction with a third
                                        ---- ----
party, (which shall not include a transfer to any subsidiary or affiliate of
STAAR), then the Founders shall sell, and STAAR shall purchase, prior to any
such sale of its Shares, the Shares belonging to the Founders.  The purchase
price for the Shares purchased pursuant to this Section 3.1(a) shall be
determined by (i) the agreement of the Founders and STAAR or (ii) if for any
reason they do not reach an agreement, using the following formula:  (x) if the
sale of STAAR's Shares closes at any time prior to December 3, 2000, the per
share value of each Founder's Shares shall be determined by multiplying
$3,000,000 times 120% and dividing the product by the number of all Shares
issued and outstanding; (y) if the sale of STAAR's Shares closes during the
period from December 3, 2000 through December 2, 2004, the per share value of
each Founder's Shares shall be determined by multiplying $3,000,000 times 150%
and dividing the product by the number of all Shares issued and outstanding; and
(z) if the sale of STAAR's Shares closes at any time after
<PAGE>

December 2, 2004, the per share value of each Founder's Shares shall be
identical to the per share price to be received by STAAR for its Shares.

          3.2.  Rights to Purchase Additional Shares.  If at any time the
                ------------------------------------
Company proposes to issue any Shares or other securities (other than debt
securities with no equity feature) to any person, each Shareholder shall have
the right to purchase, upon the same terms, a number of those Shares or other
securities (but not less than such number) in the proportion that the number of
Shares of Common Stock beneficially owned by such Shareholder bears to the total
number of the Company's Shares of Common Stock outstanding immediately prior to
such issuance.  The Company shall give notice (the "Share Purchase Notice") to
the Shareholders setting forth the identity of the person to whom it proposes to
issue Shares or other securities and the time, which shall not be fewer than
thirty (30) days, within which and the terms and conditions upon which the
Shareholders may purchase the Shares or other securities, which shall be the
same terms and conditions upon which the person to whom the proposed issuance is
to be made may purchase the Shares or other securities.  Within twenty (20) days
after the giving of the Share Purchase Notice, each Shareholder shall give
irrevocable notice of his or its decision to exercise the option under this
Section 3.2.

          3.3.  Agreement to Vote Shares.  If STAAR proposes that the Company
                ------------------------
sell, convey, lease or exchange all or substantially all of its assets in an
arm's length, bona fide transaction with a third party or engage in a merger,
              ---- ----
business combination or other transaction with substantially the same effect,
then the Founders (and any other shareholders bound by this Agreement) shall
vote their Shares in favor of the transaction, and take such other actions as
are reasonably requested by STAAR to enable the Company to consummate such
transaction.  If any Founder fails or refuses to vote his Shares as required by
this Section 3.3, each other Shareholder (other than the failing or refusing
Founder) shall have an irrevocable proxy during the term of this Agreement,
exercisable by any one of them singly, coupled with an interest, so as to vote
those Shares in accordance with this Section 3.3, and each Shareholder hereby
grants to each other Shareholder such irrevocable proxy.  To the extent
permitted by law, each Shareholder waives any right to appraisal under
California law in connection with any transaction approved in accordance with
this Section 3.3.

          4.    Directors.
                ---------

          4.1.  Election and Removal of Directors Generally
                -------------------------------------------

          (a)   The Shareholders shall vote all their Shares to establish and
maintain a board of directors elected in accordance with this Agreement.  The
Founders shall be entitled to nominate one (1) director (collectively, "Founder
Director") and STAAR shall be entitled to nominate two (2) directors (the "STAAR
Directors").  The Shareholders shall vote all of their Shares to elect the
individuals so nominated to be directors.  If the Shareholder or Shareholders
that nominated a director give written notice to the other Shareholders that the
Shareholder or Shareholders wish to remove their or its director, the
Shareholders shall vote all of their Shares in favor of removing that director.
If for any reason any director ceases to hold office, the Shareholder or
Shareholders that nominated that director shall promptly nominate an individual
to fill the vacancy so created for the unexpired term and the Shareholders shall
vote all of their Shares for the individual nominated to fill the vacancy.
<PAGE>

          4.2.  Current Directors.  Effective upon the execution and delivery of
                -----------------
this Agreement, the directors initially shall consist of Alex Urich, John R.
Wolf and William C. Huddleston.  For purposes of Section 4.1 of this Agreement,
Alex Urich shall be deemed to be the Founder Director, and William C. Huddleston
and John R. Wolf shall be deemed to be the STAAR Directors.

          4.3.  Board of Director Meetings.  The Company shall use its best
                --------------------------
efforts to ensure that meetings of its Board of Directors are held at least four
times each year and at least once each quarter.

          5.    Company Financial Information.
                -----------------------------

          5.1.  Annual Financial Statements and Budgets.  The Company shall
                ---------------------------------------
maintain a standard system of accounting in accordance with generally accepted
accounting principles applied on a consistent basis ("GAAP") and shall make and
keep books, records and accounts that, in reasonable detail, accurately and
fairly reflect its transactions.  The Company shall deliver to each Shareholder
the following:

                (a)  As soon as available, and in any event within 120 days
after the end of each fiscal year of the Company commencing with December 31,
1999, an audited consolidated balance sheet, and related statements of
operations and cash flows of the Company as of the end of such year; and

                (b)  As soon as available, but in any event prior to
commencement of each new fiscal year, a business plan and projected financial
statements for such fiscal year.

          5.2.  Monthly Financial Statements and Budgets.  The Company shall
                ----------------------------------------
deliver to the Shareholders:

          (a)   Within thirty (30) days after the end of each month, an
unaudited consolidated statement of operations and cash flows for such month and
the current fiscal year to date and an unaudited consolidated balance sheet as
of the end of each such month, setting forth in comparative form the figures for
the corresponding periods of the previous fiscal year and the Company's
projected financial statements for the current fiscal year and showing
deviations from budget;

          (b)   Promptly upon receipt, copies of all management letters from
accountants and all certificates prepared by or for the Company as to
compliance, defaults, material adverse changes, material litigation or similar
matters, but only to the extent that the delivery thereof would not result in
the loss of any generally recognizable privilege otherwise applicable thereto
(provided, however, that nothing herein shall preclude disclosure of such
 --------  -------
letters and certificates to any members of the Company's board of directors);
and

          (c)   Upon written request, the Company shall also furnish, with
reasonable promptness, such other information relating to the financial
condition, business prospects or corporate affairs of the Company as any
Shareholder may from time to time reasonably request.
<PAGE>

          5.3.  Inspection.  The Company shall permit the Shareholders, or their
                ----------
agents, at their own expense, to visit and inspect the Company's properties, to
examine the Company's books of account and records, and to discuss the Company's
affairs, finances and accounts with its officers, all at such reasonable times
as may be requested by any such Shareholder; provided, however, that the Company
                                             --------  -------
shall not be obligated pursuant to this Agreement to provide any information
that it reasonably considers to be a trade secret or to contain confidential
data unless the Shareholder shall have executed and delivered to the Company a
confidentiality agreement in a form reasonably acceptable to the Company.

          6.    Miscellaneous
                -------------

          6.1.  Definitions.  As used in this Agreement:
                -----------

                (a)  "affiliate" means a person or entity that directly or
indirectly, through one or more intermediaries, controls or is controlled by, or
is under common control with, a Shareholder;

                (b)  "personal representative" means the executor or executors
or the administrator or administrators of the estate of a deceased Founder;

                (c)  "Shares" means the shares of all classes and series of the
capital stock of the Company owned by the Shareholders, irrespective of the time
and manner of acquisition; and

                (d)  "transfer" means the making of any sale, exchange,
assignment of gift, the creation of any security interest or other encumbrance,
or any other transfer or disposition, whether voluntary or involuntary
(including, but not limited to, by levy of execution or seizure under legal
process or by operation of law), affecting title to, or the right to possession
of, any Shares in the Company.

          6.2.  Notice of Appointment of Personal Representative.  The personal
                ------------------------------------------------
representative of a deceased Founder shall give prompt notice of his or her
appointment, setting forth the address to which notices under this Agreement
shall be given to the personal representative.

          6.3.  Construction. As used in this Agreement, unless the context
                ------------
otherwise requires:  (i) references to "Section" are to a section of this
Agreement; (ii) all "Exhibits" referred to in this Agreement are to Exhibits
attached to this Agreement and are incorporated into this Agreement by reference
and made a part of this Agreement; (iii) "include", "includes" and "including"
are deemed to be followed by "without limitation" whether or not they are in
fact followed by such words or words of like import; (iv) the headings of the
various sections and other subdivisions of this Agreement are for convenience of
reference only and shall not modify, define or limit any of the terms or
provisions of this Agreement; and (v) "knowledge" of a person means the actual
knowledge of such person and the knowledge that a prudent individual could be
expected to discover or otherwise become aware of in the course of conducting a
reasonably comprehensive investigation concerning the existence of the matters
addressed.
<PAGE>

          6.4.  Remedies.  The parties will be irreparably damaged if this
                --------
Agreement is not specifically enforced.  If any dispute arises concerning any
transfer or other disposition of Shares under this Agreement, an injunction may
be issued restraining the transfer or other disposition, pending the
determination of the controversy, without any bond or other security being
required.  If any dispute arises concerning the right or obligation to purchase
or sell or vote any Shares under this Agreement, the right or obligation shall
be specifically enforceable in a court of competent jurisdiction upon
application or petition by the Company or any Shareholder.

          6.5.  Governing Law.  This Agreement shall be governed by and
                -------------
construed in accordance with the laws of the State of California applicable to
agreements made and to be performed in California.

          6.6.  Assignment.  This Agreement shall not be assignable except as
                ----------
expressly provided herein, and shall be binding upon and inure to the benefit of
the respective successors and assigns of the Company and the respective
successors, permitted assigns, heirs and legal representatives of the
Shareholders.

          6.7.  Severability.  If any provision of this Agreement, or the
                ------------
application of any provision to any person or circumstance, shall for any reason
and to any extent be invalid or unenforceable, the remainder of this Agreement
and the application of that provision to other persons or circumstances shall
not be affected but shall be enforced to the full extent permitted by law.

          6.8.  Waivers.  The failure of a party to insist upon strict adherence
                -------
to any terms of this Agreement on any occasion shall not be considered a waiver,
or deprive that party of the right thereafter to insist upon strict adherence to
that term or any other term of this Agreement.  Any waiver must be in writing.

          6.9.  Notices.  Any notices or other communications required under
                -------
this Agreement shall be in writing, shall be deemed to have been given when
delivered in person, by telex or telecopier, when delivered to a recognized next
business day courier, or, if made, when deposited in the United States mail,
first class, registered or certified, return receipt requested, with proper
postage prepaid, addressed as follows or to such other address as notice shall
have been given pursuant hereto:

     If to the Founders, to:

                Mr. Alex Urich
                27402 Via Caudaloso
                Mission Viejo, California 92691

                Mr. Michael Curtis
                26421 Pebble Creek
                Lake Forest, California 92630
<PAGE>

     If to STAAR to:

                STAAR Surgical Company
                1911 Walker Avenue
                Monrovia, California 91016
                Attn: Chief Financial Officer

with a copy to:

                Pollet Law
                10900 Wilshire Boulevard, Suite 500
                Los Angeles, California 90024
                Attn.: Andrew F. Pollet, Esq.

          6.10.  Counterparts.  This Agreement may be executed in two or more
                 ------------
counterparts, each of which shall constitute an original, but all of which
together shall constitute but a single instrument.

          6.11.  No Rights of Employment. Nothing in this Agreement shall confer
                 -----------------------
on any Founder any right to be employed by the Company or to perform services
for the Company or to interfere in any way with the right of the Company to
terminate the Founder's employment or services or to give the Founder any claim
against the Company in respect of any such termination.

          6.12.  Complete Agreement; Modification and Termination. This
                 ------------------------------------------------
Agreement contains a complete statement of all the arrangements among the
parties with respect to its subject matter, supersedes all existing agreements
among them concerning that subject matter and may be modified, waived or
terminated only by a written instrument signed by the parties to it; provided,
                                                                     --------
however, that any Shareholder may agree, in a written instrument signed by that
-------
Shareholder, to waive the benefits of any provision of this Agreement applicable
to that Shareholder without requiring the consent of any other party. This
Agreement shall terminate on the earlier of the twenty-fifth (25/th/)
anniversary of the date of this Agreement or the dissolution of the Company.

          IN WITNESS WHEREOF, the parties hereto have caused this Agreement to
be signed on the date and year first above written.

                    THE COMPANY:                 CIRCUIT TREE MEDICAL, INC.
                    -----------

                                                 By:___________________________
                                                 Name:_________________________
                                                 Title:________________________
<PAGE>

                                    STAAR:     STAAR SURGICAL COMPANY
                                    -----

                                               By:___________________________
                                               Name:_________________________
                                               Title:________________________

                                 FOUNDERS:
                                 --------
                                               ______________________________
                                               Name:  Alex Urich

                                               ______________________________
                                               Name:  Michael Curtis
<PAGE>

                                 EXHIBIT "3-A"

                          URICH EMPLOYMENT AGREEMENT
<PAGE>

                             EMPLOYMENT AGREEMENT

          This EMPLOYMENT AGREEMENT ("Agreement"), which is dated as of December
3, 1999, is made by and between CIRCUIT TREE MEDICAL, INC., a California
corporation, located at 23322 Madero Road, Suite F, Mission Viejo, California
92691 and hereinafter referred to as "Company", and ALEX URICH, whose address is
27402 Via Caudaloso, Mission Viejo, California 92691, hereinafter referred to as
"Employee", based upon the following:

                                   RECITALS
                                   --------

          WHEREAS, Company wishes to retain the services of Employee as its
President and Employee wishes to render services to Company in that capacity;

          WHEREAS, Company and Employee wish to set forth in this Agreement the
duties and responsibilities that Employee has agreed to undertake on behalf of
Company;

          WHEREAS, Company and Employee intend that this Agreement will
supersede and replace any and all other employment agreements or arrangements
for employment entered into by and between Company and Employee and that, upon
execution of this Agreement, any such employment agreements or arrangements
shall have no further force or effect.

          THEREFORE, in consideration of the foregoing and of the mutual
promises contained in this Agreement, Company and Employee (who are sometimes
individually referred to as a "party" and collectively referred to as the
"parties") agree as follows:

                                   AGREEMENT
                                   ---------

     1.   SPECIFIED PERIOD.
          ----------------

          Company hereby employs Employee pursuant to the terms of this
Agreement and Employee hereby accepts employment with Company pursuant to the
terms of this Agreement for the period beginning on the execution date of this
Agreement and ending on December 2, 2004 (the "Term").

     2.   GENERAL DUTIES.
          --------------

          Employee shall report to Company's Board of Directors (the "Board").
Employee shall devote his entire productive time, ability, and attention to
Company's business during the term of this Agreement. In his capacity as
President, Employee shall do and perform all services, acts, or things necessary
or advisable to discharge his duties under this Agreement, including, but not
limited to, those duties and responsibilities included in the Position
Description attached to this Agreement as Exhibit "A" and made a part of it.
Employee shall perform such other duties which may, from time to time, be
prescribed by the Company through its Board. Furthermore, Employee agrees to
cooperate with and work to the best of his ability with Company's management
team, which includes the Board and the officers and other employees, to
continually improve Company's reputation in its industry for quality products
and performance.

                                       1
<PAGE>

     3.   COMPENSATION.
          ------------

          (a)  Salary. During the term of this Agreement, Company shall pay to
               ------
Employee a base salary of One Hundred Thousand Dollars ($100,000) per year.

          (b)  Bonus. Employee and the Board shall meet no later than 90 days
               -----
from the start of Company's fiscal year to establish performance standards and
goals to be met by Employee, which standards and goals shall be based upon
earnings, cash flows, EBITDA and other objectives that are mutually agreed to by
Employee and the Board. Company shall pay to Employee, no later than thirty (30)
days after the completion of the fiscal year, a cash bonus (the "Annual Bonus")
in an amount that shall not be less than Fifty Thousand Dollars ($50,000) for
each year in which the performance standards and goals are met or exceeded by
Employee. Nothing in this section shall prevent Employee and the Board from
mutually agreeing to an alternative computation of the Annual Bonus, which may
be implemented and paid to Employee in place of the Annual Bonus described
herein. The Annual Bonus shall be subject to any applicable tax withholdings
and/or employee deductions.

          (c)  Employee Benefit Plans. Employee shall be entitled, during the
               ----------------------
specified period of this Agreement, to participate equally with other employees
of a similar rank in any retirement, pension, profit-sharing, health insurance,
or other plans which may now be in effect or which may be adopted by Company.
The benefit plans shall be with such underwriters and shall contain such
provisions as Company, in its sole discretion, may determine from time to time.
Company may delete benefits and otherwise amend and change the type of benefits
it provides in its sole discretion. During the Term, Company shall pay the cost
of group health insurance coverage, through Company's group health insurer, for
Employee, Employee's spouse, and Employee's children.

     4.   REIMBURSEMENT OF BUSINESS EXPENSES.
          ----------------------------------

          (a)  Reimbursement for Ordinary Expenses. Company shall promptly
               -----------------------------------
reimburse Employee for all reasonable business expenses incurred by Employee in
connection with the business of Company. However, each such expenditure shall be
reimbursable only if Employee furnishes to Company adequate records and other
documentary evidence required by federal and state statutes and regulations
issued by the appropriate taxing authorities for the substantiation of each such
expenditure as an income tax deduction.

          (b)  Reimbursement for Extraordinary Expenses. Any single business
               ----------------------------------------
expense with a cost in excess of Ten Thousand Dollars ($10,000) which is not
included in Company's budget as approved by the Board shall be deemed to be an
extraordinary business expense. Employee shall not incur any extraordinary
business expense unless the expense has been approved by the Board. If Employee
fails to obtain the approval of the Board, Company may refuse to reimburse
Employee for that expense.

          (c)  Automobile Allowance and Insurance. Company shall pay to Employee
               ----------------------------------
the sum of Five Hundred Dollars ($500) per month toward the cost of an
automobile. Payment of the aforesaid allowance shall be subject to any
applicable tax withholdings and/or employee deductions. Company shall also pay
the costs of insuring Employee as the driver of the automobile through an
insurer to be agreed upon by Employee and Company. Employee shall be responsible
for all income taxes imposed by reason of the automobile allowance and
insurance.

                                       2
<PAGE>

     5.   ANNUAL VACATION/SICK LEAVE.
          --------------------------

          Employee shall be entitled to thirty (30) days of vacation time in
addition to holiday time and sick leave in accordance with Company's general
policy for its employees.

     6.   PERSONAL CONDUCT.
          ----------------

          Employee agrees promptly and faithfully to comply with all present and
future policies, requirements, directions, requests and rules and regulations of
Company in connection with Company's business. Employee further agrees to
conform to all laws and regulations and not at any time to commit any act or
become involved in any situation or occurrence tending to bring Company into
public scandal, ridicule or which will reflect unfavorably on the reputation of
Company.

     7.   TERMINATION FOR CAUSE.
          ---------------------

          Company reserves the right to declare Employee in default of this
Agreement if Employee willfully breaches or habitually neglects the duties which
he is required to perform under the terms of this Agreement, or if Employee
commits such acts of dishonesty, fraud, misrepresentation, gross negligence or
willful misconduct as would prevent the effective performance of his duties or
which results in material harm to Company or its business. Upon such termination
the obligations of Employee and Company under this Agreement shall immediately
cease. Such termination shall be without prejudice to any other remedy to which
Company may be entitled either at law, in equity, or under this Agreement. If
Employee's employment is terminated pursuant to this paragraph, Company shall
pay to Employee, upon such termination or as soon thereafter as they may be
computed, any amounts earned but unpaid up to the termination date pursuant to
paragraph 3(a) and any declared by unpaid Annual Bonus. All other rights
Employee has under any benefit or stock option plans and programs shall be
determined in accordance with the terms and conditions of such plans and
programs.

     8.   TERMINATION WITHOUT CAUSE.
          -------------------------

          (a)  Death. Employee's employment shall terminate upon the death of
               -----
Employee. Upon such termination, the obligations of Employee and Company under
this Agreement shall immediately cease. In the event of a termination pursuant
to this paragraph, Employee shall be entitled to receive any amounts earned but
unpaid up to the termination date pursuant to paragraph 3(a) and any declared
but unpaid Annual Bonus. All other rights Employee has under any benefit or
stock option plans and programs shall be determined in accordance with the terms
and conditions of such plans and programs.

          (b)  Disability. Company reserves the right to terminate Employee's
               ----------
employment upon ten (10) days written notice if, for a period of sixty (60)
days, Employee is prevented from discharging his duties under this Agreement due
to any physical or mental disability. With the exception of the covenants
included in paragraph 3 above, upon such termination the obligations of Employee
and Company under this Agreement shall immediately cease. In the event of a
termination pursuant to this paragraph, Employee shall be entitled to receive
any amounts earned but unpaid up to the termination date pursuant to paragraph
3(a) and any declared but unpaid Annual Bonus. All other rights Employee has
under any benefit or stock option plans and programs shall be determined in
accordance with the terms and conditions of such plans and programs.

                                       3
<PAGE>

          (c)  Election By Employee. Employee's employment may be terminated at
               --------------------
any time by Employee upon not less than one hundred eighty (180) days written
notice by Employee. With the exception of the covenants included in paragraph 3
above, upon such termination the obligations of Employee and Company under this
Agreement shall immediately cease. In the event of a termination pursuant to
this paragraph, Employee shall be entitled to receive any amounts earned but
unpaid up to the termination date pursuant to paragraph 3(a) and any declared
but unpaid Annual Bonus. All other rights Employee has under any benefit or
stock option plans and programs shall be determined in accordance with the terms
and conditions of such plans and programs.

          (d)  Election By Company. Company may terminate Employee's employment
               -------------------
upon not less than thirty (30) days written notice by Company to Employee. With
the exception of the covenants included in paragraph 3 above, upon such
termination the obligations of Employee and Company under this Agreement shall
immediately cease. In the event of a termination pursuant to this paragraph,
Employee shall be entitled to receive (i) any amounts earned but unpaid up to
the termination date pursuant to paragraph 3(a) and any declared but unpaid
Annual Bonus, and (ii) compensation equal to the balance of the Employee's
unpaid base salary only (as set forth in paragraph 3(a)) through the expiration
date of the term, payable in accordance with Company's payroll procedures as if
Employee's employment by Company had continued until the expiration of the term.
All other rights Employee has under any benefit or stock option plans and
programs shall be determined in accordance with the terms and conditions of such
plans and programs.

     9.   MISCELLANEOUS.
          -------------

          (a)  Preparation of Agreement. It is acknowledged by each party that
               ------------------------
such party either had separate and independent advice of counsel or the
opportunity to avail itself or himself of same. In light of these facts it is
acknowledged that no party shall be construed to be solely responsible for the
drafting hereof, and therefore any ambiguity shall not be construed against any
party as the alleged draftsman of this Agreement.

          (b)  Cooperation. Each party agrees, without further consideration, to
               -----------
cooperate and diligently perform any further acts, deeds and things and to
execute and deliver any documents that may from time to time be reasonably
necessary or otherwise reasonably required to consummate, evidence, confirm
and/or carry out the intent and provisions of this Agreement, all without undue
delay or expense.

          (c)  Interpretation.
               --------------

               (i)  Entire Agreement/No Collateral Representations. Each party
                    ----------------------------------------------
expressly acknowledges and agrees that this Agreement, including all exhibits
attached hereto: (1) is the final, complete and exclusive statement of the
agreement of the parties with respect to the subject matter hereof; (2)
supersedes any prior or contemporaneous agreements, promises, assurances,
guarantees, representations, understandings, conduct, proposals, conditions,
commitments, acts, course of dealing, warranties, interpretations or terms of
any kind, oral or written (collectively and severally, the "Prior Agreements"),
and that any such prior agreements are of no force or effect except as expressly
set forth herein; and (3) may not be varied, supplemented or contradicted by
evidence of Prior Agreements, or by evidence of subsequent oral agreements. Any
agreement hereafter made shall be ineffective to modify, supplement or discharge
the terms of this Agreement, in whole or in part, unless such agreement is in
writing and signed by the party against whom enforcement of the modification or
supplement is sought.

                                       4
<PAGE>

               (ii)   Waiver. No breach of any agreement or provision herein
                      ------
contained, or of any obligation under this Agreement, may be waived, nor shall
any extension of time for performance of any obligations or acts be deemed an
extension of time for performance of any other obligations or acts contained
herein, except by written instrument signed by the party to be charged or as
otherwise expressly authorized herein. No waiver of any breach of any agreement
or provision herein contained shall be deemed a waiver of any preceding or
succeeding breach thereof, or a waiver or relinquishment of any other agreement
or provision or right or power herein contained.

               (iii)  Remedies Cumulative. The remedies of each party under this
                      -------------------
Agreement are cumulative and shall not exclude any other remedies to which such
party may be lawfully entitled.

               (iv)   Severability. If any term or provision of this Agreement
                      ------------
or the application thereof to any person or circumstance shall, to any extent,
be determined to be invalid, illegal or unenforceable under present or future
laws effective during the term of this Agreement, then and, in that event: (A)
the performance of the offending term or provision (but only to the extent its
application is invalid, illegal or unenforceable) shall be excused as if it had
never been incorporated into this Agreement, and, in lieu of such excused
provision, there shall be added a provision as similar in terms and amount to
such excused provision as may be possible and be legal, valid and enforceable,
and (B) the remaining part of this Agreement (including the application of the
offending term or provision to persons or circumstances other than those as to
which it is held invalid, illegal or unenforceable) shall not be affected
thereby and shall continue in full force and effect to the fullest extent
provided by law.

               (v)    No Third Party Beneficiary. Notwithstanding anything else
                      --------------------------
herein to the contrary, the parties specifically disavow any desire or intention
to create any third party beneficiary obligations, and specifically declare that
no person or entity, other than as set forth in this Agreement, shall have any
rights hereunder or any right of enforcement hereof.

               (vi)   Headings; References; Incorporation; Gender. The headings
                      -------------------------------------------
used in this Agreement are for convenience and reference purposes only, and
shall not be used in construing or interpreting the scope or intent of this
Agreement or any provision hereof. References to this Agreement shall include
all amendments or renewals thereof. Any exhibit referenced in this Agreement
shall be construed to be incorporated in this Agreement. As used in this
Agreement, each gender shall be deemed to include the other gender, including
neutral genders or genders appropriate for entities, if applicable, and the
singular shall be deemed to include the plural, and vice versa, as the context
requires.

          (d)  Enforcement.
               -----------

               (i)    Applicable Law. This Agreement and the rights and remedies
                      --------------
of each party arising out of or relating to this Agreement (including, without
limitation, equitable remedies) shall be solely governed by, interpreted under,
and construed and enforced in accordance with the laws (without regard to the
conflicts of law principles thereof) of the State of California, as if this
agreement were made, and as if its obligations are to be performed, wholly
within the State of California.

               (ii)   Consent to Jurisdiction; Service of Process. Any action or
                      -------------------------------------------
proceeding arising out of or relating to this Agreement shall be filed in and
heard and litigated solely before the state courts of California located within
the County of Los Angeles. Each party generally and unconditionally accepts the
exclusive jurisdiction of such courts and to venue therein, consents to the
service of process in any

                                       5
<PAGE>

such action or proceeding by certified or registered mailing of the summons and
complaint in accordance with the notice provisions of this Agreement, and waives
any defense or right to object to venue in said courts based upon the doctrine
of "Forum Non Conveniens". Each party irrevocably agrees to be bound by any
judgement rendered thereby in connection with this Agreement.

               (iii)  Waiver of Right to Jury Trial. Each party hereby waives
                      -----------------------------
such party's respective right to a jury trial of any claim or cause of action
based upon or arising out of this Agreement. Each party acknowledges that this
waiver is a material inducement to each other party hereto to enter into the
transaction contemplated hereby, that each other party has already relied upon
this waiver in entering into this Agreement, and that each other party will
continue to rely on this waiver in their future dealings. Each party warrants
and represents that such party has reviewed this waiver with such party's legal
counsel, and that such party has knowingly and voluntarily waived its jury trial
rights following consultation with legal counsel.

               (iv)   Attorneys' Fees and Costs. If any party institutes or
                      -------------------------
should the parties otherwise become a party to any action or proceeding based
upon or arising out of this Agreement including, without limitation, to enforce
or interpret this Agreement or any provision hereof, or for damages by reason of
any alleged breach of this Agreement, or for a declaration of rights in
connection herewith, or for any other relief, including equitable relief, in
connection herewith, the prevailing party in any such action or proceeding shall
be entitled to receive from the non-prevailing party as a cost of suit all costs
and expenses of prosecuting or defending the action or proceeding, including,
without limitation, reasonable attorneys' fees.

          (e)  No Assignment of Rights or Delegation of Duties by Employee.
               -----------------------------------------------------------
Employee's rights and benefits under this Agreement are personal to him and
therefore (i) no such right or benefit shall be subject to voluntary or
involuntary alienation, assignment or transfer; and (ii) Employee may not
delegate his duties or obligations hereunder.

          (f)  Notices. Unless otherwise specifically provided in this
               -------
Agreement, all notices, demands, requests, consents, approvals or other
communications (collectively and severally called "Notices") required or
permitted to be given hereunder, or which are given with respect to this
Agreement, shall be in writing, and shall be given by: (A) personal delivery
(which form of Notice shall be deemed to have been given upon delivery), (B) by
telegraph or by private airborne/overnight delivery service (which forms of
Notice shall be deemed to have been given upon confirmed delivery by the
delivery agency), (C) by electronic or facsimile or telephonic transmission,
provided the receiving party has a compatible device or confirms receipt thereof
(which forms of Notice shall be deemed delivered upon confirmed transmission or
confirmation of receipt), or (D) by mailing in the United States mail by
registered or certified mail, return receipt requested, postage prepaid (which
forms of Notice shall be deemed to have been given upon the fifth {5th} business
day following the date mailed). Each party, and their respective counsel, hereby
agree that if Notice is to be given hereunder by such party's counsel, such
counsel may communicate directly with all principals, as required to comply with
the foregoing notice provisions. Notices shall be addressed to the address
hereinabove set forth in the introductory paragraph of this Agreement, or to
such other address as the receiving party shall have specified most recently by
like Notice, with a copy to the other parties hereto. Any Notice given to the
estate of a party shall be sufficient if addressed to the party as provided in
this subparagraph.

          (g)  Counterparts. This Agreement may be executed in counterparts,
               ------------
each of which shall be deemed an original, and all of which together shall
constitute one and the same instrument, binding

                                       6
<PAGE>

on all parties hereto. Any signature page of this Agreement may be detached from
any counterpart of this Agreement and reattached to any other counterpart of
this Agreement identical in form hereto by having attached to it one or more
additional signature pages.

          (h)  Execution by All Parties Required to be Binding; Electronically
               ---------------------------------------------------------------
Transmitted Documents. This Agreement shall not be construed to be an offer and
---------------------
shall have no force and effect until this Agreement is fully executed by all
parties hereto. If a copy or counterpart of this Agreement is originally
executed and such copy or counterpart is thereafter transmitted electronically
by facsimile or similar device, such facsimile document shall for all purposes
be treated as if manually signed by the party whose facsimile signature appears.

     IN WITNESS WHEREOF, the parties have executed this Agreement.

                                      Company:

                                      CIRCUIT TREE MEDICAL, INC.
                                      a California corporation

                                      By:___________________________________

                                      Employee:

                                      ______________________________________
                                      ALEX URICH

                                       7
<PAGE>

                                  EXHIBIT "A"
                             POSITION DESCRIPTION

The Company's President will be responsible for the general supervision,
direction, and control over the Company's business and its officers.  In this
regard, the President will submit for approval to the Board, prior to the first
quarter of each year, the following reports for the year:

     (a) A capital budget in respect of each business entity of the Company (and
as consolidated);

     (b) Target/sales budgets in respect of each business entity of the Company
(and as consolidated);

     (c) Operating budgets in respect of each business entity of the Company
(and as consolidated);

     (d) Product development schedule;

     (e) Cash flow statement; and

     (f) Consolidated pro-forma income statement.

The foregoing list may be revised from time-to-time by the Board.

In addition to the above, the President will be responsible for the following:

     (1) determine employee staffing needs; in conjunction with approval by the
Board of Directors, hire or terminate management and executive employees and
consultants and determine appropriate compensation levels; approve hiring and
termination policies and compensation levels for rank and file employees; and
conduct employee evaluations for those employees directly supervised by the
President on a basis consistent with the Company's policies relating to such
evaluations;

     (2) assume primary responsibility for overseeing the preparation of the
Company's monthly, quarterly and yearly financial statements;

     (3) in conjunction with review and approval by the Board of Directors,
assume primary responsibility for overseeing the marketing of the Company's
products and for guiding the development of new products;

     (4) negotiate, review, approve and recommend for approval by the Board of
Directors all material contracts necessary for the operation of the Company's
business;

     (5) exercise oversight of the Company's general operations; and

     (6) develop and implement, with the approval of the Board of Directors,
long-term business and fiscal planning for the Company.

The foregoing list is not meant to be exhaustive.  The President will also
undertake any further responsibilities which must be discharged in order to
assure the smooth-running of the Company's business

                                       8
<PAGE>

and shall also perform such other duties which may, from time to time, be
prescribed by the Company through its Board.

                                       9
<PAGE>

                                 EXHIBIT "3-B"

                          CURTIS EMPLOYMENT AGREEMENT
<PAGE>

                             EMPLOYMENT AGREEMENT

          This EMPLOYMENT AGREEMENT ("Agreement"), which is dated as of December
3, 1999, is made by and between CIRCUIT TREE MEDICAL, INC., a California
corporation, located at 23322 Madero Road, Suite F, Mission Viejo, California
92691 and hereinafter referred to as "Company", and MICHAEL CURTIS, whose
address is 26421 Pebble Creek, Lake Forest, California 92630, hereinafter
referred to as "Employee", based upon the following:

                                   RECITALS
                                   --------

          WHEREAS, Company wishes to retain the services of Employee as its
Vice-President and Employee wishes to render services to Company in that
capacity;

          WHEREAS, Company and Employee wish to set forth in this Agreement the
duties and responsibilities that Employee has agreed to undertake on behalf of
Company;

          WHEREAS, Company and Employee intend that this Agreement will
supersede and replace any and all other employment agreements or arrangements
for employment entered into by and between Company and Employee and that, upon
execution of this Agreement, any such employment agreements or arrangements
shall have no further force or effect.

          THEREFORE, in consideration of the foregoing and of the mutual
promises contained in this Agreement, Company and Employee (who are sometimes
individually referred to as a "party" and collectively referred to as the
"parties") agree as follows:

                                   AGREEMENT
                                   ---------

     1.   SPECIFIED PERIOD.
          ----------------

          Company hereby employs Employee pursuant to the terms of this
Agreement and Employee hereby accepts employment with Company pursuant to the
terms of this Agreement for the period beginning on the execution date of this
Agreement and ending on December 2, 2004 (the "Term").

     2.   GENERAL DUTIES.
          --------------

          Employee shall report to Company's Board of Directors (the "Board").
Employee shall devote his entire productive time, ability, and attention to
Company's business during the term of this Agreement. In his capacity as Vice-
President, Employee shall do and perform all services, acts, or things necessary
or advisable to discharge his duties under this Agreement, including, but not
limited to, those duties and responsibilities included in the Position
Description attached to this Agreement as Exhibit "A" and made a part of it.
Employee shall perform such other duties which may, from time to time, be
prescribed by the Company through its Board. Furthermore, Employee agrees to
cooperate with and work to the best of his ability with Company's management
team, which includes the Board and the officers and other employees, to
continually improve Company's reputation in its industry for quality products
and performance.

                                       1
<PAGE>

     3.   COMPENSATION.
          ------------

          (a)  Salary. During the term of this Agreement, Company shall pay to
               ------
Employee a base salary of One Hundred Thousand Dollars ($100,000) per year.

          (b)  Bonus. Employee and the Board shall meet no later than 90 days
               -----
from the start of Company's fiscal year to establish performance standards and
goals to be met by Employee, which standards and goals shall be based upon
earnings, cash flows, EBITDA and other objectives that are mutually agreed to by
Employee and the Board. Company shall pay to Employee, no later than thirty (30)
days after the completion of the fiscal year, a cash bonus (the "Annual Bonus")
in an amount that shall not be less than Fifty Thousand Dollars ($50,000) for
each year in which the performance standards and goals are met or exceeded by
Employee. Nothing in this section shall prevent Employee and the Board from
mutually agreeing to an alternative computation of the Annual Bonus, which may
be implemented and paid to Employee in place of the Annual Bonus described
herein. The Annual Bonus shall be subject to any applicable tax withholdings
and/or employee deductions.

          (c)  Employee Benefit Plans. Employee shall be entitled, during the
               ----------------------
specified period of this Agreement, to participate equally with other employees
of a similar rank in any retirement, pension, profit-sharing, health insurance,
or other plans which may now be in effect or which may be adopted by Company.
The benefit plans shall be with such underwriters and shall contain such
provisions as Company, in its sole discretion, may determine from time to time.
Company may delete benefits and otherwise amend and change the type of benefits
it provides in its sole discretion. During the Term, Company shall pay the cost
of group health insurance coverage, through Company's group health insurer, for
Employee, Employee's spouse, and Employee's children.

     4.   REIMBURSEMENT OF BUSINESS EXPENSES.
          ----------------------------------

          (a)  Reimbursement for Ordinary Expenses. Company shall promptly
               -----------------------------------
reimburse Employee for all reasonable business expenses incurred by Employee in
connection with the business of Company. However, each such expenditure shall be
reimbursable only if Employee furnishes to Company adequate records and other
documentary evidence required by federal and state statutes and regulations
issued by the appropriate taxing authorities for the substantiation of each such
expenditure as an income tax deduction.

          (b)  Reimbursement for Extraordinary Expenses. Any single business
               ----------------------------------------
expense with a cost in excess of Ten Thousand Dollars ($10,000) which is not
included in Company's budget as approved by the Board shall be deemed to be an
extraordinary business expense. Employee shall not incur any extraordinary
business expense unless the expense has been approved by the Board. If Employee
fails to obtain the approval of the Board, Company may refuse to reimburse
Employee for that expense.

          (c)  Automobile Allowance and Insurance. Company shall pay to Employee
               ----------------------------------
the sum of Five Hundred Dollars ($500) per month toward the cost of an
automobile. Payment of the aforesaid allowance shall be subject to any
applicable tax withholdings and/or employee deductions. Company shall also pay
the costs of insuring Employee as the driver of the automobile through an
insurer to be agreed upon by Employee and Company. Employee shall be responsible
for all income taxes imposed by reason of the automobile allowance and
insurance.

                                       2
<PAGE>

     5.   ANNUAL VACATION/SICK LEAVE.
          --------------------------

          Employee shall be entitled to thirty (30) days of vacation time in
addition to holiday time and sick leave in accordance with Company's general
policy for its employees.

     6.   PERSONAL CONDUCT.
          ----------------

          Employee agrees promptly and faithfully to comply with all present and
future policies, requirements, directions, requests and rules and regulations of
Company in connection with Company's business. Employee further agrees to
conform to all laws and regulations and not at any time to commit any act or
become involved in any situation or occurrence tending to bring Company into
public scandal, ridicule or which will reflect unfavorably on the reputation of
Company.

     7.   TERMINATION FOR CAUSE.
          ---------------------

          Company reserves the right to declare Employee in default of this
Agreement if Employee willfully breaches or habitually neglects the duties which
he is required to perform under the terms of this Agreement, or if Employee
commits such acts of dishonesty, fraud, misrepresentation, gross negligence or
willful misconduct as would prevent the effective performance of his duties or
which results in material harm to Company or its business. Upon such termination
the obligations of Employee and Company under this Agreement shall immediately
cease. Such termination shall be without prejudice to any other remedy to which
Company may be entitled either at law, in equity, or under this Agreement. If
Employee's employment is terminated pursuant to this paragraph, Company shall
pay to Employee, upon such termination or as soon thereafter as they may be
computed, any amounts earned but unpaid up to the termination date pursuant to
paragraph 3(a) and any declared by unpaid Annual Bonus. All other rights
Employee has under any benefit or stock option plans and programs shall be
determined in accordance with the terms and conditions of such plans and
programs.

     8.   TERMINATION WITHOUT CAUSE.
          -------------------------

          (a)  Death.  Employee's employment shall terminate upon the death of
               -----
Employee. Upon such termination, the obligations of Employee and Company under
this Agreement shall immediately cease. In the event of a termination pursuant
to this paragraph, Employee shall be entitled to receive any amounts earned but
unpaid up to the termination date pursuant to paragraph 3(a) and any declared
but unpaid Annual Bonus. All other rights Employee has under any benefit or
stock option plans and programs shall be determined in accordance with the terms
and conditions of such plans and programs.

          (b)  Disability.  Company reserves the right to terminate Employee's
               ----------
employment upon ten (10) days written notice if, for a period of sixty (60)
days, Employee is prevented from discharging his duties under this Agreement due
to any physical or mental disability. With the exception of the covenants
included in paragraph 3 above, upon such termination the obligations of Employee
and Company under this Agreement shall immediately cease. In the event of a
termination pursuant to this paragraph, Employee shall be entitled to receive
any amounts earned but unpaid up to the termination date pursuant to paragraph
3(a) and any declared but unpaid Annual Bonus. All other rights Employee has
under any benefit or stock option plans and programs shall be determined in
accordance with the terms and conditions of such plans and programs.

                                       3
<PAGE>

          (c)  Election By Employee.  Employee's employment may be terminated
               --------------------
at any time by Employee upon not less than one hundred eighty (180) days written
notice by Employee. With the exception of the covenants included in paragraph 3
above, upon such termination the obligations of Employee and Company under this
Agreement shall immediately cease. In the event of a termination pursuant to
this paragraph, Employee shall be entitled to receive any amounts earned but
unpaid up to the termination date pursuant to paragraph 3(a) and any declared
but unpaid Annual Bonus. All other rights Employee has under any benefit or
stock option plans and programs shall be determined in accordance with the terms
and conditions of such plans and programs.

          (d)  Election By Company.  Company may terminate Employee's
               -------------------
employment upon not less than thirty (30) days written notice by Company to
Employee. With the exception of the covenants included in paragraph 3 above,
upon such termination the obligations of Employee and Company under this
Agreement shall immediately cease. In the event of a termination pursuant to
this paragraph, Employee shall be entitled to receive (i) any amounts earned but
unpaid up to the termination date pursuant to paragraph 3(a) and any declared
but unpaid Annual Bonus, and (ii) compensation equal to the balance of the
Employee's unpaid base salary only (as set forth in paragraph 3(a)) through the
expiration date of the term, payable in accordance with Company's payroll
procedures as if Employee's employment by Company had continued until the
expiration of the term. All other rights Employee has under any benefit or stock
option plans and programs shall be determined in accordance with the terms and
conditions of such plans and programs.

     9.   MISCELLANEOUS.
          -------------

          (a)  Preparation of Agreement.  It is acknowledged by each party that
               ------------------------
such party either had separate and independent advice of counsel or the
opportunity to avail itself or himself of same. In light of these facts it is
acknowledged that no party shall be construed to be solely responsible for the
drafting hereof, and therefore any ambiguity shall not be construed against any
party as the alleged draftsman of this Agreement.

          (b)  Cooperation.  Each party agrees, without further consideration,
               -----------
to cooperate and diligently perform any further acts, deeds and things and to
execute and deliver any documents that may from time to time be reasonably
necessary or otherwise reasonably required to consummate, evidence, confirm
and/or carry out the intent and provisions of this Agreement, all without undue
delay or expense.

          (c)  Interpretation.
               --------------

               (i)  Entire Agreement/No Collateral Representations.  Each party
                    ----------------------------------------------
expressly acknowledges and agrees that this Agreement, including all exhibits
attached hereto: (1) is the final, complete and exclusive statement of the
agreement of the parties with respect to the subject matter hereof; (2)
supersedes any prior or contemporaneous agreements, promises, assurances,
guarantees, representations, understandings, conduct, proposals, conditions,
commitments, acts, course of dealing, warranties, interpretations or terms of
any kind, oral or written (collectively and severally, the "Prior Agreements"),
and that any such prior agreements are of no force or effect except as expressly
set forth herein; and (3) may not be varied, supplemented or contradicted by
evidence of Prior Agreements, or by evidence of subsequent oral agreements. Any
agreement hereafter made shall be ineffective to modify, supplement or discharge
the terms of this Agreement, in whole or in part, unless such agreement is in
writing and signed by the party against whom enforcement of the modification or
supplement is sought.

                                       4
<PAGE>

               (ii)   Waiver.  No breach of any agreement or provision herein
                      ------
any obligation under this Agreement, may be waived, nor shall any extension of
time for performance of any obligations or acts be deemed an extension of time
for performance of any other obligations or acts contained herein, except by
written instrument signed by the party to be charged or as otherwise expressly
authorized herein. No waiver of any breach of any agreement or provision herein
contained shall be deemed a waiver of any preceding or succeeding breach
thereof, or a waiver or relinquishment of any other agreement or provision or
right or power herein contained.

               (iii)  Remedies Cumulative.  The remedies of each party under
                      -------------------
this Agreement are cumulative and shall not exclude any other remedies to which
such party may be lawfully entitled.

               (iv)   Severability.  If any term or provision of this Agreement
                      ------------
or the application thereof to any person or circumstance shall, to any extent,
be determined to be invalid, illegal or unenforceable under present or future
laws effective during the term of this Agreement, then and, in that event: (A)
the performance of the offending term or provision (but only to the extent its
application is invalid, illegal or unenforceable) shall be excused as if it had
never been incorporated into this Agreement, and, in lieu of such excused
provision, there shall be added a provision as similar in terms and amount to
such excused provision as may be possible and be legal, valid and enforceable,
and (B) the remaining part of this Agreement (including the application of the
offending term or provision to persons or circumstances other than those as to
which it is held invalid, illegal or unenforceable) shall not be affected
thereby and shall continue in full force and effect to the fullest extent
provided by law.

               (v)    No Third Party Beneficiary.  Notwithstanding anything else
                      --------------------------
herein to the contrary, the parties specifically disavow any desire or intention
to create any third party beneficiary obligations, and specifically declare that
no person or entity, other than as set forth in this Agreement, shall have any
rights hereunder or any right of enforcement hereof.

               (vi)   Headings; References; Incorporation; Gender.  The
                      -------------------------------------------
headings used in this Agreement are for convenience and reference purposes only,
and shall not be used in construing or interpreting the scope or intent of this
Agreement or any provision hereof. References to this Agreement shall include
all amendments or renewals thereof. Any exhibit referenced in this Agreement
shall be construed to be incorporated in this Agreement. As used in this
Agreement, each gender shall be deemed to include the other gender, including
neutral genders or genders appropriate for entities, if applicable, and the
singular shall be deemed to include the plural, and vice versa, as the context
requires.

          (d)  Enforcement.
               -----------

               (i)  Applicable Law.  This Agreement and the rights and remedies
                    --------------
of each party arising out of or relating to this Agreement (including, without
limitation, equitable remedies) shall be solely governed by, interpreted under,
and construed and enforced in accordance with the laws (without regard to the
conflicts of law principles thereof) of the State of California, as if this
agreement were made, and as if its obligations are to be performed, wholly
within the State of California.

               (ii) Consent to Jurisdiction; Service of Process.  Any action or
                    -------------------------------------------
proceeding arising out of or relating to this Agreement shall be filed in and
heard and litigated solely before the state courts of California located within
the County of Los Angeles. Each party generally and unconditionally accepts the
exclusive jurisdiction of such courts and to venue therein, consents to the
service of process in any

                                       5
<PAGE>

such action or proceeding by certified or registered mailing of the summons and
complaint in accordance with the notice provisions of this Agreement, and waives
any defense or right to object to venue in said courts based upon the doctrine
of "Forum Non Conveniens". Each party irrevocably agrees to be bound by any
judgement rendered thereby in connection with this Agreement.

               (iii)  Waiver of Right to Jury Trial.  Each party hereby waives
                      -----------------------------
such party's respective right to a jury trial of any claim or cause of action
based upon or arising out of this Agreement. Each party acknowledges that this
waiver is a material inducement to each other party hereto to enter into the
transaction contemplated hereby, that each other party has already relied upon
this waiver in entering into this Agreement, and that each other party will
continue to rely on this waiver in their future dealings. Each party warrants
and represents that such party has reviewed this waiver with such party's legal
counsel, and that such party has knowingly and voluntarily waived its jury trial
rights following consultation with legal counsel.

               (iv)   Attorneys' Fees and Costs.  If any party institutes or
                      -------------------------
should the parties otherwise become a party to any action or proceeding based
upon or arising out of this Agreement including, without limitation, to enforce
or interpret this Agreement or any provision hereof, or for damages by reason of
any alleged breach of this Agreement, or for a declaration of rights in
connection herewith, or for any other relief, including equitable relief, in
connection herewith, the prevailing party in any such action or proceeding shall
be entitled to receive from the non-prevailing party as a cost of suit all costs
and expenses of prosecuting or defending the action or proceeding, including,
without limitation, reasonable attorneys' fees.

          (e)  No Assignment of Rights or Delegation of Duties by Employee.
               -----------------------------------------------------------
Employee's rights and benefits under this Agreement are personal to him and
therefore (i) no such right or benefit shall be subject to voluntary or
involuntary alienation, assignment or transfer; and (ii) Employee may not
delegate his duties or obligations hereunder.

          (f)  Notices.  Unless otherwise specifically provided in this
               -------
Agreement, all notices, demands, requests, consents, approvals or other
communications (collectively and severally called "Notices") required or
permitted to be given hereunder, or which are given with respect to this
Agreement, shall be in writing, and shall be given by: (A) personal delivery
(which form of Notice shall be deemed to have been given upon delivery), (B) by
telegraph or by private airborne/overnight delivery service (which forms of
Notice shall be deemed to have been given upon confirmed delivery by the
delivery agency), (C) by electronic or facsimile or telephonic transmission,
provided the receiving party has a compatible device or confirms receipt thereof
(which forms of Notice shall be deemed delivered upon confirmed transmission or
confirmation of receipt), or (D) by mailing in the United States mail by
registered or certified mail, return receipt requested, postage prepaid (which
forms of Notice shall be deemed to have been given upon the fifth {5th} business
day following the date mailed). Each party, and their respective counsel, hereby
agree that if Notice is to be given hereunder by such party's counsel, such
counsel may communicate directly with all principals, as required to comply with
the foregoing notice provisions. Notices shall be addressed to the address
hereinabove set forth in the introductory paragraph of this Agreement, or to
such other address as the receiving party shall have specified most recently by
like Notice, with a copy to the other parties hereto. Any Notice given to the
estate of a party shall be sufficient if addressed to the party as provided in
this subparagraph.

          (g)  Counterparts.  This Agreement may be executed in counterparts,
               ------------
each of which shall be deemed an original, and all of which together shall
constitute one and the same instrument, binding

                                       6
<PAGE>

on all parties hereto. Any signature page of this Agreement may be detached from
any counterpart of this Agreement and reattached to any other counterpart of
this Agreement identical in form hereto by having attached to it one or more
additional signature pages.

          (h)  Execution by All Parties Required to be Binding; Electronically
               ---------------------------------------------------------------
Transmitted Documents.  This Agreement shall not be construed to be an offer
---------------------
and shall have no force and effect until this Agreement is fully executed by all
parties hereto. If a copy or counterpart of this Agreement is originally
executed and such copy or counterpart is thereafter transmitted electronically
by facsimile or similar device, such facsimile document shall for all purposes
be treated as if manually signed by the party whose facsimile signature appears.

     IN WITNESS WHEREOF, the parties have executed this Agreement.

                                             Company:

                                             CIRCUIT TREE MEDICAL, INC.
                                             a California corporation

                                             By:______________________________

                                             Employee:

                                             _________________________________
                                             MICHAEL CURTIS
                                       7
<PAGE>

                                  EXHIBIT "A"
                             POSITION DESCRIPTION

The Company's Vice-President will be responsible, in conjunction with the
Company's President, for the general supervision, direction, and control over
the Company's business and its officers. In this regard, the Vice-President will
assist the President with the preparation of the following for submission to the
Board:

     (a)  A capital budget in respect of each business entity of the Company
(and as consolidated);

     (b)  Target/sales budgets in respect of each business entity of the Company
(and as consolidated);

     (c)  Operating budgets in respect of each business entity of the Company
(and as consolidated);

     (d)  Product development schedule;

     (e)  Cash flow statement; and

     (f)  Consolidated pro-forma income statement.

The foregoing list may be revised from time-to-time by the Board.

In addition to the above, the Vice-President, along with the President, will be
responsible for the following:

     (1)  determine employee staffing needs; in conjunction with approval by the
Board of Directors, hire or terminate management and executive employees and
consultants and determine appropriate compensation levels; approve hiring and
termination policies and compensation levels for rank and file employees; and
conduct employee evaluations for those employees directly supervised by the
President on a basis consistent with the Company's policies relating to such
evaluations;

     (2)  assume primary responsibility for overseeing the preparation of the
Company's monthly, quarterly and yearly financial statements;

     (3)  in conjunction with review and approval by the Board of Directors,
assume primary responsibility for overseeing the marketing of the Company's
products and for guiding the development of new products;

     (4)  negotiate, review, approve and recommend for approval by the Board of
Directors all material contracts necessary for the operation of the Company's
business;

     (5)  exercise oversight of the Company's general operations; and

     (6)  develop and implement, with the approval of the Board of Directors,
long-term business and fiscal planning for the Company.

The foregoing list is not meant to be exhaustive.

                                       8
<PAGE>

                         [LETTERHEAD OF CIRCUIT TREE]

                                  ARTICLE III
                         REPRESENTATION AND WARRANTIES
                      OF THE COMPANY AND THE SHAREHOLDERS

                   SCHEDULE 3.3. CAPITAL STOCK OF THE COMPANY

Alex urich                          500 Shares
27402 Via Caudaloso
Mission Viejo, CA  92691

Michael Curtis                      500 Shares
26421 Pebble Creek
Lake Forest, CA  92630
<PAGE>

                         [LETTERHEAD OF CIRCUIT TREE]

                                  ARTICLE III
                        REPRESENTATION AND WARRANTIES OF
                        THE COMPANY AND THE SHAREHOLDERS

                        SCHEDULE 3.4. NON-CONTRAVENTION
<PAGE>

                         [LETTERHEAD OF CIRCUIT TREE]

                                  ARTICLE III
                         REPRESENTATION AND WARRANTIES
                      OF THE COMPANY AND THE SHAREHOLDERS

                       SCHEDULE 3.5 FINANCIAL STATEMENTS

Balance Sheet attached hereto and made a part hereof.
<PAGE>

                           CIRCUIT TREE MEDICAL, INC.
                                 BALANCE SHEET
                            AS OF DECEMBER 31, 1998

                                                     Dec. 31, '98
                                                  ----------------
ASSETS
     Current Assets
          Checking/Savings
             WF CHECKING                                -19,220.69
             WF MARKET RATE                               2,002.82
             WF Business Line                              -106.66
             BA Checking                                  3,103.97
                                                  ----------------
          Total Checking/Savings                        -14,220.56

          Accounts Receivable
              Accounts Receivable                       125,089.99
                                                  ----------------
          Total Accounts Receivable                     125,089.99

          Other Current Assets
              Petty Cash                                     55.81
              Inventory Asset                           -22,863.60
              Undeposited Funds                           7,000.00
                                                  ----------------
          Total Other Current Assets                    -15,807.79
                                                  ----------------
     Total Current Assets                                95,061.64

     Fixed Assets
          Fixed Assets                                   12,553.99
                                                  ----------------
     Total Fixed Assets                                  12,553.99
                                                  ----------------
TOTAL ASSETS                                            107,615.63
                                                  ================
LIABILITIES & EQUITY
  Liabilities
          Current Liabilities
            Accounts Payable
                Accounts Payable                         62,429.88
                                                  ----------------
            Total Accounts Payable                       62,429.88

            Credit Cards
                WELLS FARGO BANK AU                         142.14
                WELLS FARGO BANK MC                       1,372.74
                                                  ----------------
            Total Credit Cards                            1,514.88

            Other Current Liabilities
                Loan Payable-Urich                          278.50
                Payroll Liabilities
                  Federal Withholding          1,558.43
                  FICA                        -2,837.87
                  Medicare                    -2,318.42
                  SDI                         -2,746.66
                  State Withholding            2,938.68
                                         --------------

                                                                          Page 1
<PAGE>

                           CIRCUIT TREE MEDICAL, INC.
                                 BALANCE SHEET
                            AS OF DECEMBER 31, 1998

                                                 Dec. 31, '98
                                                --------------
          Total Payroll Liabilities                  -3,405.84

          Sales Tax Payable                             302.18
                                                --------------
     Total Other Current Liabilities                 -2,825.16
                                                --------------
     Total Current Liabilities                       61,119.60

     Long Term Liabilities
        Loan Payable                                   -623.00
                                                --------------
     Total Long Term Liabilities                       -623.00
                                                --------------
Total Liabilities                                    60,496.60

Equity
     Opening Bal Equity                                -954.07
     Retained Earnings                               66,222.57
     Net Income                                     -19,636.16
     Shareholder's Equity                             1,486.69
                                                --------------
Total Equity                                         47,119.03
                                                --------------
TOTAL LIABILITIES & EQUITY                          107,615.63
                                                ==============

                                                                          Page 2
<PAGE>

                         [LETTERHEAD OF CIRCUIT TREE]

                                  ARTICLE III
                         REPRESENTATION AND WARRANTIES
                      OF THE COMPANY AND THE SHAREHOLDERS

                  SCHEDULE 3.6. OPERATION SINCE BALANCE SHEET
<PAGE>

                         [LETTERHEAD OF CIRCUIT TREE]

                                  ARTICLE III
                         REPRESENTATION AND WARRANTIES
                      OF THE COMPANY AND THE SHAREHOLDERS

           SCHEDULE 3.7. NO UNDISCLOSED LIABILITIES, WORKING CAPITAL
<PAGE>

                         [LETTERHEAD OF CIRCUIT TREE]

                                  ARTICLE III
                         REPRESENTATION AND WARRANTIES
                      OF THE COMPANY AND THE SHAREHOLDERS

                              SCHEDULE 3.8. TAXES

All Tax Returns have been filed on a timely matter, except for the exception of
filing extensions. Tax Returns for 1998 have been filed; there was an extension
request for October 15, which was met. Circuit Tree Medical, Inc. shows an
overpayment and has been requested by our tax accountant Dale R. Howe PH: (949)
830-9110 to be carried over and applied to our 1999 estimated tax payment.

All Tax Returns have been filed.
<PAGE>

                         [LETTERHEAD OF CIRCUIT TREE]

                                  ARTICLE III
                         REPRESENTATION AND WARRANTIES
                      OF THE COMPANY AND THE SHAREHOLDERS

            SCHEDULE 3.9. AVAILABILITY OF ASSETS AND LEGALITY OF USE

The assets owned or leased by Circuit Tree Medical, Inc., is entitled to use
under license or other agreements used by the company are in good condition
(subject to normal wear and tear) and serviceable condition are suitable for the
uses for which they are intended. All such assets and their uses conform to all
applicable laws, regulations, rules, ordinances, codes, licenses, franchises and
permits. No written notice of any existing violation of any such matters
relating to such assets or their use has been received by Circuit Tree Medical,
Inc.
<PAGE>

                         [LETTERHEAD OF CIRCUIT TREE]

                                  ARTICLE III
                         REPRESENTATION AND WARRANTIES
                      OF THE COMPANY AND THE SHAREHOLDERS

                      SCHEDULE 3.10. GOVERNMENTAL PERMITS

Any necessary Governmental Permits have been filed to do business and/or sell
products:

1.       FDA Device Establishment Registration No. 2030501
2.       Federal Tax I.D. No. 33-0627633
3.       Seller Permit No. SREAA99643166
4.       510K(s) for:

The Wave Digital Phaco System No.  K981989
Phacoemuisifier No.  K954242
Reusable Tubing Pak No.  K962430
Phaco Handpiece No.  K954237
Disposable Tubing Pak No. K962431
<PAGE>

                         [LETTERHEAD OF CIRCUIT TREE]

                                  ARTICLE III
                         REPRESENTATION AND WARRANTIES
                      OF THE COMPANY AND THE SHAREHOLDERS

                          SCHEDULE 3.11. REAL PROPERTY
<PAGE>

                         [LETTERHEAD OF CIRCUIT TREE]

                                  ARTICLE III
                         REPRESENTATION AND WARRANTIES
                      OF THE COMPANY AND THE SHAREHOLDERS

                      SCHEDULE 3.12. REAL PROPERTY LEASES

Circuit Tree Medical, Inc. has Real Property Lease with Davis Partners
Incorporated, the Landlord being Mission Viejo Association. The term of the
lease is through August 31, 2000, monthly payments are $1,676.16 payable the
first of each month to Mission Viejo Association at 1420 Bristol Street North,
Suite 100, Newport Beach, CA Ph: (714)752-2066. The premises is located at 23322
Madero Road, Suite F, Mission Viejo, CA 92691 with an approximate rentable
square footage of 1,728.
<PAGE>

                         [LETTERHEAD OF CIRCUIT TREE]

                                  ARTICLE III
                         REPRESENTATION AND WARRANTIES
                      OF THE COMPANY AND THE SHAREHOLDERS

                        SCHEDULE 3.14. PERSONAL PROPERTY

Michael Curtis:

Mercedes Benz 1997 - residual value of $21,000.00 at the termination of the
lease April 2000.

Alex Urich

Jeep-Cherokee 1997 - residual value of $19,000.00 at the termination of the
lease March 2000.
<PAGE>

                         [LETTERHEAD OF CIRCUIT TREE]

                                  ARTICLE III
                         REPRESENTATION AND WARRANTIES
                      OF THE COMPANY AND THE SHAREHOLDERS

                    SCHEDULE 3.15. PERSONAL PROPERTY LEASES

Michael Curtis
Mercedes Benz Corporation
PH: 800-654-6222
Account No. 01-100-96921-01-19001
Monthly Payment $499.01
Lease Expires -  April 2000

Alex Urich
Gold Lease Inc.
PH: 800-677-1534
Account No. 7182633
Monthly Payment $372.66
Expiration of Lease - April 2000
<PAGE>

                         [LETTERHEAD OF CIRCUIT TREE]

                                  ARTICLE III
                         REPRESENTATION AND WARRANTIES
                      OF THE COMPANY AND THE SHAREHOLDERS

                      SCHEDULE 3.16. INTELLECTUAL PROPERTY

Patents are attached hereto and made a part hereof:

Trademarks - CLEO 2000 U.S. Trademark Application No. 75/757, 105

Circuit Tree Medical, Inc. is Y2K complaint.
<PAGE>

<TABLE>
<CAPTION>
                           CIRCUIT TREE MEDICAL, INC.
                              PATENT STATUS REPORT

TITLE                   DOCKET NUMBER      INVENTORS             APPLICATION NUMBER         PATENT NUMBER   REMARKS
-----                   -------------      ---------             ------------------         -------------   -------
<S>                     <C>               <C>                   <C>                        <C>             <C>
Non-Invasive            02376.P001         Gheorghe              08/540,501                 5,716,342       3.5 Maintenance Fee due

Pressure Sensor                            Dumbraveanu, Alex                                                8/10/2001
                        CLIENT'S           Urich, Michael        FILING DATE                ISSUE DATE
                        FILE NUMBER        Curtis                10/10/95                   02/10/98

                        COUNTRY                                  ACTION ITEM  [X] NO [ ] YES
                        USA

------------------------------------------------------------------------------------------------------------------------------------

TITLE                   DOCKET NUMBER      INVENTORS             APPLICATION NUMBER         PATENT NUMBER   REMARKS
-----                   -------------      ---------             ------------------         -------------   -------
Ultrasonic tip and a    02376.P002         Barry S. Seibel,      08/631.007                 5,836,959       3.5 Maintenance Fee due

method for                                 Alex Urich                                                       05/17/2002.
__erocular surgery      CLIENT'S                                 FILING DATE                ISSUE DATE
                        FILE NUMBER                              4/12/96                    11/17/98

                        COUNTRY                                  ACTION ITEM  [X] NO [ ] YES
                        USA

------------------------------------------------------------------------------------------------------------------------------------

TITLE                   DOCKET NUMBER      INVENTORS             APPLICATION NUMBER         PATENT NUMBER   REMARKS
-----                   -------------      ---------             ------------------         -------------   -------
Disposable Surgical     02376.P003         Alex Urich            08/819,301                 5,879,363       3.5 Maintenance Fee due
Ultrasonic                                                                                                  9/9/2002.
_________               CLIENT'S                                 FILING DATE                ISSUE DATE
                        FILE NUMBER                              03/18/97                   03/09/99

                        COUNTRY                                  ACTION ITEM  [X] NO [ ] YES
                        USA

------------------------------------------------------------------------------------------------------------------------------------

</TABLE>

                                       1
<PAGE>

<TABLE>
<CAPTION>
                           CIRCUIT TREE MEDICAL, INC.
                              PATENT STATUS REPORT

TITLE                   DOCKET NUMBER      INVENTORS             APPLICATION NUMBER         PATENT NUMBER  REMARKS
-----                   -------------      ---------             ------------------         -------------  -------
<S>                     <C>               <C>                   <C>                        <C>             <C>
Vacuum Controlled       02376.P004         Alex Urich;           09/097.099                                Response to Office Action

Surgical Ultrasound                        Michael Curtis                                                  due 9/4/99.
                        CLIENT'S                                 FILING DATE                ISSUE DATE
                        FILE NUMBER                              06/12/98

                        COUNTRY                                  ACTION ITEM  [ ] NO [ ] YES
                        USA

------------------------------------------------------------------------------------------------------------------------------------

TITLE                   DOCKET NUMBER      INVENTORS             APPLICATION NUMBER         PATENT NUMBER  REMARKS
-----                   -------------      ---------             ------------------         -------------  -------
<S>                     <C>               <C>                   <C>                        <C>             <C>
Vacuum Controlled  a    02376.P004X        Alex Urich;           09/372,476                                Awaiting response from
Surgical Ultrasound                        Michael Curtis                                                  U.S. Patent and Trademark

                        CLIENT'S                                 FILING DATE                ISSUE DATE     Office.
                        FILE NUMBER                              08/11/99

                        COUNTRY                                  ACTION ITEM  [X] NO [ ] YES
                        BJY

------------------------------------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------------------------------------

TITLE                   DOCKET NUMBER      INVENTORS             APPLICATION NUMBER         PATENT NUMBER  REMARKS
-----                   -------------      ---------             ------------------         -------------  -------
<S>                     <C>               <C>                   <C>                        <C>             <C>
Vacuum Controlled  a    02376.P004Z        Alex Urich;           60/084,852                                Awaiting response from
Surgical Ultrasound                        Michael Curtis                                                  U.S. Patent and Trademark

                        CLIENT'S                                 FILING DATE                ISSUE DATE     Office.
                        FILE NUMBER                              05/08/98

                        COUNTRY                                  ACTION ITEM  [X] NO [ ] YES
                        USA

------------------------------------------------------------------------------------------------------------------------------------

</TABLE>

                                       2
<PAGE>

<TABLE>
<CAPTION>
                           CIRCUIT TREE MEDICAL, INC.
                              PATENT STATUS REPORT

TITLE                   DOCKET NUMBER      INVENTORS             APPLICATION NUMBER         PATENT NUMBER  REMARKS
-----                   -------------      ---------             ------------------         -------------  -------
<S>                     <C>               <C>                   <C>                        <C>             <C>
Venting Apparatus       02376.P005                               09/351,066                                Awaiting response from
for Eye Surgery                                                                                            U.S. Patent and Trademark

                        CLIENT'S                                 FILING DATE                ISSUE DATE     Office
                        FILE NUMBER                              07/09/99

                        COUNTRY                                  ACTION ITEM  [X] NO [ ] YES
                        USA

------------------------------------------------------------------------------------------------------------------------------------

TITLE                   DOCKET NUMBER      INVENTORS             APPLICATION NUMBER         PATENT NUMBER  REMARKS
-----                   -------------      ---------             ------------------         -------------  -------
<S>                     <C>               <C>                   <C>                        <C>             <C>
Venting Apparatus       02376.P005Z        Alex Urich;           60/092,676                                Awaiting response from
for Eye Surgery                            Michael Curtis                                                  U.S. Patent and Trademark

                        CLIENT'S                                 FILING DATE                ISSUE DATE     Office
                        FILE NUMBER                              07/13/98

                        COUNTRY                                  ACTION ITEM  [X] NO [ ] YES
                        USA

------------------------------------------------------------------------------------------------------------------------------------

TITLE                   DOCKET NUMBER      INVENTORS             APPLICATION NUMBER         PATENT NUMBER  REMARKS
-----                   -------------      ---------             ------------------         -------------  -------
<S>                     <C>               <C>                   <C>                        <C>             <C>
_______ Incision        02376.P006         Alex Urich;           09/369,059                                Awaiting response from
Temperature Sensing                        Michael Curtis                                                  U.S. Patent and Trademark

                        CLIENT'S                                 FILING DATE                ISSUE DATE     Office
                        FILE NUMBER                              08/04/99

                        COUNTRY                                  ACTION ITEM  [X] NO [ ] YES
                        USA

------------------------------------------------------------------------------------------------------------------------------------

</TABLE>
                                       3
<PAGE>

<TABLE>
<CAPTION>
                           CIRCUIT TREE MEDICAL, INC.
                              PATENT STATUS REPORT

TITLE                   DOCKET NUMBER      INVENTORS             APPLICATION NUMBER         PATENT NUMBER  REMARKS
-----                   -------------      ---------             ------------------         -------------  -------
<S>                     <C>               <C>                   <C>                        <C>             <C>
Eye Incision            02376.P006Z        Alex Urich;           60/095,274                                Awaiting response from
Temperature Sensing                        Michael Urich                                                   U.S. Patent and Trademark

Device                  CLIENT'S                                 FILING DATE                ISSUE DATE     Office
                        FILE NUMBER                              08/04/98

                        COUNTRY                                  ACTION ITEM  [X] NO [ ] YES
                        USA
------------------------------------------------------------------------------------------------------------------------------------

TITLE                   DOCKET NUMBER      INVENTORS             APPLICATION NUMBER         PATENT NUMBER  REMARKS
-----                   -------------      ---------             ------------------         -------------  -------
Eye Incision            02376.P007                               09/186,993                                Awaiting response from
Temperature                                                                                                U.S. Patent and Trademark

Protecting Sleeve       CLIENT'S                                 FILING DATE                ISSUE DATE     Office
                        FILE NUMBER                              11/05/98

                        COUNTRY                                  ACTION ITEM  [X] NO [ ] YES
                        USA
------------------------------------------------------------------------------------------------------------------------------------

TITLE                   DOCKET NUMBER      INVENTORS             APPLICATION NUMBER         PATENT NUMBER  REMARKS
-----                   -------------      ---------             ------------------         -------------  -------
Eye Incision            02376.P007Z                              60/095,373                                Awaiting response from
Temperature                                                                                                U.S. Patent and Trademark

Protecting Sleeve       CLIENT'S                                 FILING DATE                ISSUE DATE     Office
                        FILE NUMBER                              08/05/98

                        COUNTRY                                  ACTION ITEM  [X] NO [ ] YES
                        USA

------------------------------------------------------------------------------------------------------------------------------------

</TABLE>

                                       4
<PAGE>

<TABLE>
<CAPTION>
                           CIRCUIT TREE MEDICAL, INC.
                              PATENT STATUS REPORT

TITLE                   DOCKET NUMBER      INVENTORS             APPLICATION NUMBER         PATENT NUMBER  REMARKS
-----                   -------------      ---------             ------------------         -------------  -------
<S>                     <C>               <C>                   <C>                        <C>             <C>
Ultrasonic Shredder     02376.P008Z        Alex Urich;           60/121,216                                Awaiting response from
on Surgical                                                                                                U.S. Patent and Trademark

Applications            CLIENT'S                                 FILING DATE                ISSUE DATE     Office
                        FILE NUMBER                              02/22/99

                        COUNTRY                                  ACTION ITEM  [X] NO [ ] YES
                        USA
------------------------------------------------------------------------------------------------------------------------------------

TITLE                   DOCKET NUMBER      INVENTORS             APPLICATION NUMBER         PATENT NUMBER  REMARKS
-----                   -------------      ---------             ------------------         -------------  -------
_______ Tip-Cap         02376.P009Z        Alex Urich;           60/121,215                                Awaiting response from
Sleeve With Cooling                                                                                        U.S. Patent and Trademark

Orifice                 CLIENT'S                                 FILING DATE                ISSUE DATE     Office
                        FILE NUMBER                              02/22/99

                        COUNTRY                                  ACTION ITEM  [X] NO [ ] YES
                        USA
------------------------------------------------------------------------------------------------------------------------------------

TITLE                   DOCKET NUMBER      INVENTORS             APPLICATION NUMBER         PATENT NUMBER  REMARKS
-----                   -------------      ---------             ------------------         -------------  -------
Surgical Ultrasonic     02376.P010Z                              60/155,669                                Awaiting response from
Transducer                                                                                                 U.S. Patent and Trademark

                        CLIENT'S                                 FILING DATE                ISSUE DATE     Office
                        FILE NUMBER                              09/22/99

                        COUNTRY                                  ACTION ITEM  [X] NO [ ] YES
                        USA
------------------------------------------------------------------------------------------------------------------------------------

</TABLE>

                                       5
<PAGE>

                         [LETTERHEAD OF CIRCUIT TREE]

                                   ARTICLE III
                          REPRESENTATION AND WARRANTIES
                       OF THE COMPANY AND THE SHAREHOLDERS

                 SCHEDULE 3.17. Accounts Receivable, Inventories

             There are no accounts past 90 days and the terms stated
                       per 3.17 of Article III are true.
<PAGE>

                         [LETTERHEAD OF CIRCUIT TREE]

                                   ARTICLE III
                           REPRESENTATION AND WARRANTIES
                       OF THE COMPANY AND THE SHAREHOLDERS

                          SCHEDULE 3.18 Title to Assets
<PAGE>

                         [LETTERHEAD OF CIRCUIT TREE]

                                   ARTICLE III
                          REPRESENTATION AND WARRANTIES
                       OF THE COMPANY AND THE SHAREHOLDERS

                            SCHEDULE 3.19. EMPLOYEES

         Yearly Bonus and Christmas Bonus for all employees each year based on
         Customer sales.  Circuit Tree Medical, Inc. closes for two weeks
         Christmas vacation.

         Stephanie Stanistreet-monthly salary of $3,775.28 salary increase 5%
         Minimum beginning each year and bonus. PPO Insurance, Two Dental Exams
         With 30% coverage of all work and One Eye Exam each year. Ten(10) Sick
         Days and Five (5) Personal Days each year. Paid Vacation Time: Twenty
         (20) Days-Two Weeks taken at will, Two Weeks for Christmas Vacation.

         Gheorghe Dumbraveanu-monthly salary $2,520.00 salary increase 10%
         minimum beginning each year and bonus. HMO Medical Insurance. Seven (7)
         sick days, Five (5) personal days, Twenty (20) paid vacation days.

         Derek Albert-an hourly rate of $11.00, salary increase and bonus based
         on Performance and customer demand. HMO Medical Insurance. Seven (7)
         sick Days and Two (2) personal days, Two weeks paid vacation.

         Jim Jacobson-an hourly rate of $9.00 salary increase based on
         performance And customer demand.

         Employee Contracts on record.
<PAGE>

                         [LETTERHEAD OF CIRCUIT TREE]

                                   ARTICLE III
                          REPRESENTATION AND WARRANTIES
                      OF THE COMPANY AND THE SHARE HOLDERS

                        SCHEDULE 3.20. Employees Matters
<PAGE>

                         [LETTERHEAD OF CIRCUIT TREE]

                                   ARTICLE III
                          REPRESENTATION AND WARRANTIES
                       OF THE COMPANY AND THE SHAREHOLDERS

                     SCHEDULE 3.21. EMPLOYEE BENEFITS PLANS
<PAGE>

                         [LETTERHEAD OF CIRCUIT TREE]

                                   ARTICLE III
                          REPRESENTATION AND WARRANTIES
                       OF THE COMPANY AND THE SHAREHOLDERS

                             SCHEDULE 3.22 Contracts

(G) any consignment is not applicable, all business distributors are handled
through purchase orders generated by the distributor.

(1) We have confidentiality agreements with the following persons:

Gheorghe Dumbraveanu-Employee
Derek Albert-Employee
Daniel Matew-Consultant
Things To See-Distributor
Alcon-Customer
Shenyang Silver Sea Eye Center-Distributor
Micro Surgical Technologie-Licensee

(K) Staar Surgical
<PAGE>

                         [LETTERHEAD OF CIRCUIT TREE]

                                   ARTICLE III
                          REPRESENTATION AND WARRANTIES
                       OF THE COMPANY AND THE SHAREHOLDERS

                        SCHEDULE 3.23 Status of Contracts

In reference to Schedules 3.12, 3.15, 3.21 and 3.22 Circuit Tree Medical, Inc.
is not in Breach, default and/or will not expire prior to closing date.
<PAGE>

                         [LETTERHEAD OF CIRCUIT TREE]

                                   ARTICLE III
                          REPRESENTATION AND WARRANTIES
                      OF THE COMPANY AND THE SHAREHOLDERS

          SCHEDULE 3.24. No Violation, Litigation or Regulatory Action
<PAGE>

                         [LETTERHEAD OF CIRCUIT TREE]

                                   ARTICLE III
                          REPRESENTATION AND WARRANTIES
                       OF THE COMPANY AND THE SHAREHOLDERS

                            SCHEDULE 3.25. Insurance

All Insurance Companies have remained the same since January 1.1995: The below
policies are Paid to date and will continue to remain the same prior to close
date.

Aylor Insurance Agency, Inc. PH:(800)668-3445 Account No. 1441308-98
Workers Compensation Fund Total Annual Premium $1,966.00

Aylor Insurance Agency, Inc. PH:(800)244-2043 Account NO. CALH812426
Commercial Insurance Policy-Total Premium Policy $914.00 per year.

Liability Form Coverage: ($221.00)
General Aggregate Limit                              $2,000,000
Products-Completed Operations Aggregate Limit        $2,000,000
Personal And Advertising injury limit                $1,000,000
Each Occurrence Limit                                $1,000,000
Fire Damage Limit (any One Fire)                     $  100,000
Medical Expense Limit (any one Person)               $    5,000

Property Form:($693.00)
Personal Property:
Limit of Insurance                     $25,000.00
Deductible                                 500.00
Valuation                        Replacement Cost
Theft Deductible                           500.00
Personal Property of Others
Limit of Insurance                     $10,000.00
Deductible                                 500.00
Valuation                       Actual Cash Value
Theft Deductible                           500.00
Business Income Including Rental
Limit of Insurance                     $20,000.00
No Waiting Period
Signs:
Limit of Insurance                     $10,000.00
Deductible                                 500.00
Electronic Data Processing:
Limit of Insurance                     $10,000.00
Deductible                                 500.00
<PAGE>

                         [LETTERHEAD OF CIRCUIT TREE]

                                   ARTICLE III
                          REPRESENTATION AND WARRANTIES
                       OF THE COMPANY AND THE SHAREHOLDERS

MEDICAL INSURANCE

Blue Cross of California Medical Insurance for employees: (Total Monthly
Premium)
Alex Urich and Family-PPO $566.00
Michael Curtis and Spouse ~ PPO #531.00
Stephanie Stanistreet ~ PPO $148.00
Gheorghe Dumbraveanu ~ HMO $163.00
Kaiser Permanent Medical insurance: Derek Albert $101.00 per month

Car Insurance:

Michael Curtis:
Farmers Insurance Exchange PH:(714)637-1712 Policy No 97-10635-25-43 $1,100.00
per Year covers 1997 Mercedes Benaz Model No. 220 c/230 c

Alex Urich
Automobile Club of Southern California Policy No. G6362680 $1,037.00 per year.
Covers 1997 Jeep Cherokee
<PAGE>

                         [LETTERHEAD OF CIRCUIT TREE]

                                   ARTICLE III
                          REPRESENTATION AND WARRANTIES
                       OF THE COMPANY AND THE SHAREHOLDERS

                     SCHEDULE 3.27. Customers and Suppliers

Customers:

December 1997:

Chiron Vision $174,676.31 ~ 651 Wharton Drive, Claremont, CA
Surgin, Inc. $109,900.00 ~ 14762 Bentley Circle, Tustin, CA
Sterilab $94,000.00 ~ 12720 Broken Saddle Road, Knoxville, TN
Premier Laser $75,000 ~ 3 Morgan, Irvine, CA
M. Imonti and Assoc. $45,000.00 25707 Compass Way, San Juan Capistrano, CA
Irvine Biomedical Inc. $44,000.00 ~ 2146 Michelson Drive, Suit A, Irvine ,CA
Shenyang Silver Sea Eye Center $35,500.00 ~ Huanghe Bei Da Street 128, Shenyang
China
Young Power $29,0000.00 ~ 332 S. Pomelo Avenue D, Monterey Park, CA
Roson $19,000.00 ~ 2841 Satum, Suite K, Brea, CA

December 1998:

Staar Surgical $193,000.00
Chiron Vision $131,000.00
Surgin, Inc. $97,000.00
Shenyang Silver Sea Eye Center $79,000.00
MPB Enterprises $79,000.00 2705 Billys Road, Minen, NV
Premier Laser $67,000.00
Irvine Biomedical $60,000.00
Scieran Technologies $43,000.00 ~ 27071 Cabot Rd. #127, Laguna Hills, CA
M. Imonti&Assoc. $ 26,000.00
Young Power $22,000.00

Suppliers:

December 1997 and 1998

Harry Kosalos $14,000.00/20,000.00 ~ 225511 Rimini, Laguna Hills, CA
Laguna Machine $20,000.00/30,000.00 ~ 23121 La Cadena Drive, Laguna Hills, CA
Linemaster $12,000.00/23,000.00 ~ 29 Palm Hill Rd., Woodstock, CT
Benevente $10,000.00/14,000.00 ~ 3112 S. Halladay, Santa Ana, CA
Allied Electronics $10,000.00/10,000.00 ~ P.O. Box 2325, Forth Worth TX
Eastern Air Devices $10,000.00/14,000.00 ~ P.O. Box 4653, Boston, MA
Schroff $11,000.00/9,200.00 ~ P.O. Box 861, Minneapolis, MN
Newark Electronics $26,000.00/35,000.00 P.O. Box  94151, Palatine, IL
Pacific Transformer $13,000.00/20,000.00 ~ 5399 E. Hunter Avenue Anaheim, CA
Pro Tech $30,000.00/27,0000.00 ~ Mt. Wynne Circle, Fountain Valley, CA
<PAGE>

--------------------------------------------------------------------------------
PURCHASE ORDER                          P.O. NUMBER
--------------------------------------------------------------------------------
TO:                                     DATE:
                                        ----------------------------------------
                                        DATE REQUIRED:
                                        ----------------------------------------
                                        TERMS:         NET 30
                                        ----------------------------------------
                                        SHIP VIA:
                                        ----------------------------------------
                                        F.O.B.
                                        ----------------------------------------
                                        SHIP TO:
                                        BILL TO:
PHONE:                                             Circuit Tree Medical, Inc.
FAX:                                               23322 Madero Road, Suit F
                                                   Mission Viejo, CA 92961:
ATTN:
----------------------------------------
                                        PH: 949/454-2208   Fax: 949/454-1607
PAGE ONE OF ONE
                                        ATTN:             Stephanie Stanistreet
----------------------------------------
----------------------------------------
--------------------------------------------------------------------------------
ITEM     QTY.     UNIT     PLEASE SUPPLY ITEMS BELOW     UNIT PRICE    AMOUNT
--------------------------------------------------------------------------------

                     [SAMPLE SCHEDULE 3.27 PURCHASE ORDER]

--------------------------------------------------------------------------------
                 IMPORTANT                |Please send 2 copies of your invoice.
                 ---------                |=====================================
*  This Purchase Order Number must        |
   appear on all invoices,                |
   acknowledgments, bills of lading,      | /s/ M. Curtis
   correspendence and shipping labels.    |
** Please notify us if you are unable to  |
   ship complete order by date            |-------------------------------------
   specified. Authorized Signature        | Authorized Signature
--------------------------------------------------------------------------------
<PAGE>

                         [LETTERHEAD OF CIRCUIT TREE]

                                   ARTICLE III
                          REPRESENTATION AND WARRANTIES
                       OF THE COMPANY AND THE SHAREHOLDERS

                    SCHEDULE 3.30 Transaction with Affiliates
<PAGE>

                         [LETTERHEAD OF CIRCUIT TREE]

                                   ARTICLE III
                          REPRESENTATION AND WARRANTIES
                       OF THE COMPANY AND THE SHAREHOLDERS

                SCHEDULE 4.2 NON-CONTRAVENTION, REQUIRED CONSENTS<PAGE>

                                                                   EXHIBIT 10.45

                          LICENSE & SUPPLY AGREEMENT

   THIS LICENSE AND SUPPLY AGREEMENT (the "Agreement"), dated this 6 day of May,
1999 (the "Effective Date"), is entered into by and between STAAR Surgical
Company, a Delaware corporation and its wholly-owned subsidiary STAAR Surgical
AG, a Swiss corporation (jointly "STAAR"), Lenstec, Incorporated, a Florida
corporation and Lenstec Barbados Inc., a corporation existing under the laws of
Barbados (jointly "Lenstec").

                                   RECITALS

   A.     Lenstec is the developer and manufacturer of a three-piece intraocular
lens used in ophthalmic surgery, the haptics of which are made from polyimide,
and the optic of which is a HEMA/Acrylic copolymer, the current Lenstec Model
#LH3000 (the "Product");

   B.     STAAR desires to obtain the right to license and purchase finished
Product directly from Lenstec for re-sale pursuant to the terms of this
Agreement; and

   NOW, THEREFORE, in consideration of the mutual promises above and the
agreements contained herein, the parties hereby agree as follows:

                                   AGREEMENT

                                   ARTICLE 1
                               EXCLUSIVE PRODUCT

   1.1    License of Product.  Lenstec agrees to license to STAAR on a
          -------------------
semi-exclusive basis, as set forth below, the Product for re-sale, and to
manufacture and supply the Product for STAAR, on the terms set forth in this
Agreement.  Lenstec, pursuant to an existing agreement with Santen
Pharmaceutical Co., Ltd., a Japanese corporation ("Santen") is obligated to
offer to Santen for sale under Santen's proprietary brand, any product produced
by Lenstec. Lenstec agrees to sell the Product only to STAAR, its affiliates and
Santen during the term of this Agreement. Lenstec agrees that during the term of
this agreement it will not sell a three piece Hema/Acrylic copolymer lens with
haptics made from any suitable material to anyone other than the parties named
herein in the respective territories named in paragraph 1.2 and 1.5.

  1.2     Limitations.  STAAR or its affiliated entities may not sell the
          ------------
Product in Japan.

  1.3     Private Labeling.  STAAR shall have the rights to have the Product
          ----------------
private labeled for STAAR with STAAR's labels and brand names.

  1.4     Intellectual Property/License.  By executing this Agreement, Lenstec
          ------------------------------
transfers to STAAR for use during the Effective Period, an exclusive,
non-royalty bearing license to use any trademarks, trade names, copyrights,
logos, service marks and symbols it owns which are derived from, associated
with, or used with the Product.

  1.5      Waiver of Distribution Rights by Santen.  Prior to executing this
           ---------------------------------------
Agreement, Lenstec will obtain from Santen, for the benefit of STAAR, a waivier
of Santen's distribution rights to the Product, except as such rights relate to
Japan and an agreement from Santen that STAAR and Santen shall have identical
rights to distribute the Product in the Philipines, Malaysia, Singapore,
Thailand, Korea, China, Tiawan, Vietnam and Indonesia.
<PAGE>

                                   ARTICLE 2
                             TERM AND TERMINATION

     2.1     Term.  This Agreement shall remain in effect for a period of two
             ----
(2) years from the later of (i) the date that it is executed by STAAR and
Lenstec, (the "Effective Period").  STAAR shall be entitled to extend the term
of this Agreement for an additional period of one (1) year by giving notice of
such election to Lenstec at least ninety (90) days prior to the expiration of
the Effective Period.  If STAAR extends the term of this Agreement for an
additional one (1) year period (the "Extension Period"), then the Effective
Period shall include both the initial term and the extended term.  Upon the
expiration of the Extension Period, this Agreement shall continue in full force
and effect until such time as either party gives the other party ninety (90)
days written notice of its intention to terminate this Agreement.

                                   ARTICLE 3
                               SUPPLY OF PRODUCT

     3.1     Supply Obligation.  Subject to the terms and conditions of this
             -----------------
Agreement, STAAR shall have the right to purchase the Product from Lenstec for
marketing in all countries of the world with the exception of Japan.  Lenstec
agrees to manufacture and supply the Product for STAAR under the terms and
conditions of this Agreement.  Lenstec agrees that it will not sell other
foldable lenses to any of STAAR's current distributors.

     3.2     Contract Manufacture.  Lenstec agrees to produce the Product
             --------------------
according to the Manufacturing Specifications and Requirements set forth in
Appendix A to this Agreement.  The Product shall be manufactured, packaged and
sterilized by Lenstec in its Barbados production facility.

     3.3     Forecast.  Within fifteen (15) days from the first day of the
             --------
Effective Period, STAAR shall provide to Lenstec an annual forecast and a three
(3) month projection ("Quarterly Forecast") of its purchase requirements for
Product.  Thereafter, at least five (5) days prior to the start of each three
(3) month period, STAAR shall provide to Lenstec the Quarterly Forecast of its
purchase requirements for the next quarter.

     3.4     Orders.  STAAR shall submit a purchase order ("Order") for the
             ------
Product on the 1st day of each month and Lenstec shall ship the Product to STAAR
within thirty (30) days from receipt of the purchase order.  Actual Orders for
each three (3) month period may vary from STAAR's Quarterly Forecast for the
period by no more 30%. All of STAAR's Orders for the Product shall be
acknowledged by Lenstec by a faxed acknowledgment. In no event shall any
acknowledgment or shipping document have the effect of varying, altering or
modifying the terms and provisions of this Agreement. If there is any conflict
between the acknowledgment and the terms of this Agreement, the terms of this
Agreement shall prevail.

     3.5     Order Quantities.  During the initial six (6) months of the
             ----------------
Effective Period, Lenstec shall not be obligated to deliver more than 6,000
units of Product in any single month.  Following the initial six months of the
Effective Period, Lenstec shall not be obligated to deliver more than 10,000
units of Product in any single month, unless notified by STAAR at least sixty
(60) days in advance.  In no case shall Lenstec be obligated to deliver more
than 15,000 units of Product during any one-month period.

     3.6     Shipment Instruments.  All Products supplied pursuant to this
             --------------------
Agreement will be delivered FOB Lenstec's production facility in Barbados.
Lenstec will ship finished Product pursuant to STAAR's written instructions.
All customs, duties, costs, taxes, insurance premiums and other expenses
relating to transportation and shipment of Product shall be at STAAR's expense.

                                       2
<PAGE>

     3.7     Certificate of Compliance.  All deliveries of the Product shall be
             -------------------------
accompanied by a certificate which states that the Product meets the
manufacturing and quality control release specifications which are jointly
agreed to by STAAR and Lenstec (the "Specifications"), which Specifications are
set forth on Exhibit "A" to this Agreement and made a part of it.

     3.8     Breach.  Failure by Lenstec to supply STAAR with the Product
             ------
ordered according to the terms of this Agreement (other than as a result of
force majeure, as set forth in Section 9.12) shall be considered a material
breach of this Agreement.  Failure by STAAR to provide sufficient Orders to meet
its purchase obligations under this Agreement shall be remedied as set forth in
Section 4.5.

                                   ARTICLE 4
                              PRICE AND PAYMENTS

     4.1     Pre-paid Purchase Deposit.  Within five (5) days from the first day
             -------------------------
of the Effective Period, STAAR shall pay to Lenstec the sum of one hundred
thousand U.S. dollars (U.S. $100,000).

     4.2     Price of Product.  Subject to the terms and conditions of this
             ----------------
Agreement, STAAR shall, during the first year of the Effective Period, purchase
no less than sixty-five thousand (65,000) units of the Product at a price of
forty-five U.S. dollars (U.S.$45) per unit.  During the second year of the
Effective Period, STAAR shall purchase annually no less than ninety thousand
(90,000) units of the Product at a price of forty U.S. dollars (U.S. $40.00) per
unit (unless the parties agree to another price.)  If STAAR extends the terms of
this Agreement pursuant to section 2.1 above, then  STAAR and Lenstec shall
negotiate in good faith  to agree on the number of units of Product to be
purchased by STAAR and on the price of the Product to be charged by Lenstec,
provided, however, that during the Extension Period, STAAR shall purchase no
less than ninety thousand (90,000) units of the Product annually from Lenstec
and the price per unit charged by Lenstec shall not exceed, but may be less
than, forty U.S. dollars (U.S. $40).

     4.3     Payment Terms.  One-half of the amount due for each Order shall be
             -------------
paid in U.S. dollars upon submission of the purchase order by STAAR.  The
remaining one-half shall be due and payable in U.S. dollars within fifteen days
of notice of shipment.

     4.4     Application of Pre-paid Purchase Deposit.  Lenstec will apply a $10
             ----------------------------------------
credit per unit of Product for the 10,000 units of Product ordered following the
delivery of the initial 80,000 units of Product during year 2 of the Effective
Period.  Each credit will be taken at the time an Order is received, and each
credit will reduce the remaining balance of the Pre-paid Purchase Deposit.

     4.5     Order Shortfall.  In the event that STAAR fails to provide Orders
             ---------------
equal to (i) at least 70% of its Quarterly Forecast for any quarterly period, or
(ii) its minimum annual purchase obligations under this Agreement, Lenstec shall
be entitled to reduce the balance of the Pre-paid Purchase Deposit by an amount
equal to the unit shortfall times one-half of the effective unit price for that
period.  In the event of an Order Shortfall, STAAR shall be obligated to
replenish the Pre-paid Purchase Deposit prior to an Order for additional units
of Product.

<PAGE>

     4.6    Payments.  All payments shall be forwarded to the following bank
            --------
account:

                          Barclays bank PLC New York
                          ABA 026002574
                          Chips UID 240280
                          Beneficiary:
                          Barbados Offshore Bank Unit
                          A/C# 280 90 82/4677
                          For credit to:
                          Lenstec Barbados Inc.
                          A/C# 23 103-22-58

                                   ARTICLE 5
                             PRODUCT REGISTRATION

     5.1    Product Registration.  If it so elects, which election shall be in
            --------------------
its sole and absolute discretion, STAAR shall, at its own expense, obtain the
necessary regulatory approvals for the sale of the Product. Lenstec shall
cooperate with STAAR in connection with such product registration activities and
provide such information as may be reasonably requested by STAAR to meet such
regulatory requirements. Lenstec will provide any and all information requested
by any regulatory body or agency involved in any such approval process. If any
regulatory body or agency requires a post-marketing study, then STAAR and
Lenstec will cooperate fully in completing any such study.

     5.2    Clinical Investigation Activities.  If STAAR decides to use its
            ---------------------------------
notified body and their notified body requires additional clinical studies, then
STAAR will pay the cost of the clinical trials.

     5.3    Choice of Notified Body.  STAAR shall have the right, but not the
            -----------------------
obligation, to use its notified body for distributing the Product to the markets
in Europe and other countries.  If STAAR decides to use its notified body then
Lenstec will, and will request its notified body to, cooperate fully with STAAR
and STAAR's notified body so that STAAR may accomplish such distribution,
including providing any and all information reasonably requested by STAAR's
notified body or any governmental agency, such as, but not limited to, its
technical file, design file, etc.  STAAR shall use the CE mark obtained by
Lenstec in the initial launch of the Product, and will decide within the 12
month period following the launch whether it will transfer the Product to its
notified body.

     5.4    Product Dossiers/Clinical Information.  In the event that STAAR
            -------------------------------------
materially breaches this Agreement, and such material breach is not cured within
six months of its occurrence, then STAAR will make available to Lenstec, in lieu
of all other damages to which Lenstec may be entitled as a result of said
material breach, all Product regulatory and clinical information obtained by
STAAR in connection with its product registration activities.

                                   ARTICLE 6
                                  ADVERTISING

     6.1    Advertising.  STAAR shall have the right to prepare all advertising,
            -----------
promotional material, and labeling to the Product.  STAAR and/or Lenstec will
seek approval from its respective notified body for any labeling so designated.
Lenstec will, if requested, provide its promotional information regarding the
Product and STAAR may, at its discretion, use such promotional information in
the advertising promotional material and labeling it prepares.

                                       4
<PAGE>

                                   ARTICLE 7
                      QUALITY CONTROL AND PRODUCT RECALL

     7.1  Rejection of the Product.  STAAR may reject and return the Product not
          ------------------------
conforming to the specifications provided for in Exhibit "A" hereof, or because
of: (a) failure to meet the Specifications when they are delivered; (b) material
manufacturing defects; or (c) FDA or applicable foreign agency recall because of
acts or failure to act by Lenstec.  In order to reject the Product, STAAR must
give written notice to Lenstec of STAAR's intention to reject the shipment,
which notice must be received by Lenstec within sixty (60) days of STAAR's
receipt of such Product together with an indication of the reasons for such
rejection.  If no such notice of intent to reject is received, STAAR shall be
deemed to have accepted the delivery provided, however, in the case of Product
having latent defects which upon diligent examination by STAAR upon their
receipt could not have been discovered, STAAR must give notice of STAAR's intent
to reject such Product within thirty (30) days after discovery of such defects.
In the event STAAR has paid for a shipment of the Product which has been
rejected as provided herein, STAAR shall be entitled to a refund of the purchase
price of the rejected Product (together with insurance and freight charges) at
the time it is ultimately rejected, provided, however, that if Lenstec disputes
the rejection, any appropriate refund shall be made at the time the dispute is
finally resolved. Lenstec shall notify STAAR within fifteen (15) days of its
receipt of STAAR's notice of rejection as to whether it accepts STAAR's basis
for any rejection.

     7.2  Manufacturing Standards.  Lenstec shall manufacture the Product in
          -----------------------
compliance with ISO/EN 9001 and ISO/EN 46001 for CE Marking, and in accordance
with other applicable foreign agency requirements, as requested, all in
accordance with the Specifications.  Lenstec understands and agrees that STAAR
shall have no obligation to sell the Product pursuant to the terms of this
Agreement until the Product receives the ISO and CE Mark that will allow STAAR
to sell the product under its brand name.

     7.3  Design Changes.  STAAR may, as a result of complaints, adverse events,
          --------------
recalls, or recommendations or requirements as expressed by customers or
regulatory bodies, require Lenstec to make modifications to the technical design
or manufacturing of the Product.  Lenstec will cooperate fully with STAAR in
modifying the Product, as requested.  The payment of the costs of such
modifications, if less than $10,000, will be the responsibility of Lenstec.  The
party to be responsible for payment of the costs of such modifications, if
significant (in excess of $10,000), will be negotiated in good faith by STAAR
and Lenstec.

     7.4  Records Maintenance.  STAAR and Lenstec shall maintain all records
          -------------------
regarding the Product as may be required by any applicable foreign agency or by
the FDA for IDE, PMA or CE Mark approved Product and shall supply each other,
upon request by the other, with such records and other information and reports
as may be required by the FDA or any applicable foreign agency or notified body.
Any new reports or modifications of current reports required to be prepared by
STAAR or Lenstec by the FDA, a notified body, or any applicable foreign agency
shall become an obligation under this Agreement and Lenstec and STAAR shall
assist each other, as necessary, in the preparation of such new reports or
modifications of current reports.

     7.5  Adverse Reaction Report.  The following procedures shall be
          -----------------------
established and observed by the parties hereto:

          (a)  In the event that STAAR receives any complaint, claims, or
adverse reaction reports regarding the Product, STAAR shall, within five (5)
business days, provide Lenstec with all information contained in the complaint.
Lenstec will notify STAAR immediately by facsimile transmission of any
information that it may have that affects the safe and effective use of the
Product.

                                       5
<PAGE>

          (b)  STAAR shall be responsible for evaluating such complaints and, as
     required, notifying the appropriate regulatory authorities in writing.  On
     a periodic basis, not less than annually, and, in the case of an adverse
     event, immediately by facsimile transmission, STAAR shall inform Lenstec in
     writing of the complaint and adverse reaction incidence rates of the
     Product.

     7.6  Recall.  In the event that Lenstec shall deem it necessary to recall,
          ------
or any applicable foreign agency, the notified body, or any similar regulatory
authority requests recall of the Product, Lenstec shall be responsible for and
shall bear all costs and expenses of such recall, including without limitation
expenses or obligations to third parties, the costs of notifying customers, and
costs associated with the shipment of such recalled products from customers.
However, if such recall is caused by the advertising, promotion or labeling of
STAAR or the negligence or willful misconduct of STAAR, STAAR shall bear the
costs and expenses of such recall and shall promptly reimburse Lenstec for any
amounts expended in connection therewith. In the event of any recall, the
parties shall cooperate fully with each other in effecting such recall.

     7.7  Warranties Relating to the Product.  Lenstec warrants that the
          ----------------------------------
Product, when shipped to STAAR will: (a) conform in all respects to the
Specifications outlined in Exhibit "A" or otherwise as then in effect; and (b)
not be adulterated or misbranded within the meaning or applicable foreign agency
regulations; provided, however, that no warranty is given for advertising,
promotional materials, or labeling prepared by STAAR.

     7.8  Warranties and Representations by the Parties.  To induce the other to
          ---------------------------------------------
enter into this Agreement and consummate the transactions contemplated by it,
STAAR and Lenstec hereby represent, warrant and covenant that:

          (a)  Organization and Good Standing.  STAAR and Lenstec are each (i)
               ------------------------------
corporations duly organized, validly existing and in good standing under the
laws of any state or country in which such corporation does business; and (ii)
has all requisite corporate power and authority to conduct its business and to
own, operate and lease its properties as and in the places where such business
is now conducted and such properties are now owned, leased or operated.

          (b)  Corporate Power, Authority and Enforceability.  STAAR and Lenstec
               ---------------------------------------------
each have all requisite power and authority to enter into this Agreement, and to
carry out its obligations thereunder.  The execution and delivery of this
Agreement and the performance of the obligations thereunder, have been duly
authorized by all necessary action.  This Agreement, when executed and delivered
on behalf of each party, shall constitute valid and binding obligations of each
party, enforceable against the party in accordance with its terms, except as may
be limited by applicable bankruptcy, insolvency, moratorium or similar laws of
general application relating to or affecting creditor's rights generally and
except for the limitations imposed by general principles of equity.  The
undersigned officers of STAAR and Lenstec are duly authorized and empowered to
execute and attest the Agreement for and on behalf of STAAR and Lenstec.

          (c)  To induce STAAR to enter into this Agreement and to consummate
the transactions contemplated by it, Lenstec hereby represents, warrants and
covenants that, as of the date of execution of this Agreement, it will have
obtained; (i) any necessary permission or approval, as required, from Santen to
enter into this Agreement, and (ii) the waiver contemplated by Section 1.5
above.

                                       6
<PAGE>

     7.9     Indemnification.
             ---------------

     7.9.1   Lenstec Indemnification.  Lenstec shall defend, indemnify and hold
             -----------------------
STAAR and its parent and affiliates (and each of their employees, officers and
directors) harmless from and against any and all damages, injuries, causes of
action, costs, losses and expenses, including without limitation the costs of
recalls, court costs and reasonable attorneys' fees, if any, resulting from
third party product liability claims based on the negligence or willful
misconduct of Lenstec, or any claim of infringement or violation of any patent,
or common law or statutory rights, or proprietary rights by or on account of the
use that STAAR is entitled to make of the Product, or failure of the Product to
confirm to the specification set forth in Exhibit "A" hereof, or the breach by
Lenstec of any representation, warranty, covenant, term or agreement included in
this Agreement.

     7.9.2   STAAR Indemnification.  STAAR shall defend, indemnify and hold
             --------------------
Lenstec and its affiliates (and each of their employees, officers and directors)
harmless from and against any and all damages, injuries, causes of action,
costs, losses and expenses, including without limitation court costs and
reasonable attorneys' fees, if any, resulting from third party liability claims
arising out of the breach by STAAR of any representation, warranty, covenant,
term or agreement included in this Agreement.

     7.9.3    Settlement.  If either party intends to claim indemnification from
              ----------
the other party pursuant to this Section 7.9, it shall not be entitled to settle
any of the claims for which it claims or intends to claim indemnification
without the consent of such other party, which consent shall not be unreasonably
withheld.

     7.9.4    Limitation on Indemnification.  The indemnities of this Section
              -----------------------------
7.9 shall not apply: (a) if the indemnified party fails to give the
indemnifying party prompt written notice of any claim it receives, and such
failure materially prejudices the indemnifying party; or (b) unless the
indemnifying party is given the opportunity to approve such settlement, which
approval shall not be unreasonably withheld. Furthermore, the indemnifying party
shall not be liable for attorneys' fees or expenses of litigation of the
indemnified party unless the indemnified party gives the indemnifying party the
opportunity to assume control of the defense or settlement. In addition, if the
indemnifying party assumes such control, it shall only be responsible for the
legal fees and litigation expenses of the attorneys it designates to assume
control of the litigation. In no event shall the indemnifying party assume
control of the defense of the indemnified party without the consent of the
indemnified party, which consent shall be given or not at its sole discretion.

                                   ARTICLE 8

                                CONFIDENTIALITY

     8.1     Duty of Confidentiality Relating to Trade Secrets and Proprietary
             -----------------------------------------------------------------
Information.  Each party ("Receiving Party") shall maintain in confidence and
-----------   ----
keep safe from third parties all information disclosed by the other ("Disclosing
Party") which such party knows or has reason to know comprises trade secrets and
other proprietary information of the other, including, without limitation,
information relating to the Product. Each party shall use its best efforts to
ensure that its employees, consultants and agents do not disclose to third
parties such trade secrets or proprietary information. Each party shall notify
the other promptly upon discovery of any unauthorized use or disclosure of the
other's trade secrets or proprietary information.

     8.2     Exceptions.  The obligation of confidentiality contained in this
             ----------
Agreement shall not apply to the extent that (a) the Receiving Party is required
to disclose the information by applicable law, regulation or order of a
governmental agency or a court of competent jurisdiction; (b) the Receiving
Party can demonstrate that the disclosed information was at the time of
disclosure already in the public domain other than as a result of actions or
failure to act by the Receiving Party in violation hereof; (c) the disclosed
information was rightfully known by the Receiving Party (as shown by its written
records) prior

                                       7
<PAGE>

to the date of disclosure to the Receiving Party in connection with this
Agreement; or (d) the disclosed information was received by the Receiving Party
on an unrestricted basis from a source which is neither STAAR nor Lenstec and
which is not under a duty of confidentiality to the other party.

                                   ARTICLE 9
                               PRODUCT LIABILITY

     9.1     Notification.  Each party shall promptly notify the other of any
             ------------
claim or action by reason of the manufacture, use or sale of the Product of
which it becomes aware.

     9.2     Insurance.  Lenstec shall maintain insurance coverage issued by one
             ---------
or more insurance companies, with Best Rating B+ or higher, and shall name STAAR
a co-insured thereon, adequate to cover the claims, liabilities, judgements,
losses, damages, costs and expenses (including reasonable attorney's fees)
indemnified in Article 6.

                                  ARTICLE 10
                                 MISCELLANEOUS

    10.1     Governing Law.  This Agreement shall be governed by and interpreted
             -------------
in accordance with the laws of the State of California.

    10.2     Dispute Resolution/Arbitration.  All disputes shall be amicably
             ------------------------------
resolved, and if not so resolved, they shall be subject to arbitration as
follows: (i) if Lenstec initiates a claim or demand against STAAR, then the
arbitration shall be conducted in accordance with the rules of the International
Arbitration Association and the location of arbitration shall be in southern
California and (ii) if STAAR initiates a claim or demand against Lenstec, then
the arbitration shall be conducted in accordance with the commercial arbitration
rules of the American Arbitration Association and the location of arbitration
shall be Tampa, Florida.  Further, (iii) the arbitration shall be conducted in
the English language. (iv) The award of the arbitrators will be final and
binding upon the parties.  Judgement upon the award may be entered in any court
having jurisdiction.  An application may be made to any such court for judicial
acceptance of the award and an order of enforcement. (v) Any arbitration
proceeding hereunder shall be conducted on a confidential basis. (vi) The
arbitrator shall apply the principles of the laws of the State of California.

    10.3     Notice.  Unless otherwise specifically provided in this Agreement,
             ------
all notices, demands, requests, consents, approvals or other communications
(collectively and severally called "Notices") required or permitted to be given
hereunder, or which are given with respect to this Agreement, shall be in
writing, and shall be given by: (A) personal delivery (which form of Notice
shall be deemed to have been given upon delivery), (B) by telegraph or by
private airborne/overnight delivery service (which forms of Notice shall be
deemed to have been given upon confirmed delivery by the delivery agency), (C)
by electronic or facsimile or telephonic transmission, provided the receiving
party has a compatible device or confirms receipt thereof (which forms of Notice
shall be deemed delivered upon confirmed transmission or confirmation of
receipt), or (D) by mailing in the United States mail by registered or certified
mail, return receipt requested, postage prepaid (which forms of Notice shall be
deemed to have been given upon the fifth  {5th} business day following the date
mailed).  Notices shall be addressed as follows, or to such other address as the
receiving party shall have specified most recently by like Notice, with a copy
to the other parties hereto.

                                       8
<PAGE>

                    To STAAR:  STAAR Surgical Company
                               1911 Walker Avenue
                               Monrovia, California 91016
                               Attention: John Wolf, President
                               PH: 626/303-7902
                               FAX: 626/358-3049

                 To Lenstec:   Lenstec, Inc.
                               2860 Scherer Drive, Suite 600
                               St. Petersburg, Florida 33716
                               Attention: John Clough, President
                               PH: 727/571-2272
                               FAX: 727/571-1792

        10.4    Captions.  The captions, articles, sections and subsections of
                ---------
this Agreement are solely for convenience of reference and shall not affect its
interpretation.

        10.5    Entire Agreement.  This Agreement represents the entire
                ----------------
understanding between the parties with respect to the subject matter hereof, and
supersedes all prior agreements, negotiations, understandings, letters of
intent, representations, statements and writings between the parties relating
thereto. No modifications, alteration, waiver or change in any of the terms of
this Agreement shall be valid or binding upon the parties hereto unless made in
writing and duly executed on behalf of the party to be charged therewith.

        10.6    Assignability.  This Agreement may not be assigned or
                -------------
transferred in any manner by either party without the prior written consent of
the other party, except that either party may assign or transfer this Agreement
to a third party in connection with the transfer or sale of all or substantially
all of its business to which this Agreement pertains or the merger of
consolidation of a party with or into a third party if said third party agrees
in writing to accept all of the terms and conditions of this Agreement.

        10.7    Waiver.  The waiver by either party of a breach of any provision
                ------
contained herein shall in no way be construed as a waiver of any subsequent
breach of such provision or the waiver of the provision itself.

        10.8    Invalidity of a Particular Provision.  The invalidity or
                ------------------------------------
unenforceability of any term, provision, clause or any portion thereof of this
Agreement shall in no way impair or affect the validity or enforcement of any
other provision of this Agreement.

        10.9    Survival.  The provisions which by their meaning and intent have
                --------
applicability beyond the term of this Agreement shall survive the expiration or
termination of this Agreement.

        10.10   Relationship of the Parties.  The relationship between STAAR and
                ---------------------------
Lenstec is and shall be that of vendor and vendee.  Neither party nor its agents
and employees, shall under any circumstances be deemed agents or representatives
of the other and neither shall have authority to act for and/or bind the other
in any way, or represent that it is in any way responsible for acts of the
other.  This Agreement does not establish a joint venture, agency or partnership
between the parties, nor does it create an employer/employee relationship.

        10.11   Counterparts.  This Agreement may be executed in several
                ------------
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.  If this Agreement is
executed in counterparts, no signatory hereto shall be bound until both the
parties named below have duly executed or caused to be duly executed a
counterpart of this Agreement.

<PAGE>

     10.12  Expenses.  The prevailing party in any legal action to enforce or
            --------
interpret this Agreement shall be entitled to reimbursement of its costs and
attorneys' fees in such action by the other party.

     10.13  Force Majeure.  A party shall not be liable for nonperformance or
            -------------
delay in performance caused by any event reasonably beyond the control of such
party (provided such party shall use its best efforts to return to normal
operations), including but not limited to wars, hostilities, revolutions, riots,
civil commotion, national emergency, epidemics, fire, flood, earthquake, force
of nature, explosion, embargo, or any other Act of God, or any law,
proclamation, regulation, ordinance, or other act or order of any court,
government or governmental agency.

     10.14  Time.  The parties agree that time is of the essence in the
            ----
performance of obligations under this Agreement.

     10.15.  Specific Performance.  The parties acknowledge and agree that STAAR
             --------------------
will suffer irreparable harm in the event of a material breach of Lenstec's
obligation to supply Product in accordance with the terms hereof. Accordingly,
Lenstec agrees that STAAR will, in addition to any other remedies available to
it at law or in equity, be entitled to injunctive relief to enforce Lenstec's
obligation to supply Product in accordance with the terms hereof.

     10.16  Confidentiality.  The terms and conditions of this Agreement shall
            ---------------
be confidential and shall not be disclosed by any of the parties to this
Agreement to any third party, other than to an actual or potential affiliate,
successor or assign, except that any party may disclose the terms and conditions
of this Agreement (i) to its legal or accounting advisors, as necessary, so long
as they agree to be bound by the terms of this confidentiality provision; or
(ii) if such party receives a subpoena or other process or order to produce this
Agreement, provided that such party shall, prior to any disclosure to any third
party, promptly notify the other party to this Agreement so that the party has a
reasonable opportunity to respond to such subpoena, process or order, or (iii)
as otherwise required by law. The party receiving the subpoena, process or order
shall take no action contrary to the confidentiality provisions set forth above
and shall make reasonable efforts to produce only subject to a protective order.
The party objecting shall have the burden of defending against such subpoena,
process or order. The party receiving the subpoena, process or order shall be
entitled to comply with it except to the extent that any other party is
successful in obtaining an order modifying or quashing it.

     IN WITNESS WHEREOF, the parties have caused this Agreement to be executed
as of the date first written above.

STAAR SURGICAL AG                           LENSTEC, INC.

By: /s/ John R. Wolf                        By: /s/ John Clough
    ---------------------                       ---------------------

Title: President                            Title: President
       ------------------                          ------------------

Date:  5/10/99                              Date:  5-6-99
     -------------------                           ------------------

STAAR SURGICAL COMPANY                      LENSTEC BARBADOS, INC.

By: /s/ John R. Wolf                        By: /s/ John Clough
    --------------------                       ----------------------

Title: Co-Chairman                          Title: Chairman
       -----------------                           ------------------

Date:  5/10/99                              Date:  5-6-99
       -----------------                           ------------------

                                      10

<PAGE>

                                  EXHIBIT "A"

                            PRODUCT SPECIFICATIONS

Conformity with GMP and ISO/EN 9001 Requirements:
-------------------------------------------------

All Product delivered shall be in compliance with applicable GMP and ISO
guidelines for the manufacture and sterilization of intraocular lenses for human
implantation.

Product Sterility:
------------------

For the initial 120 days of the Effective Period, Product Sterility shall be
limited to one year.  Thereafter, all Product delivered will have a sterility
expiration of five (5) years.

Product Design:
---------------
See attached engineering drawings.

Manufacturing Controls/Inspection Procedures:
---------------------------------------------
[from Lenstec's ISO SOP Manual]

                                      11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00005-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00005-of-00352.parquet"}]]